



**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Consolidated Financial Statements

June 30, 2013 and 2012

and

Audit of Federal Awards Performed
in Accordance with U.S. Office of
Management and Budget Circular A-133

June 30, 2013

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Table of Contents

	Page(s)
Independent Auditors' Report	1 – 2
Consolidated Balance Sheets	3
Consolidated Statements of Activity	4 – 5
Consolidated Statements of Cash Flows	6
Statements of Functional Expenses	7
Notes to Consolidated Financial Statements	8 – 37
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	38 – 39
Independent Auditors' Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with OMB Circular A-133	40 – 42
Schedule of Expenditures of Federal Awards	43 – 74
Notes to Schedule of Expenditures of Federal Awards	75 – 87
Schedule of Findings and Questioned Costs	88 – 90



KPMG LLP
Suite 2900
1918 Eighth Avenue
Seattle, WA 98101

Independent Auditors' Report

The Board of Trustees
Fred Hutchinson Cancer Research Center:

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Fred Hutchinson Cancer Research Center (the Center), which comprise the consolidated balance sheets as of June 30, 2013 and 2012, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Fred Hutchinson Cancer Research Center as of June 30, 2013 and 2012, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated November 1, 2013 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control over financial reporting and compliance.

KPMG LLP

November 1, 2013

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Balance Sheets

June 30, 2013 and 2012

(In thousands)

Assets	2013	2012
Current assets:		
Cash and cash equivalents	\$ 15,261	18,275
Limited use investments	8,168	15,152
Grants and contracts receivable	19,787	26,351
Notes and pledges receivable	3,484	5,269
Other receivables	19,916	17,375
Prepaid expenses and deposits	1,464	1,724
Investments	10,590	12,153
Investment in SCCA	84,838	77,786
Board-designated investments	94,195	91,093
Restricted investments	30,021	30,020
Beneficial interest in perpetual trusts	26,436	25,566
Trustee-held funds	13,035	29,623
Land, buildings, and equipment, net of accumulated depreciation of \$347,399 and \$324,915, respectively	365,875	356,080
Rental property	5,555	5,555
Deferred financing costs, net	2,152	2,483
Total assets	\$ 700,777	714,505
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued liabilities	\$ 14,105	24,447
Accrued payroll and related costs	22,615	17,287
Deferred revenue	35,453	31,466
Long-term debt	363,516	367,774
Deferred credit on cash flow hedges	30,235	40,196
Total liabilities	465,924	481,170
Net assets:		
Unrestricted	146,425	142,035
Temporarily restricted	32,926	38,055
Permanently restricted	55,502	53,245
Total net assets	234,853	233,335
Total liabilities and net assets	\$ 700,777	714,505

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statement of Activities

Year ended June 30, 2013 With Summarized Financial Information for the Year ended June 30, 2012

(In thousands)

	<u>Unrestricted</u>	<u>Temporarily restricted</u>	<u>Permanently restricted</u>	<u>Total</u>	<u>June 30, 2012</u>
Revenues and other support:					
Research grants and contracts	\$ 327,949	—	—	327,949	350,406
Contributions, net of cost of special events of \$961 in 2013 and \$1,256 in 2012	12,530	5,294	1,356	19,180	26,123
Investment income and realized gains and losses	9,487	1,175	—	10,662	13,972
Royalty income	5,466	—	—	5,466	6,511
Clinical service fee revenue	16,720	—	—	16,720	17,569
Other income	26,727	—	—	26,727	26,816
Total revenues	398,879	6,469	1,356	406,704	441,397
Net assets released from restrictions used for operations	7,590	(7,590)	—	—	—
Net assets released from restrictions used for capital	912	(912)	—	—	—
Total revenues and other support	407,381	(2,033)	1,356	406,704	441,397
Expenses:					
Program services research	331,489	—	—	331,489	340,345
Management and general	86,778	—	—	86,778	88,236
Fund-raising	9,251	—	—	9,251	6,598
Total expenses	427,518	—	—	427,518	435,179
Change in net assets from operations	(20,137)	(2,033)	1,356	(20,814)	6,218
Other changes in net assets:					
Change in net unrealized gains and losses in fair value of investments	10,569	(3,096)	31	7,504	(9,463)
Change in net foreign currency translation	(210)	—	—	(210)	—
Change in value of split-interest agreements	(306)	—	870	564	(2,742)
Change in net unrealized fair value of swap instruments	14,474	—	—	14,474	(13,710)
Total other changes in net assets	24,527	(3,096)	901	22,332	(25,951)
Total increase (decrease) in net assets	4,390	(5,129)	2,257	1,518	(19,697)
Net assets balance at beginning of year	142,035	38,055	53,245	233,335	253,032
Net assets balance at end of year	\$ <u>146,425</u>	<u>32,926</u>	<u>55,502</u>	<u>234,853</u>	<u>233,335</u>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statement of Activities

Year ended June 30, 2012 With Summarized Financial Information for the Year ended June 30, 2011

(In thousands)

	<u>Unrestricted</u>	<u>Temporarily restricted</u>	<u>Permanently restricted</u>	<u>Total</u>	<u>June 30, 2011</u>
Revenues and other support:					
Research grants and contracts	\$ 350,406	—	—	350,406	354,554
Contributions, net of cost of special events of \$1,265 in 2012 and \$1,094 in 2011	15,366	7,861	2,896	26,123	33,442
Investment income and realized gains and losses	13,013	664	295	13,972	18,299
Royalty income	6,511	—	—	6,511	18,424
Clinical service fee revenue	17,569	—	—	17,569	18,178
Other income	26,816	—	—	26,816	26,677
Total revenues	<u>429,681</u>	<u>8,525</u>	<u>3,191</u>	<u>441,397</u>	<u>469,574</u>
Net assets released from restrictions used for operations	7,067	(7,067)	—	—	—
Net assets released from restrictions used for capital	220	(220)	—	—	—
Total revenues and other support	<u>436,968</u>	<u>1,238</u>	<u>3,191</u>	<u>441,397</u>	<u>469,574</u>
Expenses:					
Program services research	340,345	—	—	340,345	338,293
Management and general	88,236	—	—	88,236	81,282
Fund-raising	6,598	—	—	6,598	5,600
Total expenses	<u>435,179</u>	<u>—</u>	<u>—</u>	<u>435,179</u>	<u>425,175</u>
Change in net assets from operations	1,789	1,238	3,191	6,218	44,399
Other changes in net assets:					
Change in net unrealized gains and losses in fair value of investments	(8,466)	(997)	—	(9,463)	10,316
Change in value of split-interest agreements	(574)	(409)	(1,759)	(2,742)	2,817
Change in net unrealized fair value of swap instruments	(13,710)	—	—	(13,710)	2,495
Total other changes in net assets	<u>(22,750)</u>	<u>(1,406)</u>	<u>(1,759)</u>	<u>(25,915)</u>	<u>15,628</u>
Total increase (decrease) in net assets	<u>(20,961)</u>	<u>(168)</u>	<u>1,432</u>	<u>(19,697)</u>	<u>60,027</u>
Net assets balance at beginning of year	162,996	38,223	51,813	253,032	193,005
Net assets balance at end of year	\$ <u>142,035</u>	<u>38,055</u>	<u>53,245</u>	<u>233,335</u>	<u>253,032</u>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statements of Cash Flows

Years ended June 30, 2013 and 2012

(In thousands)

	<u>2013</u>	<u>2012</u>
Cash flows from operating activities:		
Change in net assets	\$ 1,518	(19,697)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	27,592	25,729
Decrease in noncash deferred revenue	(1,145)	(913)
Equity in earnings of SCCA	(2,725)	(9,884)
Change in net unrealized gains in fair value of investments	(7,504)	9,463
Change in value of split-interest agreements	(564)	2,742
Change in fair value of swap instruments	(14,474)	13,710
Net realized gains on investments	(5,066)	22
Noncash contributions	(2,863)	(4,681)
Permanently restricted contributions	(1,356)	(2,896)
Changes in assets and liabilities:		
Grants and contracts receivable	6,564	4,897
Notes and pledges receivable	1,785	(1,869)
Other receivables	(2,541)	671
Prepaid expenses and deposits	264	(277)
Accounts payable and accrued liabilities	(9,497)	4,253
Accrued payroll and related costs	5,328	1,716
Deferred grant and contract revenue	4,781	5,668
Net cash provided by operating activities	<u>97</u>	<u>28,654</u>
Cash flows from investing activities:		
Additions to land, buildings, equipment, and rental property	(37,824)	(56,239)
Purchase of investments	(47,999)	(105,653)
Sale of investments	68,756	77,808
Change in trustee-held funds	16,588	29,375
Net cash used in investing activities	<u>(479)</u>	<u>(54,709)</u>
Cash flows from financing activities:		
Proceeds from new debt	142,485	—
Additions to deferred financing costs	(234)	(309)
Repayment of debt	(146,595)	(4,237)
Contributions restricted for long-term investment	1,356	2,896
Net cash used in financing activities	<u>(2,988)</u>	<u>(1,650)</u>
Change in foreign currency translation	<u>356</u>	<u>—</u>
Net (decrease) in cash and cash equivalents	<u>(3,014)</u>	<u>(27,705)</u>
Cash and cash equivalents at beginning of year	<u>18,275</u>	<u>45,980</u>
Cash and cash equivalents at end of year	\$ <u><u>15,261</u></u>	\$ <u><u>18,275</u></u>
Supplemental disclosure of cash flow information:		
Interest paid	\$ 17,152	14,133
Capital expenditures in accounts payable	395	1,249

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statements of Functional Expenses

Years ended June 30, 2013 and 2012

(In thousands)

	Program services research	Management and general	Fund-raising	Total
2013:				
Salaries and wages	\$ 143,931	35,134	5,082	184,147
Employee benefits	40,363	9,291	1,366	51,020
Subawards	64,381	—	—	64,381
Purchased services	9,243	16,674	986	26,903
Supplies	22,710	2,580	60	25,350
Other	10,339	4,851	1,716	16,906
Rent, utilities, and maintenance	2,692	11,022	41	13,755
Interest and amortization	16,135	1,789	—	17,924
Depreciation	21,690	5,442	—	27,132
Total June 30, 2013	\$ <u>331,484</u>	<u>86,783</u>	<u>9,251</u>	<u>427,518</u>
2012:				
Salaries and wages	\$ 140,901	33,104	3,893	177,898
Employee benefits	37,559	8,438	993	46,990
Subawards	79,005	—	—	79,005
Purchased services	11,759	16,264	707	28,730
Supplies	23,922	3,129	57	27,108
Other	11,318	7,506	883	19,707
Rent, utilities, and maintenance	2,649	13,166	65	15,880
Interest and amortization	12,809	1,423	—	14,232
Depreciation	20,423	5,206	—	25,629
Total June 30, 2012	\$ <u>340,345</u>	<u>88,236</u>	<u>6,598</u>	<u>435,179</u>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(1) Organization

Fred Hutchinson Cancer Research Center (the Center), a Washington not-for-profit corporation, is organized and operated exclusively for charitable, scientific, and educational purposes, within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, including without limitation (i) eliminating cancer as a cause of human suffering and death; (ii) conducting investigations into the nature and causes of cancer and related medical and public health problems; (iii) investigating methods of prevention and treatment of cancer and related diseases; (iv) conducting education in all phases of cancer research; (v) performing research in all aspects of biomedical science that have a relationship to cancer; (vi) disseminating knowledge acquired pursuant to the foregoing activities; and (vii) maintaining facilities for cancer and related biomedical research. The Center is designated by the National Cancer Institute as a comprehensive cancer research center.

Controlled Affiliates of the Center

Uganda Program on Cancer and Infectious Diseases (UPCID) is a Uganda not-for-profit corporation. It is organized and operated for the purpose of researching, detecting, treating, and preventing infection-related cancers in Uganda and throughout the world. The Center is the sole member of UPCID. The income and property of UPCID is restricted to be used in meeting its organizational objectives. The net assets of UPCID of (\$966) as of June 30, 2013 are not considered pledged assets under debt covenants.

Hutchinson Center Research Institute of South Africa (HCRISA) is a South Africa not-for-profit corporation. It is organized and operated for the purpose of promoting and conducting clinical, laboratory and other research aimed at the prevention, early detection, diagnosis, and treatment of HIV/AIDS, Tuberculosis other infectious diseases and cancer in South Africa and throughout the world. The Center is the sole member of HCRISA. The income and property of HCRISA is restricted to be used in meeting its organizational objectives. The net assets of HCRISA of (\$170) as of June 30, 2013 are not considered pledged assets under debt covenants.

Seattle Vaccine Research Fund (SVRF), a Washington State not-for-profit corporation, is exempt from federal taxes under Section 501(c)(3). It is operated for the purpose of providing anti-retrovirals to eligible participants of HIV Trials Network participants. The net assets of SVRF of \$439 as of June 30, 2013 are not considered pledged assets under debt covenants.

(2) Summary of Significant Accounting Policies

(a) *Basis of Presentation*

The consolidated financial statements include the accounts of the Center and its controlled affiliates, collectively referred to as the Center. All significant intracompany balances and transactions between the Center and its controlled affiliates have been eliminated in consolidation.

(b) *Use of Estimates*

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(c) Cash and Cash Equivalents

Included in cash and cash equivalents are cash equivalents of approximately \$3,314 and \$6,329 as of June 30, 2013 and 2012, respectively, which are invested in money market funds and highly liquid debt instruments with original maturities of three months or less.

The Center maintains cash and cash equivalents on deposit at financial institutions, which at times exceed the limits insured by the Federal Deposit Insurance Corporation. This exposes the Center to potential risk of loss in the event that the financial institution becomes insolvent.

(d) Limited use Investments

Limited use investments includes designated unrestricted financial assets set aside by the board of trustees for future capital and program purposes, over which the board of trustees retains control and may at its discretion subsequently use for other purposes. Limited use investments also include temporarily restricted assets.

(e) Investments and Trustee-Held Funds

Investments, including board-designated investments and other restricted investments, and trustee-held funds carried at fair value include cash and cash equivalents, equity securities, debt securities, and alternative investments.

(f) Investment in SCCA

The Center accounts for its 33% ownership interest in Seattle Cancer Care Alliance (SCCA) using the equity method of accounting, as further discussed in note 14.

(g) Land, Buildings, and Equipment

Land, buildings, and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized as a component of the cost of acquiring those assets. Improvements and replacements of land, buildings, and equipment are capitalized; maintenance and repairs costs are expensed.

In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360, *Property, Plant, and Equipment*, long-lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable.

As described in note 3, the Center receives reimbursement for its property, plant, and equipment through indirect cost reimbursement primarily from the federal government in connection with federal grants.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(h) *Deferred Financing Costs*

Financing costs incurred in connection with long-term obligations are deferred and amortized over the term of the credit enhancement facility for variable rate debt or the term of the debt using the effective interest method for fixed rate debt.

(i) *Deferred Grant and Contract Revenue and Research Grants and Contracts Receivable*

Deferred grant and contract revenue represent grant and contract funds received for services to be performed by the Center, which have not yet been expended under terms of the grant and contract agreements and which do not meet the criteria for reporting as contributions. The Center recognizes these amounts as revenue as such funds are expended. The Center includes certain construction grants from the federal government as deferred revenue, which are recognized as revenue at the same rate as depreciation expense.

The balance in grants and contracts receivable, as reflected on the accompanying balance sheets, represents expenditures made in accordance with the terms of provisions of the grants and contracts not yet reimbursed by cash.

(j) *Sponsored Research*

Amounts received for sponsored research are reflected in unrestricted sponsored research and released to operations when spent for the appropriate purpose. Sponsored research consists of those activities attributable to the Center's current annual research programs, such as clinical trials and other studies of cancer and related diseases.

(k) *Donor-Restricted Gifts*

Unconditional promises to give cash and other assets to the Center are reported at fair value at the date the promise is received. Conditional promises to give and intentions to give are reported at fair value at the date the gift is received or the conditions are met. The gifts are reported as either temporarily or permanently restricted support if they are received with donor stipulations that limit the use of the donated assets or contain a time restriction. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported in the statements of activity as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying financial statements.

(l) *Foreign Currency Translation and Transaction Gains and Losses*

The consolidated financial statements include foreign currency amounts attributable to foreign operations for HCRISA. The foreign currency amounts have been translated into U.S. dollars using year-end exchange rates for assets and liabilities, historical rates for net assets and average annual rates for revenues and expenditures. Unrealized gains or losses arising from fluctuations in the year-end exchange rates are recorded as net asset adjustments from foreign currency translation, and gains or losses resulting from actual foreign exchange transactions are recorded in revenues and expenses

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

in the consolidated statements of activities. The cumulative foreign currency translation losses amount to \$210 at June 30, 2013. The aggregate transaction losses included in determining the change in net assets were immaterial for the year ended June 30, 2013. There were no operations for HCRISA for the year ended June 30, 2012.

In accordance with the Accounting Standards Codification (ASC) Topic 230, *Statement of Cash Flows*, cash flows from the HCRISA's operations are calculated based on its local reporting currency and translated to U.S. dollars.

UPCID's general ledger is maintained in U.S. dollars, and their financial statements are measured using the currency of the primary economic environment in which the entity operates, which is U.S. dollars. Unrealized gains or losses arising from fluctuations in the year-end exchange rates, and gains or losses resulting from actual foreign exchange transactions are recorded in revenues and expense. Unrealized gains were immaterial for the year ended June 30, 2013.

(m) *Temporarily and Permanently Restricted Net Assets*

Temporarily restricted net assets are those that have uses that have been limited by donors to a specific time period or purpose. The Center's temporarily restricted net assets are restricted to scientific research expenses and equipment, the acquisition of long-term assets related to Center expansion, and designated noncapitalizable activities related to Center expansion.

Permanently restricted net assets have been restricted by donors to be maintained by the Center in perpetuity. The Center's permanently restricted net assets consist of various endowment funds and the Center's interest in perpetual trusts. Income earned on endowment funds is used for operations in accordance with the terms of each endowment fund.

(n) *Statements of Activities*

The statements of activities describe the results of various financial events that are included in presenting the change in the Center's net assets. Contributions received by the Center may be either unrestricted, temporarily restricted, or permanently restricted. Investment income and realized gains and losses may be temporarily restricted based on donor intent or unrestricted. Research grant and contract revenue generated by the Center and related expenses incurred are unrestricted. Changes in asset values resulting from "mark-to-market" adjustments to record unrealized gains and losses are shown as Other Changes in Net Assets. A total increase or decrease in net assets for each net asset grouping is shown to roll forward the beginning of the year balance to the end of the year balance.

(o) *Federal Income Taxes*

The Center has obtained a determination letter from the Internal Revenue Service that it is exempt from federal income taxes under Section 501(c)(3), except for unrelated business income.

(p) *Fair Value Measurements*

Fair value is defined as the price that the Center would receive upon selling an asset in an orderly transaction to an independent buyer in the principal or most advantageous market of the investment.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

FASB ASC 820-10-50, *Fair Value Measurement*, established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs, and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based upon market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available. The three-tier hierarchy is summarized below:

- Level 1 – Valuation inputs are quoted prices in active markets for identical investments. At June 30, 2013 and 2012, Level 1 measurements include primarily cash and cash equivalents, domestic and global equities, equity funds, and bond funds.
- Level 2 – Valuation inputs are quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. At June 30, 2013 and 2012, Level 2 measurements included fixed income and debt securities, such as U.S. government obligations, mortgage-backed securities, corporate bonds, municipal obligations, interest rate swaps, and certain hedged equity and real asset funds.
- Level 3 – Valuation inputs are derived from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Center's estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of discounted cash flow models and similar techniques. At June 30, 2013 and 2012, Level 3 securities included hedged equity funds, private equity and venture capital funds, privately held equities, beneficial interests in charitable trusts, and beneficial interests in perpetual trusts.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The fair value hierarchy does not necessarily correspond to a financial instrument's relative liquidity in the market or to its level of risk.

The fair value of alternative investments is reported based on information provided by the respective alternative investment funds' managers. The alternative investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the fund's underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of the Center's interest therein, its classification in level 2 or 3 is based on the Center's ability to redeem its interest at or near the balance sheet date. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

See note 4, Investments, Board-Designated Investments, Restricted Investments, and Trustee-Held Funds, for a summary of the inputs used as of June 30, 2013, in determining the fair value of the Center's investments. See note 13, Fair Value Measurements and the Fair Value Option, for fair value disclosures.

(q) Fair Value Option

FASB ASC Section 825, *Financial Instruments*, gives an entity the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument-by-instrument basis, with changes in fair value reported in change in net assets from operations. The Center has elected not to adopt the provisions of this standard for the years ended June 30, 2013 and 2012.

(r) Recent Accounting Pronouncements

In October 2012, the FASB issued ASU No. 2012-05, *Statement of Cash Flows (Topic 230): Not-for-Profit Entities: Classification of the Sale Proceeds of Donated Financial Assets in the Statement of Cash Flows*. ASU 2012-05 requires all cash receipts from the sale of donated financial assets to be classified as cash flows from operations with two exceptions related to donor limitations and restrictions. This standard will be effective for the Center's 2014 financial statements. The adoption of this standard is not expected to have a material impact on the Center's financial statements.

(3) Due from Government Agencies

The Center incurs facilities and administrative (F&A) costs to support its research activities. Research programs are charged for these costs through an F&A cost rate, which is applied to modified total direct research costs. Both direct and F&A costs are recovered by the Center from research programs supported by federal and other grant revenue.

The provisional federal F&A rate for grant and contract supported programs is determined by prospective negotiation with the Department of Health and Human Services (DHHS) based on an estimate of the costs that will be incurred during the period to which the rate applies. Any difference between the costs recovered through the provisional F&A cost rate and actual F&A costs incurred represents an estimated F&A settlement with the federal government, which will be included in future rates. No estimated settlement was recorded as of June 30, 2013 or 2012.

(4) Investments, Limited Use Investments, Board-Designated Investments, Other Restricted Investments, and Trustee-Held Funds

(a) Return Objectives and Risk Parameters

The Center has adopted investment and spending policies for its endowment that will provide resources to programs supported by the endowment. The endowment includes those assets of donor-restricted funds that the Center must hold in perpetuity as well as certain board-designated investments. Under this policy, as approved by the Center's board of trustees, the primary objective of the investment of the endowment is to provide a rate of total return, including all gains and losses, realized and unrealized, which exceeds the rate of inflation (as represented by the Consumer Price

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

Index-All Urban Consumers) plus 5% over the long term. The Center defines the long term as five years and more. Consistent returns are to be emphasized over individual year results, although the possibility of loss in a given year cannot be ignored. The endowment should experience risk (volatility and variability of return) no greater than that of the market. The Center defines the market as the portfolio's asset allocation policy applied to the Russell 3000 Index, the Morgan Stanley Capital Europe, Australia, Far East (EAFE) Index or its equivalent, and the iShares Barclays Aggregate Bond Index.

(b) *Strategies Employed for Achieving Objectives*

The Center relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends) to achieve its long-term rate of return objectives. The Center utilizes an efficient frontier approach to establish the appropriate asset allocation balancing long-term return objectives within prudent risk constraints. The Finance Committee of the Center's board of trustees reviews the Center's asset allocation at least once a year.

(c) *Spending Policies and How the Investment Objectives Relate to Spending Policies*

The Center's spending policy for endowment funds is to appropriate for distribution each year 5% of the endowment fund's average fair value over the prior three years, provided that the fair value of the endowment fund exceeds the corpus. For a portion of the Center's board-designated investments, the Center does not appropriate for distribution any amount of investment return as all of the return earned is held to grow the fund for future repayment of long-term debt. For the remaining board-designated investments, the Center makes all investment return available for expenditure to support research. In establishing these policies, the Center considered the long-term expected returns on its endowment and board-designated investments.

(d) *Funds with Deficiencies*

Unless otherwise agreed with the donor, the Center's policy has been to maintain the value of the original corpus of each individual donor-restricted endowment fund. From time to time, the fair value of assets in such endowment funds may fall below this level or such other level as may have been agreed to by the donor or required by law. Losses on the investments of a donor-restricted endowment fund reduce temporarily restricted net assets to the extent that donor-imposed restrictions on net appreciation of the fund have not been met before a loss occurs and any remaining loss reduces unrestricted net assets. As of June 30, 2013 and 2012, the aggregate reduction from unrestricted net assets totaled \$43 and \$300, respectively.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(e) Investments

The following table summarizes the Center's investments (excluding trustee-held funds and equity method investments) by major category, as well as related strategy, liquidity, and funding commitment as of June 30 (in thousands):

	<u>June 30, 2013</u>	<u>June 30, 2012</u>	<u>Redemption or liquidation</u>	<u>Days notice</u>	<u>Unfunded commitment</u>
Long-term investment strategies:					
Fixed income and debt securities:					
U.S. Treasuries and agencies	\$ 1,426	1,967	Daily	One	N/A
Treasury inflation-protected index fund	149	147	Daily	One	N/A
Mortgage-backed securities	1,528	1,841	Daily	One	N/A
Collateralized mortgage obligations	387	351	Daily	One	N/A
Asset-backed securities	258	367	Daily	One	N/A
Municipal obligations	105	221	Daily	One	N/A
U.S. corporate bonds	1,073	1,303	Daily	One	N/A
Private placements	98	105	Daily	One	N/A
Foreign currency exchange fund	—	102	Daily	One	N/A
U.S. and global intermediate term bond fund	199	6,068	Daily	One	N/A
Short-term bond fund	5,182	561	Daily	One	N/A
Intermediate-term bond fund	2,053	—	Daily	One	N/A
Nontraditional bond fund	1,973	—	Daily	One	N/A
High-yield bond fund	252	400	Daily	One	N/A
Other bond funds	811	585	Daily	One	N/A
Total	<u>15,494</u>	<u>14,018</u>			
Domestic equities:					
Large cap growth	5,579	5,158	Daily	One	N/A
Equity index funds	1,782	158	Daily	One	N/A
Large cap growth funds	—	116	Daily	One	N/A
Large cap value funds	6,205	5,632	Daily	One	N/A
Large cap blend funds	—	1,058	Daily	One	N/A
Mid cap growth funds	—	98	Daily	One	N/A
Small cap growth funds	2,155	2,028	Monthly	30	N/A
Total	<u>15,721</u>	<u>14,248</u>			

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	June 30, 2013	June 30, 2012	Redemption or liquidation	Days notice	Unfunded commitment
Global (ex-U.S.) equities:					
Developed markets	\$ 157	478	Daily	One	N/A
Developed markets funds	6,289	7,566	Daily	One	N/A
Emerging markets growth funds	3,294	4,425	Monthly	30	N/A
Emerging markets diversified funds	2,455	3,686	Daily	One	N/A
Emerging markets small cap funds	2,156	—	Monthly	60	N/A
Emerging markets index funds	385	—	Daily	One	N/A
Large cap blend funds	4,657	4,372	Monthly	15	N/A
Large cap blend funds	1,981	1,723	Daily	One	N/A
World allocation funds	7,198	4,101	Daily	One	N/A
Global index funds	841	—	Daily	One	N/A
American depositary receipt	55	—	Daily	One	N/A
Natural resources funds	203	—	Daily	One	N/A
	<u>29,671</u>	<u>26,351</u>			
Total					
Hedged equities:					
Global long/short	2,768	2,449	Quarterly	45	N/A
Global long/short	1,198	988	Quarterly	60	N/A
Global long/short	1,353	1,098	Annually	60	N/A
U.S. long/short	1,362	1,187	Quarterly	30	N/A
U.S. long/short	1,261	1,055	Quarterly	45	N/A
U.S. long/short	1,175	1,105	Quarterly	60	N/A
U.S. long/short	2,697	1,052	Annually	45	N/A
U.S. long/short	—	959	Annually	60	N/A
U.S. long/short	1,125	1,009	Annually	184	N/A
Multistrategy event driven	—	397	Note (1)	Note (1)	N/A
Multistrategy event driven	2,359	2,091	Quarterly	45	N/A
Multistrategy event driven	1,534	1,810	Quarterly	60	N/A
Multistrategy event driven	2,156	1,974	Annually	45	N/A
Multistrategy distressed credit	288	—	Illiquid	N/A	N/A
Multistrategy distressed credit	2,167	1,782	Quarterly	45	N/A
Multistrategy distressed credit	1,848	1,630	Every 2 years	90	N/A
Multistrategy value opportunistic	5,788	4,742	Annually	90	N/A
Multistrategy value opportunistic	2,446	2,021	Every 2 years	60	N/A
World bond funds	—	255	Daily	One	N/A
Long/short equity funds	—	56	Daily	One	N/A
	<u>31,525</u>	<u>27,660</u>			
Total					

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	<u>June 30, 2013</u>	<u>June 30, 2012</u>	<u>Redemption or liquidation</u>	<u>Days notice</u>	<u>Unfunded commitment</u>
Private equity and venture capital funds	\$ 6,450	6,973	Monthly	30	N/A
Private equity and venture capital funds	3,184	2,834	Quarterly	90	—
Private equity and venture capital funds	4,811	6,405	Illiquid (2)	N/A	Note (8)
Private equity and venture capital funds	1,838	2,120	Illiquid (3)	N/A	Note (9)
Private equity and venture capital funds	<u>6,708</u>	<u>6,110</u>	Illiquid (4)	N/A	Note (10)
Total	<u>22,991</u>	<u>24,442</u>			
Real assets:					
Global inflation hedged assets	8,027	9,029	Monthly	10	N/A
Commodity index fund	145	54	Daily	One	N/A
Commodity funds	249	143	Daily	One	N/A
Real estate fund	<u>51</u>	<u>45</u>	Daily	One	N/A
Total	<u>8,472</u>	<u>9,271</u>			
Other equity securities	5,748	7,879	Illiquid (5)	N/A	N/A
Other real and personal property	721	721	Illiquid (6)	N/A	N/A
Collateral posted with counterparty	—	3,200	Note (7)	N/A	N/A
Cash and cash equivalents	<u>12,631</u>	<u>20,628</u>	Daily	One	N/A
Total investments	<u>\$ 142,974</u>	<u>148,418</u>			

- (1) This item was liquidated in 2012; remaining balance is held in side pocket investments and 5% holdback was received in 2013.
- (2) These limited partnerships are expected to liquidate within 1 year.
- (3) These limited partnerships are expected to liquidate within 2 – 3 years.
- (4) These limited partnerships are expected to liquidate within 4 – 5 years.
- (5) Shares held in a nonpublic entity.
- (6) This item consists primarily of artwork that cannot be sold until 2030.
- (7) This item represents cash posted with counterparty on cash flow hedge transactions.
- (8) \$409 unfunded commitment in 2013, \$633 unfunded commitment in 2012.
- (9) \$84 unfunded commitment in 2013, \$141 unfunded commitment in 2012.
- (10) \$610 unfunded commitment in 2013, \$1,411 unfunded commitment in 2012.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

The financial statement captions included in the investment detail above as of June 30 were as follows (in thousands):

	<u>2013</u>	<u>2012</u>
Limited use investments	\$ 8,168	15,152
Investments	10,590	12,153
Board-designated investments	94,195	91,093
Restricted investments	<u>30,021</u>	<u>30,020</u>
	<u>\$ 142,974</u>	<u>148,418</u>

At June 30, 2013 and 2012, the Center had approximately \$14,000 and \$23,000, respectively, in investments that are not readily marketable. These are investments for which liquidation is at the discretion of the fund manager. These investments represent 10% and 16% of total investments and 6% and 10% of net assets at June 30, 2013 and 2012, respectively. These investment instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of regulatory oversight, dependence upon key individuals, emphasis on speculative investments (both derivatives and nonmarketable investments), and nondisclosure of portfolio composition. Because of these risks, the recorded value for these investments may differ from the value that would have been used had a ready market for such investments existed. Such differences could be material.

The Center has funds invested in 30 limited partnerships and companies with ownership interests ranging from 0.01% to 4.58% at June 30, 2013 and 2012. In 2013, three of these partnerships are venture capital funds, four are private equity, eighteen are hedge funds, three are debt funds, and two are real estate funds.

The Center's restricted investments contain endowment funds with donor restrictions for a variety of purposes. The Center's board-designated investments include funds designated by the board of trustees to function as endowments. The board of trustees may also periodically remove designations on funds previously designated. As required by GAAP, net assets associated with endowment funds, including funds designated by the board of trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

The following tables show the net asset composition of the Center's endowment funds by type of fund as of June 30, 2013 and 2012:

	<u>2013</u>			
	<u>Unrestricted</u>	<u>Temporarily restricted</u>	<u>Permanently restricted</u>	<u>Total</u>
Donor-restricted endowment funds	\$ (43)	2,735	27,286	29,978
Board-designated endowment funds	<u>85,669</u>	<u>8,570</u>	<u>—</u>	<u>94,239</u>
Total	<u>\$ 85,626</u>	<u>11,305</u>	<u>27,286</u>	<u>124,217</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2012			
	Unrestricted	Temporarily restricted	Permanently restricted	Total
Donor-restricted endowment funds	\$ (300)	1,197	25,623	26,520
Board-designated endowment funds	88,270	3,123	—	91,393
Total	<u>\$ 87,970</u>	<u>4,320</u>	<u>25,623</u>	<u>117,913</u>

The following tables show the activity that has occurred within the endowment net asset accounts for the years ended June 30, 2013 and 2012:

	2013			
	Unrestricted	Temporarily restricted	Permanently restricted	Total
Endowment net assets, beginning of year	\$ 87,970	4,320	25,623	117,913
Investment return:				
Investment income	1,134	414	—	1,548
Net realized gain	1,994	761	—	2,755
Net unrealized gain (loss)	5,801	1,792	—	7,593
Total investment return	8,929	2,967	—	11,896
Contributions	—	5,050	1,663	6,713
Distributions	(7,681)	—	—	(7,681)
Board transfers in	408	—	—	408
Board transfers out	(4,000)	—	—	(4,000)
Appropriation of endowment assets for expenditure	—	(1,032)	—	(1,032)
Endowment net assets, end of year	<u>\$ 85,626</u>	<u>11,305</u>	<u>27,286</u>	<u>124,217</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2012			Total
	Unrestricted	Temporarily restricted	Permanently restricted	
Endowment net assets, beginning of year	\$ 63,734	6,244	24,252	94,230
Investment return:				
Investment income	1,076	338	—	1,414
Net realized gain	20	4	—	24
Net unrealized gain (loss)	<u>(2,715)</u>	<u>(999)</u>	<u>—</u>	<u>(3,714)</u>
Total investment return	(1,619)	(657)	—	(2,276)
Contributions	244	31	1,371	1,646
Distributions	—	—	—	—
Board transfers in	25,782	—	—	25,782
Board transfers out	(171)	—	—	(171)
Appropriation of endowment assets for expenditure	<u>—</u>	<u>(1,298)</u>	<u>—</u>	<u>(1,298)</u>
Endowment net assets, end of year	\$ <u>87,970</u>	<u>4,320</u>	<u>25,623</u>	<u>117,913</u>

The components of trustee-held funds and the purposes for which they are being held as of June 30 are as follows:

	2013	2012
Trustee-held funds:		
Cash equivalents	\$ 2,437	18,639
U.S. government and agency obligations	8,919	9,245
Corporate bonds	<u>1,679</u>	<u>1,739</u>
	\$ <u>13,035</u>	<u>29,623</u>
Purpose for which funds are held:		
Series 2012B Bond Project Fund	\$ 2,433	—
Series 2011C Bond Project Fund	—	18,526
Series 2011B Cost of Issuance	—	17
Series 2011C Cost of Issuance	—	80
Debt service reserve funds	<u>10,602</u>	<u>11,000</u>
	\$ <u>13,035</u>	<u>29,623</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

Components of investment income for the years ended June 30 are as follows:

	<u>2013</u>	<u>2012</u>
Interest	\$ 1,975	2,314
Dividends	1,807	1,807
Net realized gains (losses)	5,066	(22)
Equity in earnings of SCCA investment	<u>2,648</u>	<u>10,540</u>
	11,496	14,639
Less investment management fees	<u>(834)</u>	<u>(667)</u>
	<u>\$ 10,662</u>	<u>13,972</u>

(5) Land, Buildings, and Equipment

Summaries of land, buildings, and equipment at cost as of June 30 are as follows:

	<u>2013</u>	<u>2012</u>
Land	\$ 52,389	52,389
Buildings and improvements	463,599	380,209
Equipment	184,612	172,996
Construction in progress	<u>12,674</u>	<u>75,401</u>
	713,274	680,995
Less accumulated depreciation	<u>(347,399)</u>	<u>(324,915)</u>
	<u>\$ 365,875</u>	<u>356,080</u>

Buildings are depreciated on a straight-line basis over 45 years, while improvements and equipment are depreciated over 3 to 30 years, depending on the nature of the asset. Interest expense on borrowed funds during construction is a component of the cost of assets. The amount capitalized represents interest on funds expended for construction. Capitalization of interest ceases when the asset is placed in service. The Center capitalized \$949,000 and \$3,488,000 and of interest in 2013 and 2012, respectively.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(6) Notes and Pledges Receivable

Components of notes and pledges receivable as of June 30 are as follows:

	<u>2013</u>	<u>2012</u>
Amounts due in:		
Less than one year	\$ 2,537	3,365
One to five years	3,318	4,460
Less:		
Unamortized discount	(65)	(102)
Allowance for uncollectible pledges	<u>(2,306)</u>	<u>(2,454)</u>
Notes and pledges receivable, net	<u>\$ 3,484</u>	<u>5,269</u>

As of June 30, 2013 and 2012, the notes and pledges receivable balances include pledges with a donor-restricted purpose of \$3,002 and \$4,615, respectively. The discounts on those amounts are computed at the rate commensurate with the risks applicable to the year in which the promise is received. Pledges have been discounted using a rate ranging from 2.5% to 5%.

(7) Long-Term Debt

Summaries of long-term debt as of June 30 are as follows:

	<u>2013</u>	<u>2012</u>
Series 2007 Revenue Bonds at a fixed interest rate of 4.72% secured by a deed of trust due in amounts ranging from \$145 in 2014 to \$4,359 in 2015	\$ 4,504	4,643
Series 2009A Revenue Bonds at fixed interest rates ranging from 3.50% to 6.00% secured by a deed of trust due in amounts ranging from \$2,895 in 2014 to \$4,930 in 2033	106,870	109,715
Series 2010 Revenue Bonds at a variable interest rate averaging 1.48% and 1.50% for the years ended June 30, 2013 and 2012 secured by a deed of trust due in amounts ranging from \$926 in 2014 to \$2,228 in 2032	28,278	29,160
Series 2011A Revenue Bonds at fixed interest rates ranging from 0.50% to 6.00% secured by a deed of trust due in amounts ranging from \$965 in 2014 to \$4,795 in 2035	82,895	83,650
Series 2011B Revenue Bonds at a variable interest rate averaging 0.15% secured by a deed of trust due in amounts ranging from \$6,100 in 2035 to \$9,130 in 2041	—	57,525
Series 2011C Revenue Bonds at a variable interest rate averaging 0.16% secured by a deed of trust due in amounts ranging from \$8,325 in 2035 to \$13,530 in 2041	—	84,500

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	<u>2013</u>	<u>2012</u>
Series 2012A Revenue Bonds at a variable interest rate averaging 1.26% for the period ended June 30, 2013 secured by a deed of trust due in amounts ranging from \$6,110 in 2035 to \$9,165 in 2041	\$ 57,685	—
Series 2012B Revenue Bonds at a variable interest rate averaging 1.29% for the period ended June 30, 2013 secured by a deed of trust due in amounts ranging from \$8,355 in 2035 to \$13,578 in 2041	<u>84,800</u>	—
	365,032	369,193
Unamortized bond (discount)	<u>(1,516)</u>	<u>(1,419)</u>
	\$ <u>363,516</u>	\$ <u>367,774</u>
Fair value disclosure (note 13)	\$ 387,398	410,325

On August 30, 2012, the Center issued through the Washington Health Care Facilities Authority (the Authority) \$57,685 of tax-exempt revenue bonds Series 2012A (2012A Bonds) and an \$84,800 tax-exempt revenue bond Series 2012B (2012B Bond). The 2012A Bonds are variable rate bonds used to refund the 2011B bonds. The 2012A Bonds were issued under a private placement with JP Morgan Chase Bank, N.A. The 2012B Bond is a variable rate bond used to refund the 2011C Bonds. The 2012B Bond was issued under a private placement with Bank of America, N.A. and all interest and principal payments are made directly to the bank.

On June 30, 2011, the Center issued through the Authority \$84,150 of tax-exempt revenue bonds Series 2011A (2011A Bonds), \$57,525 of tax-exempt revenue bonds Series 2011B (2011B Bonds) and \$84,500,000 of tax-exempt revenue bonds Series 2011C (2011C Bonds). The 2011A Bonds are fixed rate bonds issued under the Center's credit rating with interest rates ranging from 0.50% to 6.00% used to refund a portion of the 2001A Bonds and the 2009B Bonds. The 2011B Bonds are variable rate bonds used to refund a portion of the 2001A Bonds and the 2009B Bonds, and fund most of the repayment of a bridge loan used to acquire the 1100 Eastlake Building. The 2011C Bonds are variable rate bonds used to refund a portion of the 2001A Bonds and the 2009B Bonds, fund the remainder of the bridge loan repayment and fund the alterations to be made to the 1100 Eastlake Building.

With the issuance of the 2011B Bonds, the Center entered into a reimbursement agreement with JP Morgan Chase Bank, N.A. to provide an irrevocable direct pay letter of credit to secure payment of principal and interest on the 2011B Bonds. The direct pay letter of credit provides security on the 2011B Bonds. The direct pay letter of credit was terminated when the 2011B Bonds were refinanced on August 30, 2012. Remaining financing costs associated with the issuance of the 2011B Bonds were expensed in 2013.

With the issuance of the 2011C Bonds, the Center entered into a reimbursement agreement with Bank of America, N.A. to provide an irrevocable direct pay letter of credit to secure payment of principal and interest on the 2011C Bonds. The direct pay letter of credit provides security on the 2011C Bonds. The

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

direct pay letter of credit was terminated when the 2011C bonds were refinanced on August 30, 2012. Remaining costs associated with the issuance of the 2011C Bonds were capitalized in 2013.

On November 24, 2009, the Center issued through the Authority \$114,920 of tax-exempt revenue bonds Series 2009A (2009A Bonds). The 2009A Bonds are fixed rate bonds issued under the Center's credit rating with interest rates ranging from 3.50% to 6.00% and were used to refund the 2001B Bonds and 2002 Bonds.

On November 15, 2007, the Center issued through the Authority \$5,200 of tax-exempt revenue bonds Series 2007 (2007 Bonds). The 2007 Bonds are fixed rate bonds used to reimburse the Center for the purchase of property on the Center's campus. The deed of trust only secures this specific property on the Center's campus.

On November 4, 2010, the Center issued through the Authority a \$30,000 tax-exempt revenue bond Series 2010 (2010 Bond). The 2010 Bond is a variable rate bond used to purchase the Yale Building from National Healthcare Research and Education Finance Corporation (NHREFCO) (see note 11). The 2010 Bond was issued under a private placement with JP Morgan Chase Bank, N.A. and all interest and principal payments are made directly to the bank.

The bond documents for the 2009A Bonds, 2010 Bond, 2011A Bonds, 2011B Bonds, 2011C Bonds, 2012A Bonds and 2012B Bond have covenants that require the Center to provide to the Authority, pursuant to a deed of trust, a mortgage and security interest in substantially all of the real estate and improvements owned by the Center, a security interest in the funds held by the trustees, and in the gross receivables and equipment owned by the Center. The bond documents for the 2011B Bonds and 2011C Bonds require the Center to maintain unrestricted and unencumbered cash, cash equivalents, and marketable debt and equity securities of at least 75 days of cash operating expenses less subaward expenses and net income available for debt service must exceed 150% of the debt service in the same year. The bond documents for the 2012A Bonds and 2012B Bond require the Center to maintain unrestricted and unencumbered cash, cash equivalents, and marketable debt and equity securities of at least 80 days of cash operating expenses less subaward expenses and net income available for debt service must exceed 150% of the debt service in the same year. The bond documents for the 2009A Bonds require the establishment and maintenance of a debt service reserve fund. Additional covenants include a restriction on the creation of additional liens on the Center's property, a restriction on the issuance of additional debt, and a requirement that net income available for debt service must exceed 125% of the debt service in the same year.

The following schedule shows future long-term maturities by year (in thousands):

2014	\$	4,931
2015		9,461
2016		5,366
2017		5,777
2018		6,155
Thereafter		333,342
	\$	<u>365,032</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(8) Retirement Plan

The Center has a defined-contribution plan for its salaried employees. Employees are generally eligible after one year of service. The Center contributes 7% of each eligible employee's compensation up to the Social Security wage base limit and 12% on compensation above the limit. For certain management employees, the Center contributes 10% of compensation up to the Social Security wage base limit and 15% above the limit.

Retirement plan expense for the years ended June 30, 2013 and 2012 was \$13,207 and \$12,798, respectively.

(9) Perpetual Trusts and Charitable Remainder Trusts

The Center is the beneficiary of irrevocable perpetual trusts and charitable remainder trusts for which the Center is not the trustee. These funds held in trust by others represent resources neither in the possession nor under the control of the Center and are administered by outside trustees. When the Center is notified of the existence of an irrevocable perpetual trust, the Center recognizes its beneficial interest in the outside trust at fair value as a contribution. The contribution is classified as an increase in permanently restricted net assets based on restrictions placed by the donor. The changes in the fair value of the irrevocable perpetual trusts are reflected as investment changes restricted by donors, in permanently restricted net assets on the statements of activity.

When the Center is notified of an irrevocable charitable remainder trust for which it is not the trustee, the Center recognizes its beneficial interest in the outside trust as a contribution at fair value, which is measured as the present value of the estimated expected future benefits to be received. The contribution is classified as an increase in temporarily restricted net assets based on restriction placed by the donor upon the Center's beneficial interest in the assets. Periodic adjustments recorded to the beneficial interest to reflect changes in the fair value, life expectancy, and discount rate are recognized based on information from outside trustees. Any charitable remainder trusts for which the Center is not the trustee are reflected as a receivable from trusts and are included in other receivables in the accompanying consolidated balance sheets. These amounts as of June 30, 2013 and 2012 were \$1,849 and \$6,567, respectively.

(10) Annuities

The Center administers, through a third party, gift annuities for which it is obligated to make periodic distributions to designated beneficiaries. When contributed assets are initially received, the assets are recorded at fair value within the investments balance, and contribution revenue is recorded equal to the value of the contributed assets received less the annuity liability. The present value of the payments due to the beneficiaries totaled \$4,344 and \$4,474 at June 30, 2013 and 2012, respectively. The annuity liability is revalued annually based upon actuarially computed present values. Present values are based on expected life expectancy of the annuitant and discount rates range between 4% and 10%. The Center maintains segregated funds that exceed the actuarial value of the annuity liability as required by state law. The gift annuity payable is recorded in accrued liabilities.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(11) Commitments and Contingencies

(a) Operating Leases

Certain equipment and facilities utilized by the Center in its operations are leased. The related future minimum rental payments for these operating leases with noncancelable terms in excess of one year as of June 30, 2013 are as follows:

2014	\$	3,847
2015		3,098
2016		2,588
2017		2,647
2018		1,660
Thereafter		7,755
	\$	<u>21,595</u>

Rental expense for all operating leases for the years ended June 30, 2013 and 2012 was \$4,866 and \$8,348, respectively.

In conjunction with purchase and renovation of office and lab space in the 1100 Eastlake Building, the Center gave notice on March 31, 2011 of its intent to terminate its lease obligation for the 1616 Eastlake Building. Under the terms of the operating lease, beginning on October 1, 2012, the Center reduced the amount of space leased from approximately 106,000 net rentable square feet to approximately 40,000 net rentable square feet. However, the lease term for most of the 40,000 net rentable square feet is extended through September 30, 2017. On May 11, 2012, the Center entered into a lease amendment to reduce the amount of space leased by approximately 13,000 net rentable square feet to approximately 27,000 net rentable square feet. The Center expects to continue to utilize the office portion of this space and has subleased the lab portion of this space as of June 30, 2013.

In 2011, the Center recorded a payable for \$3,101 and an expense associated with the anticipated shortfall to be generated from sublease revenue compared with the obligated lease payments included in the amounts shown above. In 2012, the payable was reduced to \$1,351 to reflect modifications to future cash flows resulting from the May 11, 2012 amendment and the sublease of a portion of the remaining leased space.

(b) Litigation and Compliance with Laws and Regulations

The Center is involved in litigation and regulatory investigations arising in the normal course of its business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the Center's future financial position or results from operations.

The research industry is subject to numerous federal, state, and local laws and regulations. Some of these laws govern licensure, accreditation, and government program participation requirements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

Government agencies are actively conducting investigations concerning possible violations of these statutes and regulations by research facilities. Violations of these laws and regulations could result in expulsion from government programs, together with the imposition of significant fines and penalties. Management believes that the Center is in material compliance with all applicable laws and regulations. Compliance with laws and regulations is subject to future government review and interpretation of such laws and regulations as well as regulatory actions unknown or unasserted at this time.

(c) *Contingent Liability*

The Center received federal grant funding for a portion of the construction of its South Lake Union Campus. Because the Center received federal grant funding for a portion of this facility, the government retains an interest in the net proceeds received if the facility is sold. The Center has not recorded any liability related to this interest as it is contingent upon the sale of the facility, and management has determined the probability of this transaction occurring to be remote.

(d) *United States Department for International Development (USAID) Grant*

The USAID awarded a construction grant of \$500 to the Center to begin to build a new research and medical facility for UPCID in Kampala, Uganda. The grant has a cost-share arrangement that requires the Center to fund an additional \$900 during the grant award period. Construction began in fiscal year 2013 and is expected to be completed in fiscal year 2014 at a total project cost of \$9,100.

(12) Professional Liability Insurance

The Center has claims-made professional and general liability insurance for 2013 and 2012. The Center has accrued an actuarial estimate of unreported instances and claims as of June 30, 2013, which is included in accounts payable.

(13) Fair Value Measurements and the Fair Value Option

(a) *Fair Value Calculation Methodology*

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:

Cash and Cash Equivalents – The carrying amount (cost) approximates fair value because of the short maturity of those instruments.

Investments and Trustee-Held Funds – Investments in equity and debt securities, trustee-held funds, beneficial interest in charitable remainder trusts and perpetual trusts are measured at fair value based on quoted market prices, if available, or estimated using quoted market prices for similar securities. Alternative investments are measured at fair value based on each fund's net asset value as a practical expedient. Other equity securities, which are shares held in a nonpublic entity, are measured at fair value based on management's valuation model. Management's model utilizes data and assumptions that are not observable to market participants.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

Long-Term Debt – The carrying amount of long-term debt with variable interest rates approximates fair value because interest rates are adjusted either daily or weekly for the variable rate demand bonds. The carrying amount of the fixed rate debt is calculated based upon the net present value of the future cash outflows of the associated fixed rate debt discounted at the interest rates in effect as of June 30, 2013.

Cash Flow Hedges – The carrying amounts of the interest rate swaps are at estimated fair values based on the net present value of the associated variable cash flows, adjusted for the Center’s and the respective counterparty’s nonperformance risk.

(b) Fair Value Hierarchy

The following tables present assets and liabilities that are measured at fair value on a recurring basis (including items that are required to be measured at fair value and items for which the fair value option has been elected) at June 30, 2013 and 2012 (in thousands):

	2013			
	June 30, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Investments:				
Long-term investment strategies:				
Fixed income and debt securities:				
U.S. Treasuries and agencies	\$ 1,426	—	1,426	—
Treasury inflation-protected index fund	149	—	149	—
Mortgage-backed securities	1,528	—	1,528	—
Collateralized mortgage obligations	387	—	387	—
Asset-backed securities	258	—	258	—
Municipal obligations	105	—	105	—
U.S. corporate bonds	1,073	—	1,073	—
Private placements	98	—	—	98
Foreign currency exchange fund	—	—	—	—
U.S. and global intermediate-term bond fund	199	199	—	—
Short-term bond fund	5,182	5,182	—	—
Intermediate-term bond fund	2,053	2,053	—	—
Nontraditional bond fund	1,973	1,973	—	—
High-yield bond fund	252	252	—	—
Other bond funds	811	344	467	—
Total	15,494	10,003	5,393	98

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2013			
	June 30, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Domestic equities:				
Large cap growth	\$ 5,579	5,579	—	—
Equity index funds	1,782	—	1,782	—
Large cap value funds	6,205	6,205	—	—
Small cap growth funds	2,155	2,155	—	—
Total	<u>15,721</u>	<u>13,939</u>	<u>1,782</u>	<u>—</u>
Global (ex-U.S.) equities:				
Developed markets	157	157	—	—
Developed markets funds	6,289	6,289	—	—
Emerging markets growth funds	3,294	—	3,294	—
Emerging markets diversified funds	2,455	2,455	—	—
Emerging markets small cap funds	2,156	2,156	—	—
Emerging markets small cap funds	385	—	385	—
Large cap blend funds	6,638	1,981	4,657	—
World allocation funds	7,198	7,198	—	—
Global index fund	841	—	841	—
American depository receipt	55	55	—	—
Natural resources fund	203	—	203	—
Total	<u>29,671</u>	<u>20,291</u>	<u>9,380</u>	<u>—</u>
Hedged equities:				
Global long/short	5,319	—	2,768	2,551
U.S. long/short	7,620	—	3,798	3,822
Multistrategy event driven	6,049	—	2,359	3,690
Multistrategy distressed credit	4,303	—	2,167	2,136
Multistrategy value opportunistic	8,234	—	—	8,234
Total	<u>31,525</u>	<u>—</u>	<u>11,092</u>	<u>20,433</u>
Private equity and venture capital funds				
	22,991	—	6,450	16,541
Total	<u>22,991</u>	<u>—</u>	<u>6,450</u>	<u>16,541</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2013			
	June 30, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Real assets:				
Global inflation hedged assets	\$ 8,027	—	8,027	—
Commodity index fund	145	—	145	—
Commodity funds	249	249	—	—
Real estate fund	51	51	—	—
Total	<u>8,472</u>	<u>300</u>	<u>8,172</u>	<u>—</u>
Other equity securities	5,748	102	—	5,646
Other real and personal property	721	—	—	721
Cash and cash equivalents	12,631	12,631	—	—
Total investments	<u>\$ 142,974</u>	<u>57,266</u>	<u>42,269</u>	<u>43,439</u>
Other receivables:				
Beneficial interest in charitable remainder trusts	\$ 1,849	—	—	1,849
Beneficial interest in perpetual trusts	26,436	—	—	26,436
Trustee-held funds	13,035	2,437	10,598	—
Liabilities:				
Deferred credit on cash flow hedges	(30,235)	—	(30,235)	—

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2012			
	June 30, 2012	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Investments:				
Long-term investment strategies:				
Fixed income and debt securities:				
U.S. Treasuries and agencies	\$ 1,967	—	1,967	—
Treasury inflation-protected index fund	147	147	—	—
Mortgage-backed securities	1,841	—	1,841	—
Collateralized mortgage obligations	351	—	351	—
Asset-backed securities	367	—	367	—
Municipal obligations	221	—	221	—
U.S. corporate bonds	1,303	—	1,303	—
Private placements	105	—	—	105
Foreign currency exchange fund	102	—	102	—
U.S. and global intermediate-term bond fund	6,068	6,068	—	—
Short-term bond fund	561	561	—	—
High-yield bond fund	400	400	—	—
Other bond funds	585	535	—	50
Total	<u>14,018</u>	<u>7,711</u>	<u>6,152</u>	<u>155</u>
Domestic equities:				
Large cap growth	5,158	5,158	—	—
Equity index funds	158	158	—	—
Large cap growth funds	116	116	—	—
Large cap value funds	5,632	5,632	—	—
Large cap blend funds	1,058	1,058	—	—
Mid cap growth funds	98	98	—	—
Small cap growth funds	2,028	2,028	—	—
Total	<u>14,248</u>	<u>14,248</u>	<u>—</u>	<u>—</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2012			
	June 30, 2012	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Global (ex-U.S.) equities:				
Developed markets	\$ 478	478	—	—
Developed markets funds	7,566	7,566	—	—
Emerging markets growth funds	4,425	—	4,425	—
Emerging markets diversified funds	3,686	3,686	—	—
Large cap blend funds	6,095	1,723	4,372	—
World allocation funds	4,101	4,101	—	—
Total	<u>26,351</u>	<u>17,554</u>	<u>8,797</u>	<u>—</u>
Hedged equities:				
Global long/short	4,535	—	2,449	2,086
U.S. long/short	6,367	—	3,347	3,020
Multistrategy event driven	6,272	—	2,091	4,181
Multistrategy distressed credit	3,412	—	1,782	1,630
Multistrategy value opportunistic	6,763	—	—	6,763
World bond funds	255	255	—	—
Long/short equity funds	56	56	—	—
Total	<u>27,660</u>	<u>311</u>	<u>9,669</u>	<u>17,680</u>
Private equity and venture capital funds	24,442	—	6,973	17,469
Real assets:				
Global inflation hedged assets	9,029	—	9,029	—
Commodity index fund	54	54	—	—
Commodity funds	143	143	—	—
Real estate fund	45	45	—	—
Total	<u>9,271</u>	<u>242</u>	<u>9,029</u>	<u>—</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2012			
	June 30, 2012	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Other equity securities	\$ 7,879	—	—	7,879
Other real and personal property	721	—	—	721
Collateral posted with counterparty	3,200	3,200	—	—
Cash and cash equivalents	20,628	20,628	—	—
Total investments	\$ 148,418	63,894	40,620	43,904
Other receivables:				
Beneficial interest in charitable remainder trusts	\$ 7,567	—	—	7,567
Beneficial interest in perpetual trusts	25,566	—	—	25,566
Trustee-held funds	29,623	18,639	10,984	—
Liabilities:				
Deferred credit on cash flow hedges	(40,196)	—	(40,196)	—

The following tables presents the Center's activities for assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended June 30, 2013 and 2012 (in thousands):

	2013							
	Fixed income and debt securities	Hedged equities	Private equity and venture capital funds	Beneficial interests in perpetual trusts	Other equity securities	Other real and personal property	Beneficial interests in charitable trusts	Total
Beginning balance, July 1, 2012	\$ 155	17,680	17,469	25,566	7,879	721	7,567	77,037
Transfers into Level 3	20	—	—	—	—	—	—	20
Transfers out of Level 3	(79)	—	—	—	—	—	(4,827)	(4,906)
Net realized gains (losses)	6	591	351	—	—	—	—	948
Net unrealized gains (losses)	(3)	2,476	(130)	870	611	—	107	3,931
Purchases, issues, sales, and settlements:								
Purchases	198	—	1,184	—	—	—	(998)	384
Sales	(199)	(314)	—	—	(2,844)	—	—	(3,357)
Return of capital distribution	—	—	(2,333)	—	—	—	—	(2,333)
Ending balance, June 30, 2013	\$ 98	20,433	16,541	26,436	5,646	721	1,849	71,724

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

	2012							Total
	Fixed income and debt securities	Hedged equities	Private equity and venture capital funds	Beneficial interests in perpetual trusts	Other equity securities	Other real and personal property	Beneficial interests in charitable trusts	
Beginning balance, July 1, 2011	\$ 209	4,605	17,875	27,331	9,837	827	7,229	67,913
Transfers into Level 3	—	—	—	—	—	—	—	—
Transfers out of Level 3	(36)	—	—	—	—	—	—	(36)
Net realized gains (losses)	(5)	388	(950)	—	—	—	—	(567)
Net unrealized gains (losses)	(7)	(162)	466	(1,765)	(1,113)	(106)	(413)	(3,100)
Purchases, issues, sales, and settlements:								
Purchases	67	15,000	1,133	—	—	—	1,091	17,291
Sales	(73)	(2,151)	—	—	(845)	—	—	(3,069)
Return of capital distribution	—	—	(1,055)	—	—	—	(340)	(1,395)
Ending balance, June 30, 2012	\$ 155	17,680	17,469	25,566	7,879	721	7,567	77,037

Of the net unrealized gains included in net assets for the year ended June 30, 2013, \$870 is included in permanently restricted net assets, \$628 of net unrealized gain is included in temporarily restricted net assets, and \$2,433 is included in unrestricted net assets. Of the net unrealized losses included in net assets for the year ended June 30, 2012, \$1,765 is included in permanently restricted net assets, \$367 of net unrealized loss is included in temporarily restricted net assets, and \$968 is included in unrestricted net assets. The financial statements as of and for the year ended June 30, 2013 do not include any nonrecurring fair value measurements relating to assets or liabilities for which the Center has adopted the provisions of fair value accounting. All nonrecurring fair value measurements for 2013 and 2012 involved nonfinancial assets, and the Center will not adopt the provisions for nonrecurring fair value measurements involving nonfinancial assets and nonfinancial liabilities.

(14) Related-Party Transactions

In June 1998, the SCCA was formed. The SCCA is a joint venture between the University of Washington Academic Medical Center (UWMC), Children's Hospital and Regional Medical Center (now Seattle Children's Hospital (Seattle Children's)), and the Center. As a separately incorporated nonprofit corporation, the SCCA is organized for the purpose of developing and offering a comprehensive program of integrated cancer care services in the Northwest that will enhance the cancer research, teaching, and clinical programs of the Center, UWMC, and Seattle Children's. The SCCA is one of several Medicare-designated cancer hospitals in the United States. Members of the SCCA share equally in capital contributions and in the results of operations. The SCCA began operations in January 2001. The SCCA coordinates adult inpatient services with the UWMC and pediatric inpatient services with Seattle Children's, while operating its own ambulatory cancer care service facility. The Center is accounting for its investment in the SCCA under the equity method.

Under the terms of the Members' Agreement, the Center has certain financial obligations to the SCCA, including funding its share of capital contributions. From 1998 through 2001, the Center contributed a total of \$13,562 in cash capital contributions, which have been recorded as Investment in SCCA on the balance sheets. The Center's obligations to the SCCA were fully paid as of June 30, 2001. In addition, in 2001 the Center contributed its existing outpatient cancer care program valued at \$12,124, equipment, supplies, and

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

other assets valued at \$1,800, and a ground lease valued at \$3,600 to the SCCA. The Center records the amortization of these contributed assets for 2013 and 2012, in investment income.

The following is a summary of the SCCA's financial position and results as of and for the years ended June 30, 2013 and 2012 (in thousands):

	<u>2013</u>	<u>2012</u>
Assets	\$ 440,985	415,597
Liabilities	\$ 157,923	153,585
Net assets	<u>283,062</u>	<u>262,012</u>
Total liabilities and net assets	<u>\$ 440,985</u>	<u>415,597</u>
	<u>2013</u>	<u>2012</u>
Revenues	\$ 393,731	346,578
Less expenses	(363,819)	(324,716)
Plus nonoperating (loss) income	<u>(23,334)</u>	<u>8,502</u>
Excess of revenues over expenses	6,578	30,364
Net assets released from restriction for capital	85	145
Grant contributions restricted for capital acquisition	740	1,115
Net change in unrealized gains (losses) on investments	<u>13,253</u>	<u>(13,874)</u>
Increase in unrestricted net assets	<u>\$ 20,656</u>	<u>17,750</u>

The Center has entered into service agreements to provide support services to the SCCA. The service agreements are for administrative services, facilities usage, and patient care housing. The Center recognized \$12,340 and \$11,704 of other income for the years ended June 30, 2013 and 2012, respectively, as a result of these agreements.

The Center recognized other income (see below) for the years ended June 30, 2013 and 2012, respectively, for fees associated with licenses, data collection, and research and development services provided by the Center to the SCCA.

(15) Other Income

The Center has entered into inpatient service agreements with UWMC, Seattle Children's, and the SCCA through 2014 for which the Center receives various payments related to research and development support, data collection and analysis, physician assistant services, consulting services, and license rights to use the Center's name in connection with the inpatient cancer services program. Fees for services during the years ended June 30, 2013 and 2012 from UWMC total \$11,979 and \$12,225, respectively, from Seattle Children's total \$1,135 and \$1,072, respectively, and from the SCCA total \$6,203 and \$6,796,

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

respectively. Of these amounts, \$6,517 and \$6,557 are included in other receivables as of June 30, 2013 and 2012, respectively.

(16) Accounting for Derivative Instruments and Hedging Activities

Accounting principles require that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded on the balance sheet as either an asset or liability measured at its fair value. These principles require that changes in the derivative instrument's fair value be recognized currently.

(a) Initial Hedging Transactions

In July 1999, the Center entered into an interest rate swap associated with the Series 2000 variable rate bonds (Series 2000 Swap) to take advantage of favorable long-term fixed rates. The fixed interest rate paid by the Center was 5.19%. The notional amount (\$72,000) and the timing of principal and interest payments of the hedging transaction matched those of the Series 2000 Bonds.

The Center entered into two interest rate swaps associated with the Series 2001A variable rate bonds (Series 2001A Swaps), one in October 2000 and one in November 2001, to take advantage of favorable long-term fixed rates. In the October 2000 transaction, the notional amount was \$63,000 and the interest rate was fixed at 5.26%. In the November 2001 transaction, the notional amount was \$40,000 and the interest rate was fixed at 4.58%. The timing of principal and interest payments for both transactions was aligned with principal and interest payments on the Series 2001A Bonds.

(b) Replacement Swaps

In October 2008, the Center entered into two new interest rate swaps to replace the swaps that were terminated. One of the swaps is associated with the Series 2000 Bonds (Series 2000 Replacement Swap) and one is associated with the Series 2001A Bonds (Series 2001A Replacement Swap). The notional amount, timing of principal payments, and timing of interest payments for each of the Replacement Swaps are similar to the terms of the bonds with which they are associated. In the case of the Series 2000 Replacement Swap, the interest rate paid by the Center is fixed at 5.19% while the counterparty pays the Center an indexed rate plus 20 basis points. In the case of the Series 2001A Replacement Swap, the interest rate paid by the Center is fixed at 4.97% while the counterparty pays the Center an indexed rate plus 0.20%. Upon entering into the Replacement Swaps, the Center received a payment of \$7,150 for the Series 2000 Replacement Swap and \$7,690 for the Series 2001A Replacement Swap from the counterparty. These payments were recorded as deferred credits on cash flow hedges on the balance sheet. The fair value is the estimated amount the bank would receive or pay to terminate the swap agreement at the reporting date, taking into account current interest rates and the current creditworthiness of the swap counterparties. The fair value of the Series 2000 Replacement Swap included in liabilities was \$12,802 at June 30, 2013 and \$16,554 at June 30, 2012. The fair value of the Series 2001A Replacement Swap included in liabilities was \$17,433 at June 30, 2013 and \$23,642 at June 30, 2012. The fair value of the swap instruments will change in future time periods as interest rates change and as the time period remaining for the hedged transaction shortens. Provided that the Center holds the swaps to maturity, the value of the derivative will be zero.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2013 and 2012

(In thousands)

(c) *Amendment to Series 2001A Replacement Swap*

In May 2011, the Center amended the Series 2001A Replacement Swap to change the rate paid by the counterparty from a tax-exempt indexed rate plus 0.20% to 67% of three month LIBOR plus 0.64%. All other terms of the Series 2001A Replacement Swap, including notional amount, timing, and amount of principal payments remain unchanged.

(d) *Collateral Posted with Swap Counterparty*

The replacement swap agreements contain terms that require the Center to post collateral with the counterparty if the mark-to-market amount to terminate the Series 2000 Replacement Swap and the Series 2001A Replacement swap exceeds \$40,000. As of June 30, 2012, the Center posted collateral of \$3,200 with the counterparty, and this amount is included in other restricted investments. As of June 30, 2013, no collateral was needed nor posted with the counterparty.

(17) Subsequent Events

The Center evaluated subsequent events from June 30, 2013 to November 1, 2013, the date on which these financial statements were issued.



KPMG LLP
Suite 2900
1918 Eighth Avenue
Seattle, WA 98101

**Independent Auditors' Report on Internal Control Over Financial Reporting and
on Compliance and Other Matters Based on an Audit of Financial Statements
Performed in Accordance With *Government Auditing Standards***

The Board of Trustees
Fred Hutchinson Cancer Research Center:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Fred Hutchinson Cancer Research Center (the Center), which comprise the consolidated balance sheet as of June 30, 2013, and the related consolidated statements of activities, cash flows, and functional expenses for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated November 1, 2013.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Center's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Center's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

November 1, 2013



KPMG LLP
Suite 2900
1918 Eighth Avenue
Seattle, WA 98101

**Independent Auditors' Report on Compliance for Each Major Program;
Report on Internal Control Over Compliance; and Report on Schedule of
Expenditures of Federal Awards Required by OMB Circular A-133,
*Audits of States, Local Governments, and Non-Profit Organizations***

The Board of Trustees
Fred Hutchinson Cancer Research Center:

Report on Compliance for Each Major Federal Program

We have audited Fred Hutchinson Cancer Research Center's (the Center) compliance with the types of compliance requirements described in the *OMB Circular A-133 Compliance Supplement* that could have a direct and material effect on each of the Center's major federal programs for the year ended June 30, 2013. The Center's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the Center's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the Center's compliance.

Opinion on Each Major Federal Program

In our opinion, the Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal programs for the year ended June 30, 2013.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with OMB Circular A-133 and which are described in the accompanying schedule



of findings and questioned costs as items 2013-01 and 2013-02. Our opinion on the major federal program is not modified with respect to this matter.

The Center's responses to the noncompliance findings identified in our audit are described in the accompanying schedule of findings and questioned costs. The Center's responses were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of the Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Center's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by OMB Circular A-133

We have audited the consolidated financial statements of the Center as of and for the year ended June 30, 2013, and have issued our report thereon dated November 1, 2013, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by OMB Circular A-133 and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other



records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditure of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

November 1, 2013

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
Research and Development Cluster:					
Direct Grants – Department of Health and Human Services:					
NATIONAL CANCER INSTITUTE:					
N/A	ARRA – NCI CIS CONTRACT MOD #3 – SMOKING CESSATION	HHSN261201000004C	9/30/10	9/29/12	\$ 76,123
N/A	CDC/NCI IAA – SMOKING CESSATION COUNSELING	HHSN261201000004C	9/20/12	9/19/13	806,470
N/A	CIRCULATING VITAMIN D LEVELS AND RISK OF BREAST AND COLORECTAL CANCER: A POOLED ANALYSIS	SCC13-028533	2/1/13	6/30/13	12,494
N/A	INTERGOVERNMENTAL PERSONNEL AGREEMENT (IPA)	NBS 1783968	7/1/12	6/30/13	93,893
N/A	MANUSCRIPT DEVELOPMENT FOR HEAL STUDY OF BREAST CANCER PROGNOSIS	HHSN261201100487P	9/15/11	9/14/12	25,299
N/A	MANUSCRIPT DEVELOPMENT FOR HEAL STUDY OF BREAST CANCER PROGNOSIS	HHSN261201200401P	9/17/12	9/16/13	48,401
N/A	NATIONAL CANCER INSTITUTE'S CONTACT CENTER	HHSN261201000004C	12/1/11	11/30/12	2,921,469
N/A	NATIONAL CANCER INSTITUTE'S CONTACT CENTER	HHSN261201000004C	12/1/12	4/30/13	3,100,622
N/A	NATIONAL CANCER INSTITUTE'S CONTACT CENTER	HHSN261201000004C	5/1/13	10/31/13	1,017,051
N/A	YR 3 – SEER: SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM	HHSN261201000029C	8/1/10	9/29/13	3,290,232
93.310	STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF ENGINEERED HOMING ENDONUCLEASES	RL1 CA133833	7/1/11	6/30/13	108,034
93.393	A COHORT STUDY OF SESSILE SERRATED POLYPS AND SUBSEQUENT COLORECTAL NEOPLASIA	R01 CA168338	4/22/13	3/31/14	14,416
93.393	A MULTISTATE STUDY OF CANCER TREATMENT AND OUTCOME AMONG AMERICAN INDIANS	R01 CA125231	8/1/11	7/31/12	17,532
93.393	A MULTISTATE STUDY OF CANCER TREATMENT AND OUTCOME AMONG AMERICAN INDIANS	R01 CA125231	8/1/12	7/31/14	181,507
93.393	A POOLED ANALYSIS OF RISK FACTORS OF SMALL INTESTINE CANCER	R03 CA150038	8/1/11	7/31/12	4,630
93.393	A PROSPECTIVE STUDY OF COLORECTAL CANCER: ONE-CARBON METABOLISM AND INFLAMMATION	R01 CA120523	2/1/12	1/31/14	485,870
93.393	ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	R01 CA151251	5/1/11	4/30/12	607
93.393	ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	R01 CA151251	5/1/12	4/30/13	593,591
93.393	ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	R01 CA151251	5/1/13	4/30/14	44,370
93.393	ADIPOSE TISSUE INFLAMMATION AND ESTROGEN SYNTHESIS	R21 CA143248	7/1/11	6/30/13	78,512
93.393	ASSOCIATION BETWEEN HIV AND SURVIVAL AFTER CANCER DIAGNOSIS	R03 CA153371	9/1/11	8/31/12	11,768
93.393	BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	R01 CA136725	9/1/11	8/31/14	1,180,451
93.393	BIOMATHEMATICAL EVALUATION OF COLON CANCER SCREENING AND PREVENTION	R01 CA107028	1/1/12	12/31/12	190,617
93.393	BIOMATHEMATICAL EVALUATION OF COLON CANCER SCREENING AND PREVENTION	R01 CA107028	1/1/13	12/31/13	138,019
93.393	BREAST CANCER RISK AND MOLECULAR CHANGE AFTER CHERNOBYL	R01 CA118914	8/1/11	7/31/12	76,131
93.393	BREAST CANCER RISK AND MOLECULAR CHANGE AFTER CHERNOBYL	R01 CA118914	8/1/12	7/31/14	576,307
93.393	CHARACTERIZING NOVEL ESTROGEN BIOMARKERS IMPLICATED IN BREAST CANCER INITIATION	R03 CA162173	1/1/13	12/31/13	1,913
93.393	COHORT STUDY OF GLUCOSAMINE AND CHONDROITIN SUPPLEMENT USE AND CANCER RISK	R01 CA142545	1/1/12	12/31/13	235,001
93.393	COLON CANCER PATHWAYS: HYPERPLASTICS POLYPS AND ADENOMAS	R01 CA097325	5/1/09	4/30/12	1,166
93.393	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	U01 CA137088	8/10/11	7/31/12	706,810
93.393	COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	U01 CA137088	8/1/12	7/31/14	958,487
93.393	CONSORTIUM STUDY OF MODIFIABLE CAUSES OF DEATH IN ASIANS	R03 CA153116	8/1/11	11/30/12	10,601
93.393	CRUCIFEROUS VEGETABLE FEEDING AND INFLAMMATION: EFFECT OF GST GENOTYPES	R01 CA142695	7/1/11	6/30/12	440
93.393	DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	U01 CA164930	9/26/12	8/31/13	255,861
93.393	DEVELOPMENT OF A COMPREHENSIVE MODEL FOR COLORECTAL CANCER RISK PREDICTION	R01CA170122	9/12/12	8/31/13	55,789
93.393	EPIDEMIOLOGIC FACTORS AND SURVIVAL BY MOLECULAR SUBTYPES OF OVARIAN CANCER	R01 CA168758	4/1/13	3/31/14	36,040
93.393	ESTROGEN PATHWAY GENES AND ASSOCIATION WITH PROSTATE CANCER RISK	R03 CA137799	9/1/09	8/31/12	24,028
93.393	EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	R01 CA134245	8/1/09	7/31/10	(1,240)
93.393	EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	R01 CA134245	8/1/11	7/31/12	42,949
93.393	EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	R01 CA134245	8/1/12	7/31/14	186,382
93.393	EXPLORING THE RELATIONSHIP OF VITAMIN D AND CHILDHOOD BRAIN TUMORS	R03 CA165071	2/16/12	1/31/13	40,952
93.393	EXPLORING THE RELATIONSHIP OF VITAMIN D AND CHILDHOOD BRAIN TUMORS	R03 CA165071	2/1/13	1/31/14	62,979
93.393	GENETIC EPIDEMIOLOGY OF PROSTATE CANCER	R01 CA080122	6/1/08	5/31/12	(613)
93.393	GENETIC MECHANISMS OF SURVIVORSHIP DISPARITIES AFTER UNRELATED HCT	U01 CA162194	8/12/11	7/31/12	100,023

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.393	GENETIC MECHANISMS OF SURVIVORSHIP DISPARITIES AFTER UNRELATED HCT	U01 CA162194	8/1/12	7/31/13	\$ 275,982
93.393	GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN COLON CANCER	R01 CA059045	6/1/11	5/31/13	296,937
93.393	GUT MICROBIOTA AND COLONIC GENE EXPRESSION: A LIGRAN TRIAL IN HUMANS	U01 CA162077	9/9/11	8/31/12	296,771
93.393	GUT MICROBIOTA AND COLONIC GENE EXPRESSION: A LIGRAN TRIAL IN HUMANS	U01 CA162077	9/1/12	8/31/13	436,623
93.393	GWAS IDENTIFIED COLORECTAL CANCER SNPS AND COLORECTAL POLYP RISK	R03 CA153323	8/1/11	7/31/13	29,127
93.393	HORMONES AND COLON CANCER: EPIGENETIC SUBTYPES, RISK, AND SURVIVAL	R01 CA076366	6/1/09	5/31/12	(734)
93.393	HPV VACCINATION IN THE CAMBODIAN COMMUNITY	R21 CA159908	7/6/11	6/30/12	1,099
93.393	HPV VACCINATION IN THE CAMBODIAN COMMUNITY	R21 CA159908	7/1/12	6/30/14	197,332
93.393	HUMAN PAPILLOMAVIRUS (HPV): BIOLOGY, CLINICAL SIGNIFICANCE, AND EPIDEMIOLOGY	P01 CA042792	7/1/11	6/30/13	919,997
93.393	HUMAN PAPILLOMAVIRUS ASSOCIATION WITH SUBSETS OF COLORECTAL CANCER	R03 CA137752	8/1/10	7/31/12	748
93.393	IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	R01 CA131255	7/1/11	5/31/12	9,525
93.393	IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	R01 CA131255	6/1/12	5/31/13	307,918
93.393	IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	R01 CA131255	6/1/13	5/31/14	12,510
93.393	INFLAMMATION PATHWAYS IN BREAST CANCER	R01 CA116786	8/1/10	7/31/12	37,408
93.393	INFRASTRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORY	UM1 CA167462	4/1/13	3/31/14	102,828
93.393	INTERACTION OF VITAMIN D AND VITAMIN A WITH LUNG CANCER RISK IN NONSMOKING FEMALES	R03 CA067696	1/1/13	12/31/13	16,483
93.393	INTERACTIONS OF HPV ONCOGENES WITH THE P53 PATHWAY	R01 CA064795	6/15/11	5/31/12	111
93.393	INTERACTIONS OF HPV ONCOGENES WITH THE P53 PATHWAY	R01 CA064795	6/1/12	5/31/13	464,253
93.393	INTERACTIONS OF HPV ONCOGENES WITH THE P53 PATHWAY	R01 CA064795	6/1/13	5/31/14	38,144
93.393	INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF FOOD INTAKE	U01 CA135133	1/1/12	12/31/12	304,217
93.393	INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF FOOD INTAKE	U01 CA135133	1/1/13	12/31/13	181,430
93.393	LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	R01 CA054498	9/20/12	7/31/13	526,431
93.393	LIPID GENOTYPES, PHENOTYPES, AND COLORECTAL ADENOMAS: ELUCIDATING MECHANISMS	R03 CA171014	9/10/12	8/31/13	85,790
93.393	METHODS FOR ASSESSING GENETIC ASSOCIATION WITH TIME-VARYING PHENOTYPE	R01 CA119225	7/1/10	6/30/12	(7,666)
93.393	MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	U01 CA157224	9/1/11	8/31/12	299,886
93.393	MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	U01 CA157224	9/1/12	8/31/13	699,507
93.393	MOLECULAR CORRELATES OF OUTCOMES IN CLINICAL TRIALS OF COLON CANCER	R01 CA176272	4/22/13	3/31/14	14,326
93.393	MOLECULAR EPIDEMIOLOGY OF LUNG CANCER	R01 CA111703	8/1/10	7/31/13	282,979
93.393	MOLECULAR EPIDEMIOLOGY OF TESTICULAR CARCINOMA	R01 CA085914	5/1/09	4/30/12	(9,445)
93.393	MYC ONCOPROTEIN FUNCTION	R37 CA057138	7/1/11	6/30/12	2,277
93.393	MYC ONCOPROTEIN FUNCTION	R37 CA057138	7/1/12	12/31/13	830,558
93.393	NIGHT SHIFT WORK AND HORMONE LEVELS IN MEN	R01 CA116400	6/1/11	5/31/13	595,566
93.393	NOVEL PATHOGEN ASSOCIATED CANCERS (PQ12)	R01 CA170386	9/24/12	7/31/13	347,647
93.393	NSAID AND COX/PG METABOLISM AND COLORECTAL CANCER	R01 CA112516	7/10/09	6/30/12	8,265
93.393	NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	R01 CA119171	5/1/11	4/30/12	(1,654)
93.393	NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	R01 CA119171	5/1/12	4/30/13	665,254
93.393	NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	R01 CA119171	5/23/13	4/30/14	129,589
93.393	OUTCOMES-BASED GUIDELINE DEVELOPMENT FOR PROSTATE CANCER SCREENING AND TREATMENT	R01 CA131874	8/1/11	7/31/13	296,511
93.393	PHENOTYPE-BASED APPROACH TO FIND GENE INTERACTIONS UNDERLYING BREAST CANCER RISK	R01 CA129604	8/1/11	7/31/13	92,593
93.393	PLASMA VITAMIN D LEVELS AND PROSTATE CANCER OUTCOMES	R03 CA153111	7/1/11	12/30/12	5,047
93.393	PROACTIVE SMOKING CESSATION FOR ADOLESCENTS	R01 CA082569	12/1/11	11/30/12	421,767
93.393	PROACTIVE SMOKING CESSATION FOR ADOLESCENTS	R01 CA082569	12/1/12	11/30/13	511,202
93.393	PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	U01 CA163304	9/19/11	8/31/12	267,857
93.393	PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	U01 CA163304	9/1/12	8/31/13	1,017,392
93.393	PROSTAGLANDIN SYNTHESIS, GENETICS AND COLORECTAL CANCER	R01 CA114467	3/1/10	2/28/13	403,144
93.393	RANDOMIZED TRIAL OF WEB-DELIVERED ACCEPTANCE THERAPY FOR SMOKING CESSATION	R01 CA166646	1/1/13	12/31/13	105,659
93.393	RETROVIRAL CODED FUNCTIONS	R01 CA018282	2/1/11	1/31/13	(3,807)
93.393	RISK FACTORS FOR THE SECOND PRIMARY BREAST CANCER AMONG DCIS SURVIVORS	R01 CA097271	1/1/12	12/31/12	523,492

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.393	RISK FACTORS FOR THE SECOND PRIMARY BREAST CANCER AMONG DCIS SURVIVORS	R01 CA097271	1/1/13	12/31/14	\$ 248,396
93.393	STATISTICAL METHODS FOR CLINICAL STUDIES	R01 CA090998	8/1/11	7/31/13	107,217
93.393	STATISTICAL METHODS FOR MEDICAL STUDIES	P01 CA053996	7/15/11	6/30/12	5,534
93.393	STATISTICAL METHODS FOR MEDICAL STUDIES	P01 CA053996	8/20/12	6/30/13	627,922
93.393	STEROID HORMONES GENES AND OVARIAN CANCER RISK	R01 CA112523	6/1/10	5/31/12	(47)
93.393	STRESS MANAGEMENT AND VACCINE RESPONSE AMONG WOMEN AT RISK FOR BREAST CANCER	R21 CA134813	7/1/10	12/31/12	104,685
93.393	TELOMERASE-REGULATED GENE EXPRESSION IN NORMAL AND TUMOR CELLS	R01 CA120294	8/1/10	7/31/12	(217)
93.393	TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	R01 CA151989	8/8/11	8/31/12	255,730
93.393	TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	R01 CA151989	9/1/12	8/31/13	497,470
93.393	THE COLON CANCER FAMILY REGISTRY	U24 CA074794	9/1/11	8/31/13	564,971
93.393	THE ROLE OF COORDINATING CENTERS IN COLLABORATIVE CANCER-EPIDEMIOLOGY STUDIES	R03 CA150036	9/1/11	8/31/12	24,323
93.393	THE ROLE OF COORDINATING CENTERS IN COLLABORATIVE CANCER-EPIDEMIOLOGY STUDIES	R03 CA150036	9/1/12	1/31/14	60,332
93.393	TRANSFORMING GROWTH FACTOR-BETA SIGNALING AND COLON CANCER	R01 CA115513	1/1/11	6/30/12	(736)
93.393	VITAMIN D AND PROSTATE CANCER: BIOMARKERS AND GENETIC VARIATION	R01 CA138639	2/1/12	1/31/14	227,608
93.393	VITAMIN D EFFECT ON BODY COMPOSITION DURING BEHAVIORAL WEIGHT LOSS IN WOMEN	R03CA162482	4/1/12	3/31/13	49,750
93.393	VITAMIN D EFFECT ON BODY COMPOSITION DURING BEHAVIORAL WEIGHT LOSS IN WOMEN	R03CA162482	4/1/13	3/31/14	8,395
93.393	WEIGHT LOSS AND CANCER BIOMARKERS IN WOMEN: OXIDATIVE STRESS AND INFLAMMATION	R01 CA161131	4/15/12	3/31/13	224,386
93.393	WEIGHT LOSS AND CANCER BIOMARKERS IN WOMEN: OXIDATIVE STRESS AND INFLAMMATION	R01 CA161131	4/1/13	3/31/14	6,444
93.393	WEIGHT LOSS AND EXERCISE EFFECTS ON TELOMERE LENGTH IN POSTMENOPAUSAL WOMEN	R21 CA155823	12/1/11	11/30/12	102,818
93.393	WOMEN'S HEALTH INITIATIVE CANCER SURVIVOR COHORT	UM1 CA173642	2/15/13	1/31/14	80,584
93.394	AFFINITY-BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	U01 CA152746	7/1/11	6/30/12	37,984
93.394	AFFINITY-BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	U01 CA152746	7/1/12	6/30/13	672,736
93.394	AN INTEGRATED COMPUTATIONAL AND FUNCTIONAL GENOMICS DISCOVERY ENGINE FOR PRECLINICALLY VALIDATED CANCER DRUG TARGETS	U01 CA176303	6/18/13	4/30/14	28,837
93.394	BARRETT'S ESOPHAGUS: PREDICTORS OF PROGRESSION	P01 CA091955	7/1/11	6/30/13	366,769
93.394	BIOLOGY AND PROGNOSTIC IMPLICATIONS OF FLT3 MUTATIONS IN AML	R01 CA114563	9/20/12	7/31/13	330,233
93.394	BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	U01 CA152637	7/1/11	6/30/12	24,219
93.394	BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	U01 CA152637	7/1/12	6/30/13	945,497
93.394	CIRCULATING MICRORNAS AS A BIOMARKER OF COLORECTAL CANCER RECURRENCE	R03 CA165153	3/8/12	2/28/13	66,143
93.394	CIRCULATING MICRORNAS AS A BIOMARKER OF COLORECTAL CANCER RECURRENCE	R03 CA165153	3/1/13	2/28/14	10,164
93.394	CONFIRMATION STUDIES OF BLOOD-BASED BIOMARKERS OF RISK FOR BREAST CANCER	R21 CA161713	7/1/12	6/30/13	232,515
93.394	DISCOVERY AND OPTIMIZATION OF AML PROGNOSTIC BIOMARKERS	R01 CA160872	5/1/12	3/31/13	492,773
93.394	DISCOVERY AND OPTIMIZATION OF AML PROGNOSTIC BIOMARKERS	R01 CA160872	4/1/13	3/31/14	93,866
93.394	EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER	U24 CA086368	7/1/11	6/30/12	8,895
93.394	EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER	U24 CA086368	7/1/12	6/30/13	1,987,055
93.394	EXERCISE EFFECTS ON SERUM BIOMARKERS OF ANGIOGENESIS	R03 CA152847	4/1/12	3/31/13	45,880
93.394	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	U01 CA152756	7/1/11	6/30/12	72,280
93.394	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	U01 CA152756	7/1/12	6/30/13	588,889
93.394	INTEGRATING DIAGNOSTICS WITH THERAPEUTIC STRATEGIES IN CHRONIC MYELOID LEUKEMIA	R01 CA140371	7/1/11	6/30/12	2,502
93.394	INTEGRATING DIAGNOSTICS WITH THERAPEUTIC STRATEGIES IN CHRONIC MYELOID LEUKEMIA	R01 CA140371	7/1/12	6/30/13	393,853
93.394	IRF8 AS A BIOMARKER OF AGING, MALIGNANT TRANSFORMATION, AND AML PROGNOSIS	R21 CA139256	12/1/10	6/30/12	(2,016)
93.394	MARKERS FOR HCV-RELATED HCC: PLASMA PROFILING, TARGETING STRATEGIES AND VALIDATION	R01 CA120719	3/1/12	12/31/12	121,945

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.394	PERIPHERAL BLOOD BIOPSY FOR MOLECULAR DIAGNOSIS OF PANCREATIC CANCER	R21 CA159240	3/1/12	2/28/13	\$ 171,362
93.394	PERIPHERAL BLOOD BIOPSY FOR MOLECULAR DIAGNOSIS OF PANCREATIC CANCER	R21 CA159240	3/1/13	2/28/14	27,620
93.394	PROFILING CANCER NEOANTIGEN REPERTOIRES AND VALIDATING IMMUNOTHERAPY TARGETS	U01 CA176270	5/1/13	4/30/14	56,359
93.394	PROGNOSTIC AND FUNCTIONAL SIGNIFICANCE OF ADHESION MOLECULES IN PEDIATRIC AML	R21 CA161894	4/16/12	3/31/13	190,119
93.394	PROGNOSTIC AND FUNCTIONAL SIGNIFICANCE OF ADHESION MOLECULES IN PEDIATRIC AML	R21 CA161894	4/1/13	3/31/14	30,933
93.394	PROTEIN BIOMARKERS IN CHILDHOOD ACUTE MYELOID LEUKEMIA	R21 CA164545	3/1/12	2/28/13	111,864
93.394	PROTEIN BIOMARKERS IN CHILDHOOD ACUTE MYELOID LEUKEMIA	R21 CA164545	3/1/13	2/28/14	75,020
93.394	SINGLE-CELL METHODS FOR ANALYSIS OF CLONAL HETEROGENEITY AND EVOLUTION IN CANCER	R01 CA175215	5/1/13	4/30/14	31,057
93.394	STATISTICAL METHODS FOR EVALUATING MARKERS FOR TREATMENT SELECTION	R01 CA152089	1/1/12	12/31/12	112,566
93.394	STATISTICAL METHODS FOR EVALUATING MARKERS FOR TREATMENT SELECTION	R01 CA152089	1/1/13	12/31/13	212,378
93.394	TREC COORDINATION CENTER	U01 CA116850	6/10/11	5/31/12	2,200
93.394	TREC COORDINATION CENTER	U01 CA116850	6/1/12	5/31/13	1,127,208
93.394	TREC COORDINATION CENTER	U01 CA116850	6/1/13	5/31/14	97,879
93.395	ADOPTIVE T CELL THERAPY OF MELANOMA TARGETING NY-ESO-1	R01 CA104711	2/1/12	12/31/12	165,284
93.395	ADULT LEUKEMIA RESEARCH CENTER	P01 CA018029	3/1/11	8/31/12	414,460
93.395	ADULT LEUKEMIA RESEARCH CENTER	P01 CA018029	9/25/12	6/30/13	3,788,793
93.395	ALPHA RADIOIMMUNOTHERAPY FOR LYMPHOMA TREATMENT	R01 CA172582	1/1/13	12/31/13	130,692
93.395	BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT	R01 CA136639	6/1/12	5/31/13	338,614
93.395	BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT	R01 CA136639	6/1/13	5/31/14	15,064
93.395	BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES USING NOVEL RADIOIMMUNOTHERAPEUTIC APPROACHES TO DECREASE RELAPSE	R01 CA138720	1/1/12	12/31/12	89,952
93.395	BONE MARROW TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES USING NOVEL RADIOIMMUNOTHERAPEUTIC APPROACHES TO DECREASE RELAPSE	R01 CA138720	1/1/13	12/31/13	98,026
93.395	BUILDING SUSTAINABLE TRANSLATIONAL RESEARCH TEAMS IN HIV-ASSOCIATED MALIGNANCIES	D43 CA153720	8/1/11	7/31/12	79,869
93.395	BUILDING SUSTAINABLE TRANSLATIONAL RESEARCH TEAMS IN HIV-ASSOCIATED MALIGNANCIES	D43 CA153720	9/14/12	7/31/14	333,184
93.395	CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	U01 CA154967	9/7/11	8/31/12	274,998
93.395	CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	U01 CA154967	9/1/12	8/31/13	1,589,611
93.395	CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	R01 CA154897	7/1/11	4/30/12	(42)
93.395	CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	R01 CA154897	5/1/12	4/30/13	353,216
93.395	CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	R01 CA154897	5/1/13	4/30/14	40,652
93.395	CD45 PRETARGETED RADIOIMMUNOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML)	R01 CA109663	2/1/12	1/31/13	136,768
93.395	CD45 PRETARGETED RADIOIMMUNOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA (AML)	R01 CA109663	2/1/13	1/31/14	39,158
93.395	CHLOROTOXIN AS A TARGETING AGENT FOR CANCER THERAPIES	R01 CA135491	6/1/11	5/31/12	(28,812)
93.395	CHLOROTOXIN AS A TARGETING AGENT FOR CANCER THERAPIES	R01 CA135491	6/1/12	7/31/13	319,802
93.395	CLINICAL SIGNIFICANCE OF MAJOR HISTOCOMPATIBILITY (MHC) HAPLOTYPES IN HEMATOPOIETIC CELL TRANSPLANTATION (HCT)	R01 CA100019	2/1/12	8/6/13	187,787
93.395	DEVELOPMENT OF CAMBINOL ANALOGUES AS ANTILYMPHOMA AGENTS	R01 CA129132	3/1/12	7/31/13	224,431
93.395	DIRECTED EVOLUTION OF PEPTIDE INHIBITORS OF MYC-MAX DIMERIZATION (PQ18)	R21 CA170721	9/1/12	8/31/13	123,180
93.395	HEMATOPOIETIC CHEMOPROTECTION IN GLIOBLASTOMA PATIENTS	R01 CA114218	8/1/11	7/31/14	190,813
93.395	IMPACT OF HIV AND HHV-8 COINFECTION ON ANTIRETROVIRAL THERAPY EFFICACY IN AFRICA	R01 CA138165	7/1/11	6/30/12	2,749
93.395	IMPACT OF HIV AND HHV-8 COINFECTION ON ANTIRETROVIRAL THERAPY EFFICACY IN AFRICA	R01 CA138165	7/1/12	6/30/13	249,121
93.395	IMPACT OF HIV AND HHV-8 COINFECTION ON ANTIRETROVIRAL THERAPY EFFICACY IN AFRICA	R01 CA138165	7/1/13	6/30/14	109
93.395	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	R01 CA118953	3/1/13	2/28/14	97,426
93.395	IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD)	R01 CA118953	6/1/11	2/28/13	309,974
93.395	INFANT AND TODDLER BRAIN TUMORS	R01 CA155360	4/1/12	3/31/13	235,212

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
93.395	INFANT AND TODDLER BRAIN TUMORS	R01 CA155360	4/1/13	3/31/14	\$ 76,449
93.395	INHIBITION OF B-CATENIN SIGNALING FOR TREATMENT OF HEPATOCELLULAR CARCINOMA	21 CA143714	6/1/11	8/31/12	2,278
93.395	INTERNET STUDIES TO ENHANCE LONG-TERM SURVIVORSHIP AFTER HEMATOLOGIC MALIGNANCY	R01 CA160684	9/9/11	7/31/12	93,879
93.395	INTERNET STUDIES TO ENHANCE LONG-TERM SURVIVORSHIP AFTER HEMATOLOGIC MALIGNANCY	R01 CA160684	8/2/12	7/31/13	557,196
93.395	LATE EFFECTS OF TREATMENT IN WILMS-TUMOR SURVIVORS AND OFFSPRING	R01 CA054498	12/1/10	6/30/12	(1,778)
93.395	METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMIA	R01 CA112530	8/1/10	7/31/13	180,694
93.395	MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	P01 CA078902	2/1/12	1/31/13	1,166,902
93.395	MIXED HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	P01 CA078902	2/1/13	1/31/14	659,681
93.395	OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER	R01 CA161112	9/22/11	7/31/12	82,371
93.395	OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER	R01 CA161112	8/1/12	7/31/13	419,222
93.395	PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS	R01 CA076287	1/1/12	12/31/13	220,414
93.395	RESISTANCE TO CANCER THERAPEUTICS THROUGH MICROENVIRONMENT DAMAGE RESPONSES	R01 CA165573	3/1/11	1/31/13	183,783
93.395	RESISTANCE TO CANCER THERAPEUTICS THROUGH MICROENVIRONMENT DAMAGE RESPONSES	R01 CA165573	2/1/13	1/31/14	114,582
93.395	SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER	U10 CA038926	1/1/12	12/31/12	2,477,752
93.395	SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER	U10 CA038926	1/1/13	12/31/13	1,820,838
93.395	TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY, FLUDARABINE, AND TBI FOLLOWED BY HLA-MATCHED, ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THE TREATMENT OF MULTIPLE MYELOMA	R21 CA155911	9/9/11	8/31/12	23,284
93.395	TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY, FLUDARABINE, AND TBI FOLLOWED BY HLA-MATCHED, ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THE TREATMENT OF MULTIPLE MYELOMA	R21 CA155911	9/1/12	8/31/14	151,380
93.395	TARGETED THERAPY IN EX VIVO MEDULLOBLASTOMA/PNET	R01 CA114567	4/18/12	3/31/13	171,948
93.395	TARGETED THERAPY IN EX VIVO MEDULLOBLASTOMA/PNET	R01 CA114567	4/1/13	3/31/14	50,628
93.395	TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	R01 CA136551	6/1/11	5/31/12	10,684
93.395	TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	R01 CA136551	6/1/12	5/31/13	481,756
93.395	TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	R01 CA136551	6/1/13	5/31/14	20,409
93.395	THE FANCONI ANEMIA-BRCA PATHWAY AND CHEMOSENSITIVITY OF HUMAN CANCER	R01 CA125636	6/1/11	5/31/12	(109)
93.395	THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	P01 CA044991	8/3/11	7/31/12	223,123
93.395	THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	P01 CA044991	8/1/12	7/31/13	1,789,553
93.396	CELL CYCLE REGULATION IN NORMAL AND CANCER CELLS	R01 CA118043	8/1/10	7/31/12	2,928
93.396	CELL POLARITY IN SELF-RENEWAL AND DIFFERENTIATION OF STEM/PROGENITOR CELLS	R01 CA131047	7/1/11	6/30/12	(8,545)
93.396	CELL POLARITY IN SELF-RENEWAL AND DIFFERENTIATION OF STEM/PROGENITOR CELLS	R01 CA131047	7/1/12	6/30/13	344,594
93.396	CELL-CELL ADHESION AND SIGNAL TRANSDUCTION	R01 CA098161	5/1/11	4/30/12	(6,450)
93.396	CELL-CELL ADHESION AND SIGNAL TRANSDUCTION	R01 CA098161	5/1/12	4/30/13	262,406
93.396	CROSS -SPECIES NETWORK APPROACH TO PREDICT EPISTATIC CANCER SUSCEPTIBILITY GENES	R01 CA138215	9/1/11	8/31/12	117,073
93.396	CROSS -SPECIES NETWORK APPROACH TO PREDICT EPISTATIC CANCER SUSCEPTIBILITY GENES	R01 CA138215	9/1/12	8/31/14	367,775
93.396	CX43 PHOSPHORYLATION MODULATES KRAS MEDIATED PANCREAS CANCER PROGRESSION	R21 CA149554	2/1/12	1/31/13	121,932
93.396	DISSECTING THE ROLES OF STELLATE CELLS IN PANCREAS CANCER PROGRESSION	R21 CA152249	6/1/11	7/18/12	4,929
93.396	EVOLUTION OF CANCER-SPECIFIC MOLECULAR REQUIREMENTS FOR GLOBLASTOMA MULTIFORME (PQ8)	R21 CA170722	8/20/12	7/31/13	184,781
93.396	GENETIC PROGRESSION OF PANCREATIC MUCINOUS CYSTIC NEOPLASMS TO INVASIVE CARCINOMA	R01 CA129357	2/1/12	1/31/13	201,493
93.396	GENETIC PROGRESSION OF PANCREATIC MUCINOUS CYSTIC NEOPLASMS TO INVASIVE CARCINOMA	R01 CA129357	2/1/13	1/31/14	123,543
93.396	INVASION AND METASTASIS IN PROSTATE CANCER	R01 CA102365	3/1/12	2/28/13	182,166
93.396	INVASION AND METASTASIS IN PROSTATE CANCER	R01 CA102365	3/1/13	2/28/14	179,568
93.396	LYMPH NODE ALTERATIONS IN CANCER	R01 CA068328	3/1/12	11/30/12	162,813
93.396	METABOLISM, PROTEIN, AND MIRNA CROSS-TALK IN CELL CYCLE AND TUMOR PROGRESSION	R01 CA158921	5/1/12	3/31/13	266,064

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.396	METABOLISM, PROTEIN, AND MIRNA CROSS-TALK IN CELL CYCLE AND TUMOR PROGRESSION	R01 CA158921	4/1/13	3/31/14	\$ 80,310
93.396	NORMAL AND CANCER STEM CELLS OF THE MAMMARY GLAND	R01 CA131425	8/1/11	7/31/12	38,793
93.396	NORMAL AND CANCER STEM CELLS OF THE MAMMARY GLAND	R01 CA131425	8/1/12	7/31/14	243,089
93.396	NORMAL AND NEOPLASTIC REGULATION OF CYCLIN E	R01 CA102742	1/1/12	12/31/12	228,154
93.396	NORMAL AND NEOPLASTIC REGULATION OF CYCLIN E	R01 CA102742	1/1/13	12/31/13	197,965
93.396	PREVENTIVE INTERVENTIONS LEADERSHIP U01	U01 CA141550	9/1/11	8/31/12	131,756
93.396	PREVENTIVE INTERVENTIONS LEADERSHIP U01	U01 CA141550	9/1/12	8/31/13	317,112
93.396	REGULATION OF CELL GROWTH AND PROLIFERATION BY MYC	R01 CA020525	2/1/12	1/31/13	398,802
93.396	REGULATION OF CELL GROWTH AND PROLIFERATION BY MYC	R01 CA020525	2/1/13	1/31/14	261,969
93.396	SRC FAMILY KINASES AND CELL GROWTH REGULATION	R01 CA041072	1/1/11	12/31/12	3,494
93.396	STIMULATION OF TUMORIGENESIS BY NKG2D	R01 CA174470	2/1/13	1/31/14	303,526
93.396	STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS	R01 CA114536	1/1/12	12/31/12	228,404
93.396	STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS	R01 CA114536	1/1/13	12/31/13	159,032
93.396	THE HIPPO PATHWAY IN PROSTATE GLAND HOMEOSTASIS AND PROSTATE CANCER	R01 CA176844	5/1/13	2/28/14	54,878
93.396	TUMOR SUPPRESSION BY THE FBW7 UBIQUITIN LIGASE	R01 CA084069	8/1/11	7/31/12	31,696
93.396	TUMOR SUPPRESSION BY THE FBW7 UBIQUITIN LIGASE	R01 CA084069	8/1/12	7/31/13	266,375
93.396	USING MOUSE MODELS TO UNDERSTAND RETINOBLASTOMA INITIATION AND PROGRESSION	R01 CA148867	7/20/12	12/31/12	125,685
93.396	USING MOUSE MODELS TO UNDERSTAND RETINOBLASTOMA INITIATION AND PROGRESSION	R01 CA148867	1/1/13	12/31/13	158,959
93.397	CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	P30 CA015704	1/1/12	12/31/12	6,862,737
93.397	CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	P30 CA015704	1/1/13	12/31/13	4,621,910
93.397	CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	U54 CA153502	9/1/11	8/31/12	251,128
93.397	CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	U54 CA153502	9/1/12	8/31/13	654,046
93.397	PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	P50 CA083636	7/1/11	6/30/12	4,095
93.397	PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM	P50 CA083636	7/1/12	6/30/13	2,120,150
93.397	PARTNERSHIP FOR THE ADVANCEMENT OF CANCER RESEARCH: NEW MEXICO STATE UNIVERSITY (NMSU) – FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC) (2 OF 2)	U54 CA132381	9/1/11	8/31/13	678,210
93.397	SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	P50 CA138293	9/1/11	8/31/12	441,494
93.397	SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	P50 CA138293	9/1/12	8/31/13	1,856,826
93.398	ADDRESSING PSYCHOSOCIAL DISPARITIES IN RURAL HISPANIC CANCER SURVIVORS	K01 CA154938	9/12/11	8/31/12	20,034
93.398	ADDRESSING PSYCHOSOCIAL DISPARITIES IN RURAL HISPANIC CANCER SURVIVORS	K01 CA154938	9/1/12	8/31/13	107,633
93.398	ALLOGENEIC STEM CELL TRANSPLANT WITH GRAFTS DEPLETED OF NAIVE T CELLS FOR LEUKEMIA	K23 CA154532	7/1/12	6/30/13	166,818
93.398	ANTIBODY DIRECTED DELIVERY OF SHORT INTERFERING RNA FOR THE TREATMENT OF OVARIAN CANCER	K08 CA163603	9/6/12	8/31/13	115,189
93.398	CANCER SURVIVORSHIP: DECREASING THE RISK OF COLON CANCER MORTALITY	K05 CA152715	8/1/11	7/31/12	5,932
93.398	CANCER SURVIVORSHIP: DECREASING THE RISK OF COLON CANCER MORTALITY	K05 CA152715	8/1/12	7/31/13	111,944
93.398	CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGY	K12 CA076930	9/1/11	8/31/12	72,015
93.398	CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGY	K12 CA076930	9/1/12	8/31/13	416,560
93.398	CHROMOSOME, METABOLISM, AND CANCER TRAINING GRANT	T32 CA009657	7/1/11	6/30/12	(4,521)
93.398	CHROMOSOME, METABOLISM, AND CANCER TRAINING GRANT	T32 CA009657	7/1/12	6/30/13	403,880
93.398	DETERMINANTS OF LATE CARDIOVASCULAR MORBIDITY AMONG SURVIVORS OF HEMATOPOIETIC CELL TRANSPLANTATION	K07 CA151775	8/1/11	7/31/12	13,975
93.398	DETERMINANTS OF LATE CARDIOVASCULAR MORBIDITY AMONG SURVIVORS OF HEMATOPOIETIC CELL TRANSPLANTATION	K07 CA151775	8/1/12	7/31/13	138,533
93.398	ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROL	K05 CA124911	7/1/11	8/5/12	14,551
93.398	ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION AND CONTROL	K05 CA124911	8/6/12	7/31/13	106,618
93.398	HUMAN HERPESVIRUS-8 REPLICATION AND KAPOSI SARCOMA RESPONSE TO TREATMENT	K23 CA150931	8/5/11	7/31/12	17,600
93.398	HUMAN HERPESVIRUS-8 REPLICATION AND KAPOSI SARCOMA RESPONSE TO TREATMENT	K23 CA150931	8/1/12	7/31/13	120,707
93.398	LIFESTYLE FACTORS AND SURVIVAL OUTCOMES FOR COLORECTAL CANCER MOLECULAR SUBTYPES	K07 CA172298	2/13/13	1/31/14	36,430
93.398	MECHANISMS OF BHLH MEDIATED LINEAGE SPECIFICATION	K08 CA169014	8/1/12	7/31/13	123,323
93.398	OPTIMIZATION OF ADOPTIVE IMMUNOTHERAPY WITH AUTOLOGOUS CD20-SPECIFIC T CELLS	K23 CA154874	4/1/13	3/31/14	31,338

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.398	PEDIATRIC ONCOLOGY RESEARCH TRAINING PROGRAM	T32 CA009351	7/1/11	7/31/12	\$ 11,226
93.398	PEDIATRIC ONCOLOGY RESEARCH TRAINING PROGRAM	T32 CA009351	8/1/12	7/31/13	228,802
93.398	QUIESCENT TC17 PROGRAMMED CD8 T CELLS AND THEIR ROLE IN GRAFT VERSUS HOST DISEASE	K99 CA154608	8/1/11	7/31/12	17,188
93.398	QUIESCENT TC17 PROGRAMMED CD8 T CELLS AND THEIR ROLE IN GRAFT VERSUS HOST DISEASE	K99 CA154608	8/1/12	5/31/13	169,677
93.398	RADIOIMMUNOTHERAPY FOR MULTIPLE MYELOMA	K08 CA151682	9/1/11	8/31/12	30,391
93.398	RADIOIMMUNOTHERAPY FOR MULTIPLE MYELOMA	K08 CA151682	9/1/12	8/31/13	135,422
93.399	PROSPECTIVE STUDY ON SELENIUM, GENETICS OF SELENOENZYMES, AND COLORECTAL CANCER	R01 CA120582	7/1/12	6/30/13	173,945
93.399	QUANTITATIVE METHODS FOR SPECTRAL AND IMAGE DATA IN PROTEOMICS RESEARCH	R01 CA126205	9/1/10	8/31/13	105,452
93.399	THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	P50 CA097186	9/1/11	8/31/13	1,240,255
93.399	UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	P50 CA148143	5/1/11	4/30/12	(6,868)
93.399	UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	P50 CA148143	5/1/12	4/30/13	1,705,392
93.399	UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	P50 CA148143	5/1/13	4/30/14	177,379
93.701	ARRA – ACCURACY OF SELF-REPORTED PRENATAL SMOKING IN CHILD CANCER EPIDEMIOLOGY STUDIES	R03 CA141487	8/1/10	7/31/12	8,628
93.701	ARRA – CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	P30 CA015704	6/1/09	5/31/13	90,729
93.701	ARRA – CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	P30 CA015704	9/30/09	9/29/13	261,647
93.701	ARRA – CANTRAN: A TOOL TO TRANSLATE INTERMEDIATE ENDPOINTS TO MORTALITY IN CE STUDIES	RC4 CA155806	8/31/10	8/30/13	466,344
93.701	ARRA – CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER GENOMICS-CANCERGEN	UC2 CA148570	9/1/10	8/31/13	1,166,627
93.701	ARRA – HISPANIC COMMUNITY NETWORK TO REDUCE CANCER DISPARITIES	U01 CA114633	9/30/09	9/29/12	9,563
93.701	ARRA – MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN COMPLEX BIOLOGICAL SAMPLES	RC2 CA148286	9/1/10	8/31/13	781,537
93.701	ARRA – MECHANISM-BASED CLASSIFICATION AND TARGETING OF CASTRATION-RESISTANT PROSTATE CANCER	RC1 CA146849	9/1/10	8/31/12	19,717
93.701	ARRA – MODELING US PROSTATE CANCER TRENDS: PSA, TREATMENT AND RA*	U01 CA088160	8/1/09	7/31/12	2,401
93.701	ARRA – NSAID AND COX/PG METABOLISM AND COLORECTAL CANCER	R01 CA112516	8/1/09	7/31/12	11,483
93.701	ARRA – ORAL CANCER: MOLECULAR PROFILES AND CLINICAL OUTCOMES	R01 CA095419	9/1/10	8/31/12	178,914
93.701	ARRA – PARTNERSHIP FOR THE ADVANCEMENT OF CANCER RESEARCH: NEW MEXICO STATE UNIVERSITY (NMSU) – FRED HUTCHINSON CANCER RESEARCH CENTER (FHCRC) (2 OF 2)	U54 CA132381	9/30/09	9/29/12	43,927
93.701	ARRA – THE TIME-DISTRIBUTION METHOD FOR MEASURING CLINICALLY VALID QUALITY OF LIFE STATES	R21 CA131651	6/1/10	5/31/12	11,315
93.855	IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	U54 CA163438	9/1/12	8/31/13	815,544
	Total – NATIONAL CANCER INSTITUTE				<u>95,693,880</u>
93.701	NATIONAL CENTER FOR RESEARCH RESOURCES: ARRA – DATA CENTER CORE CONSOLIDATION	G20 RR030856	3/25/10	6/24/13	1,263,828
	Total – NATIONAL CENTER FOR RESEARCH RESOURCES				<u>1,263,828</u>
93.307	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES: COLLABORATION FOR A HEALTHY COMMUNITY	R24 MD008068	4/29/13	12/31/13	52,565
93.307	PARTNERSHIP FOR A HISPANIC DIABETES PREVENTION PROGRAM	R24 MD001621	3/1/12	2/28/14	365,765
93.701	ARRA – A STUDY OF CANCER DIAGNOSIS AS A RISK FACTOR FOR PERSONAL BANKRUPTCY	RC1 MD004135	8/1/10	7/31/12	39,620
	Total – NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES				<u>457,950</u>
N/A	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE: CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE	N01-WH-2-2110	9/30/92	9/30/12	1,533,352

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	HHSN268201100046C	9/1/11	8/31/12	\$ 6,883,191
N/A	CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	HHSN268201100046C	9/1/12	8/31/13	10,532,277
N/A	CORE ASSAYS MEDICAL RESEARCH LABORATORIES INTERNATIONAL (MRLI) – W1, W3	N01-WH-2-2110	10/1/05	9/30/12	158,600
N/A	TELOMERES DYNAMICS, CARDIOVASCULAR RISK, AND LONGEVITY IN OLDER WOMEN	HHSN268201300007C	3/29/13	3/28/14	17,467
93.701	ARRA – CTRIP: NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR CORD BLOOD TRANSPLANT	RC2 HL101844	9/1/10	6/30/13	674,374
93.701	ARRA – PHYSICAL ACTIVITY IN THE CAMBODIAN COMMUNITY: AN EXPLORATORY STUDY	R21 HL094337	8/1/10	7/31/12	19,539
93.701	ARRA – TOWARDS A MODEL OF FANCONI ANEMIA	RC1 HL100270	9/1/10	6/30/13	124,589
93.837	BLOOD AND MARROW CLINICAL TRIALS NETWORK – HUTCHINSON CENTER CORE CLINICAL SITE	U10 HL069246	7/1/12	6/30/13	175,163
93.837	CARDIOVASCULAR DISEASE BIOMARKERS AND MEDIATION OF HORMONE THERAPY EFFECTS	R21 HL109527	8/1/11	7/31/12	15,224
93.837	CARDIOVASCULAR DISEASE BIOMARKERS AND MEDIATION OF HORMONE THERAPY EFFECTS	R21 HL109527	8/1/12	7/31/14	62,653
93.837	CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS	U01 HL099993	5/1/11	4/30/12	(171,114)
93.837	CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS	U01 HL099993	5/1/12	4/30/13	1,392,726
93.837	CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS	U01 HL099993	5/1/13	4/30/14	109,690
93.837	DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION	R21 HL108257	7/1/11	6/30/12	11,145
93.837	DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION	R21 HL108257	7/1/12	6/30/14	175,229
93.837	EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	U01 HL100395	5/1/12	4/30/13	1,173,576
93.837	EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	U01 HL100395	5/1/13	4/30/14	100,139
93.837	IMPACT OF COMORBIDITIES ON OUTCOMES OF ALLOGENEIC TRANSPLANTATION	R00 HL088021	3/1/12	2/28/13	171,736
93.837	IMPACT OF COMORBIDITIES ON OUTCOMES OF ALLOGENEIC TRANSPLANTATION	R00 HL088021	3/1/13	2/28/14	81,132
93.837	INFECTIONS IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS	K24 HL093294	7/1/11	6/30/12	733
93.837	INFECTIONS IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS	K24 HL093294	7/1/12	6/30/13	187,014
93.837	LAGLIDADG DELIVERY AND GENE REPAIR IN CANINE HEMATOPOIETIC STEM CELLS (7 OF 11)	RL1 HL092554	7/1/11	6/30/13	512,099
93.837	MICRORNAs REGULATING THE FANCONI ANEMIA-BRCA PATHWAY	R21 HL092978	9/1/09	8/31/12	(2,461)
93.837	NATURAL KILLER CELL RECEPTOR DIVERSITY AND CMV IN HEMATOPOIETIC CELL TRANSPLANTATION	K23 HL096831	7/1/12	6/30/13	148,104
93.837	NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	P50 HL110787	5/16/12	4/30/13	1,205,888
93.837	NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	P50 HL110787	5/1/13	4/30/14	337,737
93.837	OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	R01 HL105065	9/1/11	4/30/12	75,992
93.837	OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	R01 HL105065	5/1/12	4/30/13	1,295,290
93.837	OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	R01 HL105065	5/1/13	4/30/14	94,074
93.837	STATISTICAL INFERENCE IN GENOME-WIDE ASSOCIATION AND SEQUENCING STUDIES	R01 HL114901	7/15/12	6/30/13	225,055
93.837	THE STRONG WOMEN HEALTHY HEARTS FOLLOW-UP STUDY: INDIVIDUAL, LEADERSHIP AND BUILT ENVIRONMENT FACTORS.	K01 HL108807	9/1/11	5/31/12	(541)
93.837	THE STRONG WOMEN HEALTHY HEARTS FOLLOW-UP STUDY: INDIVIDUAL, LEADERSHIP AND BUILT ENVIRONMENT FACTORS.	K01 HL108807	6/1/12	8/31/12	20,616
93.838	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	U01 HL102547	9/1/11	8/31/12	471,993
93.838	A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	U01 HL102547	9/1/12	8/31/14	647,202
93.838	GENETIC ANALYSIS OF AIRFLOW OBSTRUCTION AFTER STEM CELL TRANSPLANTATION	R01 HL088201	6/1/11	5/31/13	240,180
93.838	GENETIC ANALYSIS OF AIRFLOW OBSTRUCTION AFTER STEM CELL TRANSPLANTATION	R01 HL088201	6/1/13	5/31/14	6,065
93.838	NEUTROPHIL ELASTASE LINKS IDIOPATHIC PULMONARY FIBROSIS AND LUNG CANCER	R01 HL108979	7/15/11	6/30/12	(48,894)
93.838	NEUTROPHIL ELASTASE LINKS IDIOPATHIC PULMONARY FIBROSIS AND LUNG CANCER	R01 HL108979	7/1/12	6/30/13	385,228
93.839	ACTIVATION AND SILENCING OF GENE EXPRESSION DURING HEMATOPOIESIS – OLD	R01 HL065440	5/1/11	4/30/12	(730)
93.839	ACTIVATION AND SILENCING OF GENE EXPRESSION DURING HEMATOPOIESIS – OLD	R01 HL065440	5/1/12	4/30/13	797,875
93.839	ACTIVATION AND SILENCING OF GENE EXPRESSION DURING HEMATOPOIESIS – OLD	R01 HL065440	5/1/13	4/30/14	163,035
93.839	BIOMARKER DISCOVERY IN CHRONIC GRAFT-VS-HOST DISEASE	R01 HL094260	7/1/11	12/30/12	43,459
93.839	BMT CTN 1101 ANCILLARY COST-EFFECTIVENESS ANALYSIS	R01 HL116291	8/8/12	7/31/13	161,390
93.839	CELL DEATH AND CLONAL SURVIVAL IN MYELODYSPLASTIC SYNDROME	R01 HL082941	9/1/08	8/31/10	(69)
93.839	CORD BLOOD EXPANSION AND TRANSPLANTATION IN A NONHUMAN PRIMATE MODEL	R01 HL084345	6/1/09	5/31/12	21,293

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.839	DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	R01 HL098489	1/1/11	12/31/11	\$ (1,042)
93.839	DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	R01 HL098489	1/1/12	12/31/12	615,269
93.839	DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	R01 HL098489	1/1/13	12/31/13	177,547
93.839	ENGRAFTMENT AND INVIVO SELECTION OF HIV-PROTECTED STEM CELLS	R01 HL116217	8/1/12	5/31/13	285,126
93.839	ENGRAFTMENT AND INVIVO SELECTION OF HIV-PROTECTED STEM CELLS	R01 HL116217	6/1/13	5/31/14	19,960
93.839	GENE THERAPY FOR FANCONI ANEMIA	R01 HL085693	7/1/09	9/30/13	153,947
93.839	HEMATOPOIETIC CELL TRANSPLANTATION AND IRON OVERLOAD	R01 HL095999	4/1/12	3/31/13	424,915
93.839	HEMATOPOIETIC CELL TRANSPLANTATION AND IRON OVERLOAD	R01 HL095999	4/1/13	3/31/14	68,899
93.839	IMPROVING ALLOGENIC TRANSPLANT OUTCOMES IN MYELOID MALIGNANCIES	K23 HL084054	2/1/11	4/30/12	(24)
93.839	MOLECULAR CONTROL OF HEMATOPOIETIC STEM CELL FATE	P01 HL084205	5/1/11	4/30/13	291,709
93.839	POPULATION PHARMACOKINETICS/PHARMACODYNAMICS IN NONABLATIVE STEM CELL	R01 HL091744	1/1/11	12/31/12	161,867
93.839	SHWACHMAN-DIAMOND SYNDROME: MOLECULAR PATHOGENESIS	R01 HL079582	6/1/11	5/31/12	204
93.839	SHWACHMAN-DIAMOND SYNDROME: MOLECULAR PATHOGENESIS	R01 HL079582	6/1/12	5/31/14	436,146
93.839	STATINS FOR PREVENTION OF GVHD	R01 HL108307	4/1/12	3/31/13	325,169
93.839	STATINS FOR PREVENTION OF GVHD	R01 HL108307	4/1/13	3/31/14	117,559
93.839	STEM CELL TRANSPLANTATION: BASIC/CLINICAL RESEARCH	P01 HL036444	8/1/10	7/31/12	4,773
93.839	WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	R01 HL105914	1/1/12	12/31/12	1,126,312
93.839	WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	R01 HL105914	1/1/13	12/31/13	1,018,382
	Total – NATIONAL HEART, LUNG, AND BLOOD INSTITUTE				35,455,033
	NATIONAL HUMAN GENOME RESEARCH INSTITUTE:				
93.172	ADAPTIVE-STATISTICAL METHODS FOR GENETIC ASSOCIATION STUDIES	R01 HG006124	3/1/12	2/28/13	205,793
93.172	ADAPTIVE-STATISTICAL METHODS FOR GENETIC ASSOCIATION STUDIES	R01 HG006124	3/1/13	2/28/14	76,368
93.172	BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	U41 HG004059	3/1/12	2/28/13	1,137,506
93.172	BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	U41 HG004059	3/1/13	2/28/14	449,337
93.172	EPIDEMIOLOGY OF PUTATIVE GENETIC VARIANTS IN THE WOMEN'S HEALTH INITIATIVE	U01 HG004790	6/1/11	5/31/14	1,036,815
93.172	GENOME-WIDE PROFILING OF HISTONE VARIANTS IN DROSOPHILA AND CAENORHABDITIS	U01 HG004274	4/1/10	3/31/13	81,729
93.172	GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES IN THE WHI	U01 HG005152	8/1/11	7/31/14	1,022,102
93.172	TILLING THE ZEBRAFISH GENOME: A REVERSE GENETIC APPROACH	R01 HG002995	9/1/10	9/14/12	48,331
93.301	NOVEL COMPUTATIONAL TOOLS FOR STUDYING THE HUMAN MICROBIOME	R01 HG005966	7/1/11	6/30/12	11,866
93.301	NOVEL COMPUTATIONAL TOOLS FOR STUDYING THE HUMAN MICROBIOME	R01 HG005966	7/1/12	6/30/14	347,697
93.310	NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	R01 HG005816	7/1/11	6/30/12	19,029
93.310	NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	R01 HG005816	7/1/12	6/30/14	677,935
	Total – NATIONAL HUMAN GENOME RESEARCH INSTITUTE				5,114,508
	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES:				
N/A	PHASED MHC HAPLOTYPE-BASED GENOTYPING IN MACAQUES	HHSN272201100026C	8/1/11	7/31/15	2,438,021
93.310	RADIATION DOSE-DEPENDENT INTERVENTIONS	U19 AI067770	8/1/09	7/31/12	29,768
93.701	ARRA – ROLE OF CTL AVIDITY IN EPITOPE VARIANT RECOGNITION AND IMMUNE CONTROL OF HIV	R21 AI078809	8/1/10	7/31/12	57,799
93.855	ACQUISITION AND LOSS OF NEISSERIA MENINGITIDIS CARRIAGE IN HOUSEHOLDS IN MALI	R03 AI092121	3/1/12	8/28/13	69,552
93.855	B7-BASED, CD28, OR CTLA-4 SPECIFIC AGONISTS AND ANTAGONISTS FOR TOLERANCE INDUCTION	R21 AI097786	3/1/12	2/28/13	121,635
93.855	B7-BASED, CD28, OR CTLA-4 SPECIFIC AGONISTS AND ANTAGONISTS FOR TOLERANCE INDUCTION	R21 AI097786	3/1/13	2/28/14	62,626
93.855	CD8 TAU CELL CONTRACTION AND MEMORY FORMATION	R00-AI079159	6/1/12	9/30/13	192,046
93.855	CD8+ CELL IMMUNITY TO CYTOMEALOVIRUS	R01 AI053193	2/1/12	1/31/13	261,079

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
93.855	CD8+ CELL IMMUNITY TO CYTOMEGALOVIRUS	R01 AI053193	2/1/13	1/31/14	\$ 125,049
93.855	CELL-STRESS INDUCED IMMUNE RESPONSES	R37 AI030581	5/1/10	4/30/12	(713)
93.855	CHARACTERIZATION OF (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	R01 AI1103981	8/2/12	7/31/13	455,424
93.855	CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	P01 AI030731	7/1/11	6/30/12	216,315
93.855	CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	P01 AI030731	7/1/12	6/30/13	1,520,655
93.855	CMV ENTRY-SPECIFIC NEUTRALIZING ANTIBODY IN PRIMARY INFECTION IN TRANSPLANTATION	K23 AI097234	5/15/12	4/30/13	80,034
93.855	CMV ENTRY-SPECIFIC NEUTRALIZING ANTIBODY IN PRIMARY INFECTION IN TRANSPLANTATION	K23 AI097234	5/1/13	4/30/14	12,348
93.855	COMPREHENSIVE ASSESSMENT OF ALPHA/BETA T-CELL RECEPTOR DIVERSITY	R56 AI081860	9/15/10	8/31/12	(1,363)
93.855	COMPUTATIONAL APPROACHES TO STUDYING IMMUNODOMINANCE	K25 AI087397	9/1/11	8/31/12	33,622
93.855	COMPUTATIONAL APPROACHES TO STUDYING IMMUNODOMINANCE	K25 AI087397	9/1/12	8/31/13	110,857
93.855	CONSTRAINTS ON THE EVOLUTION OF INFLUENZA OSELTAMIVIR RESISTANCE	K22 AI093789	9/1/11	8/31/12	(3,094)
93.855	CONSTRAINTS ON THE EVOLUTION OF INFLUENZA OSELTAMIVIR RESISTANCE	K22 AI093789	9/1/12	1/31/14	51,619
93.855	CYTOTOXIC T-CELL REPOSES TO HSV IN HIV-INFECTED PERSONS	R01 AI042528	4/1/12	3/31/13	359,279
93.855	CYTOTOXIC T-CELL REPOSES TO HSV IN HIV-INFECTED PERSONS	R01 AI042528	4/1/13	3/31/14	16,517
93.855	DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE MACAQUE SHIV MODEL	R01 AI080326	9/1/10	8/31/11	(395)
93.855	DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE MACAQUE SHIV MODEL	R01 AI080326	9/1/11	8/31/12	159,181
93.855	DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE MACAQUE SHIV MODEL	R01 AI080326	9/1/12	8/31/14	340,999
93.855	DISCOVERING TISSUE-SPECIFIC BIOMARKERS OF RADIATION INJURY IN SILAC-LABELED MICE	R01 AI101832	6/6/12	5/31/13	329,015
93.855	DISCOVERING TISSUE-SPECIFIC BIOMARKERS OF RADIATION INJURY IN SILAC-LABELED MICE	R01 AI101832	6/1/13	5/31/14	12,894
93.855	EARLY AND REINFECTION IN HIGH RISK WOMEN	R37 AI038518	3/1/12	2/28/13	595,729
93.855	EARLY AND REINFECTION IN HIGH RISK WOMEN	R37 AI038518	3/1/13	2/28/14	148,933
93.855	ELUCIDATION OF A BACTERIAL CELL SHAPE GENERATING PROGRAM AND PATHOGENIC FUNCTIONS	R01 AI094839	12/1/11	11/30/12	171,677
93.855	ELUCIDATION OF A BACTERIAL CELL SHAPE GENERATING PROGRAM AND PATHOGENIC FUNCTIONS	R01 AI094839	12/1/12	11/30/13	190,154
93.855	FOAMY VIRUS ZOOONOTIC TRANSMISSION FROM NEW WORLD MONKEYS	R21 AI097832	2/8/12	1/31/13	148,627
93.855	FOAMY VIRUS ZOOONOTIC TRANSMISSION FROM NEW WORLD MONKEYS	R21 AI097832	2/1/13	1/31/14	69,405
93.855	GENETIC REQUIREMENTS OF HELICOBACTER PYLORI INFECTION	R01 AI054423	7/1/11	6/30/12	(697)
93.855	GENETIC REQUIREMENTS OF HELICOBACTER PYLORI INFECTION	R01 AI054423	7/1/12	6/30/13	427,048
93.855	HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	U01 AI069197	7/1/11	6/30/12	427,847
93.855	HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	U01 AI069197	7/1/12	6/30/13	540,212
93.855	HIV HOST-CELL INTERACTIONS	R01 AI030927	7/1/11	6/30/12	(4,036)
93.855	HIV HOST-CELL INTERACTIONS	R01 AI030927	7/1/12	6/30/13	493,071
93.855	HPV CAPSID ANTIBODIES	R01 AI038382	2/1/12	1/31/13	238,312
93.855	HPV CAPSID ANTIBODIES	R01 AI038382	2/1/13	1/31/14	93,365
93.855	HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION OF NONDIVIDING CELLS	R01 AI073085	7/1/10	6/30/12	(221)
93.855	HVTN LABORATORY PROGRAM	UM1 AI068618	6/1/11	5/31/12	738,544
93.855	HVTN LABORATORY PROGRAM	UM1 AI068618	6/1/12	12/31/13	12,338,040
93.855	HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	U01 AI068635	6/1/11	5/31/12	78,633
93.855	HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	U01 AI068635	6/1/12	12/31/13	11,439,324
93.855	HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	UM1 AI068614	6/1/11	5/31/12	1,440,928
93.855	HVTN: LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIAL	UM1 AI068614	6/1/12	12/31/13	38,564,446
93.855	IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	U54 CA163438	9/1/11	8/31/12	512,006
93.855	IMMUNOBIOLOGY OF TOLERANCE FAHCT	P01 AI033484	8/1/10	7/31/11	(29)
93.855	IMMUNOBIOLOGY OF TOLERANCE FAHCT	P01 AI033484	8/1/11	7/31/12	88,900
93.855	IMMUNOBIOLOGY OF TOLERANCE FAHCT	P01 AI033484	8/1/12	7/31/13	1,099,303
93.855	IMPROVED METHODS FOR ASSESSING IMMUNE CORRELATES IN HIV-1 VACCINE TRIALS	R03 AI104370	1/1/13	12/31/13	25,611
93.855	INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUS	R01 AI093808	6/6/11	5/31/12	871
93.855	INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUS	R01 AI093808	6/1/12	5/31/13	357,656
93.855	INITIATION OF THE IMMUNE RESPONSE TO ASPERGILLUS FUMIGATUS	R01 AI093808	6/1/13	5/31/14	16,625
93.855	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	UM1 AI068617	6/1/11	5/31/12	100,403

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.855	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: HIV PREVENTION TRIALS NETWORK	UM1 AI068617	6/1/12	12/31/13	\$ 7,182,697
93.855	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICROBICIDE TRIALS NETWORK	UM1 AI068615	6/1/11	5/31/12	76,645
93.855	LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS: MICROBICIDE TRIALS NETWORK	UM1 AI068615	6/1/12	12/31/13	5,074,380
93.855	METHODS FOR EVALUATING VACCINE EFFICACY	R37 AI032042	6/1/11	5/31/12	6,859
93.855	METHODS FOR EVALUATING VACCINE EFFICACY	R37 AI032042	6/1/12	5/31/13	458,829
93.855	METHODS FOR EVALUATING VACCINE EFFICACY	R37 AI032042	6/1/13	5/31/14	45,748
93.855	POXVIRAL ANTAGONISM OF THE IFIT-MEDIATED ANTIVIRAL RESPONSE	R21 AI099936	2/1/12	1/31/13	126,497
93.855	POXVIRAL ANTAGONISM OF THE IFIT-MEDIATED ANTIVIRAL RESPONSE	R21 AI099936	2/1/13	1/31/14	83,632
93.855	PREDOCTORAL FELLOW – LAURA MARTINEZ	F31 AI098424	3/16/12	3/15/13	21,001
93.855	PREDOCTORAL FELLOW – LAURA MARTINEZ	F31 AI098424	3/16/13	3/15/14	14,060
93.855	PREGNANCY, MICROCHIMERISM, AND AUTOIMMUNE DISEASE	R01 AI041721	5/1/11	1/30/13	114,488
93.855	PREP EXPOSURE DURING HIV-1 INFECTION AND THE RISK OF LOW-FREQUENCY ARV RESISTANCE	R21 AI104449	2/15/13	1/31/14	91,270
93.855	REGULATORY T CELL MODULATION OF IMMUNITY TO MUCOSAL VIRAL INFECTIONS	R01 AI087657	6/1/12	5/31/13	357,368
93.855	REGULATORY T CELL MODULATION OF IMMUNITY TO MUCOSAL VIRAL INFECTIONS	R01 AI087657	6/1/13	5/31/14	12,390
93.855	SEATTLE VACCINE TRIALS UNIT	UM1 AI069481	1/1/12	12/31/12	356,769
93.855	SEATTLE VACCINE TRIALS UNIT	UM1 AI069481	1/1/13	12/31/13	212,862
93.855	STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS	R37 AI054165	4/1/12	3/31/13	260,711
93.855	STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS	R37 AI054165	4/1/13	3/31/14	56,060
93.855	STATISTICAL METHODS IN HIV/AIDS RESEARCH	R01 AI089341	5/1/12	4/30/14	391,525
93.855	T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	R01 AI091701	5/1/12	4/30/13	289,763
93.855	T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	R01 AI091701	5/1/13	4/30/14	3,082
93.855	T CELL MODULATION BY NKG2D	R01 AI052319	9/1/11	8/31/12	100,438
93.855	T CELL MODULATION BY NKG2D	R01 AI052319	9/1/12	8/31/13	343,525
93.855	TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	U19 AI096111	7/8/11	6/30/12	229,497
93.855	TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	U19 AI096111	7/1/12	6/30/13	2,771,097
93.855	THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION	R01 AI076105	3/1/12	5/31/13	428,521
93.855	THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS	R01 AI061628	12/1/11	11/30/12	319,024
93.855	THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS	R01 AI061628	12/1/12	11/30/13	279,149
93.855	TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION	R01 AI026672	4/1/12	5/31/13	271,872
93.855	TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION	R01 A0026672	6/1/13	6/30/14	13,046
93.856	MINIMIZING MASS PANIC WITH SALIVA TESTS FOR RADIATION EXPOSURE	R01 AI080330	6/1/11	5/31/12	1,456
93.856	MINIMIZING MASS PANIC WITH SALIVA TESTS FOR RADIATION EXPOSURE	R01 AI080330	6/1/12	5/31/14	289,152
	Total – NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES				97,674,869
	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES:				
93.846	D4Z4 CODING TRANSCRIPTS AND FSHD	R01 AR045203	2/1/12	1/31/13	222,353
93.846	D4Z4 CODING TRANSCRIPTS AND FSHD	R01 AR045203	2/1/13	1/31/14	99,949
93.846	LINEAGE DETERMINATION IN MUSCLE	R01 AR045113	5/1/11	4/30/12	(371)
93.846	LINEAGE DETERMINATION IN MUSCLE	R01 AR045113	5/1/12	4/30/13	240,839
93.846	LINEAGE DETERMINATION IN MUSCLE	R01 AR045113	5/1/13	4/30/14	41,565
93.846	PBX HOMEODOMAIN PROTEINS IN SKELETAL MUSCLE DIFFERENTIATION	R03 AR057477	9/1/11	8/31/12	13,375
93.846	PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYSTROPHY	R01 AR056949	7/1/11	6/30/12	16,937
93.846	PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYSTROPHY	R01 AR056949	7/1/12	6/30/13	827,375
93.846	ROLE OF AIR POLLUTION IN RHEUMATOID ARTHRITIS INCIDENCE AND EXACERBATION	R03 AR056818	6/1/11	5/31/13	58,879
	Total – NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES				1,520,901
	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING:				
93.286	THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	R01 EB008400	5/1/12	4/30/13	363,066
93.286	THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	R01 EB008400	5/1/13	4/30/14	64,224
	Total – NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING				427,290

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.172	NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT: TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	R01 HD076585	9/15/12	8/31/13	\$ 460,242
93.865	CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	R01 HD058304	7/1/11	7/31/12	99,883
93.865	GENETIC MECHANISMS OF HINDBRAIN SEGMENTATION	R01 HD037909	6/1/09	5/31/12	3,709
93.865	MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	P01 HD064915	7/1/11	6/30/12	403,521
93.865	MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	P01 HD064915	7/1/12	6/30/13	1,433,335
93.865	PREGNANCY OUTCOMES IN WOMEN WITH DISABILITIES: EXPLORATORY RESEARCH	R21 HD073024	4/15/13	3/31/14	4,720
	Total – NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT				2,405,410
93.121	NATIONAL INSTITUTE OF DENTAL AND CRANIAL RESEARCH: IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND GENITAL MUCOSAL IMMUNITY	R01 DE019063	6/1/11	5/31/13	312,510
93.121	PAVING THE WAY FOR A NOVEL THERAPEUTIC APPROACH TO COMBAT HIV	DP2 DE023321	9/30/12	8/31/17	141,950
	Total – NATIONAL INSTITUTE OF DENTAL AND CRANIAL RESEARCH				454,460
93.847	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES: ACUTE RENAL FAILURE: MECHANISMS AND ADAPTIVE RESPONSES	R01 DK038432	1/1/12	12/31/12	228,346
93.847	ACUTE RENAL FAILURE: MECHANISMS AND ADAPTIVE RESPONSES	R01 DK038432	1/1/13	12/31/13	201,315
93.847	CORE CENTER OF EXCELLENCE IN HEMATOLOGY	P30 DK056465	7/1/11	6/30/12	27,980
93.847	CORE CENTER OF EXCELLENCE IN HEMATOLOGY	P30 DK056465	7/1/13	6/30/14	1,858,499
93.847	FUNCTION OF HUMAN AND MOUSE BETA-GLOBIN LOCUS CONTROL REGIONS	R37 DK044746	4/1/12	3/31/13	749,543
93.847	FUNCTION OF HUMAN AND MOUSE BETA-GLOBIN LOCUS CONTROL REGIONS	R37 DK044746	4/1/13	3/31/14	193,680
93.847	GENERATING IPS CELLS BY REPROGRAMMING USING SMALL MOLECULES	K08 DK082783	1/1/12	12/31/12	63,206
93.847	GENERATING IPS CELLS BY REPROGRAMMING USING SMALL MOLECULES	K08 DK082783	1/1/13	12/31/13	73,230
93.847	GENETIC DISCOVERY OF NEW REGULATORS OF FATTY ACID SYNTHESIS	R01 DK085113	4/1/12	7/1/12	(56)
93.847	QUANTITATIVE MODELS AND METHODS FOR GENETIC ORGANIZATION	K25 DK082791	7/1/11	6/30/12	(91)
93.847	QUANTITATIVE MODELS AND METHODS FOR GENETIC ORGANIZATION	K25 DK082791	7/1/12	12/31/12	46,912
93.847	RNA AS A HORMONE: SYSTEMIC SIGNALING IN MAMMALS VIA CIRCULATING, CELL-FREE SMALL RNA'S	R01 DK085714	9/1/11	8/31/12	251,658
93.847	RNA AS A HORMONE: SYSTEMIC SIGNALING IN MAMMALS VIA CIRCULATING, CELL-FREE SMALL RNA'S	R01 DK085714	9/1/12	8/31/13	448,953
93.847	SHARED HOST GENETICS AND BACTERIAL ADAPTATION IN THE TRANSMISSION OF H. PYLORI	K01 DK090103	3/5/12	12/31/12	48,627
93.847	SHARED HOST GENETICS AND BACTERIAL ADAPTATION IN THE TRANSMISSION OF H. PYLORI	K01 DK090103	1/1/13	12/31/13	41,975
93.847	STARVATION MEDIATED LONGEVITY IN C. ELEGANS ADULTS	R01 DK079273	5/1/11	4/30/12	(102,706)
93.847	STARVATION MEDIATED LONGEVITY IN C. ELEGANS ADULTS	R01 DK079273	5/1/12	10/31/12	102,885
93.847	TRANSCRIPTIONAL CONTROL OF STROMA DEPENDENT APOPTOSIS IN MDS	K08 DK085156	6/1/11	5/31/12	97
93.847	TRANSCRIPTIONAL CONTROL OF STROMA DEPENDENT APOPTOSIS IN MDS	K08 DK085156	6/1/12	5/31/13	147,597
93.847	TRANSCRIPTIONAL CONTROL OF STROMA DEPENDENT APOPTOSIS IN MDS	K08 DK085156	6/1/13	5/31/14	13,299
93.849	DEVELOPMENT AND SAFETY EVALUATION OF CHEMO-PROTECTIVE GENE THERAPY VECTORS	K01 DK076973	9/1/11	8/31/12	29,106
	Total – NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES				4,424,055
93.113	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES: BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS USING METABOLIC FOOTPRINTING	R01 ES020819	9/21/11	6/30/12	20,937
93.113	BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS USING METABOLIC FOOTPRINTING	R01 ES020819	7/1/12	6/30/13	377,357
93.113	BISPHENOL A LEVELS AND ENDOMETRIOSIS RISK IN REPRODUCTIVE-AGE WOMEN	R03 ES019976	4/1/12	3/31/14	112,170
93.113	CADMIUM EXPOSURE AND RISK OF BREAST CANCER IN THE WOMEN'S HEALTH INITIATIVE	R01 ES019667	9/1/11	5/31/12	97,506
93.113	CADMIUM EXPOSURE AND RISK OF BREAST CANCER IN THE WOMEN'S HEALTH INITIATIVE	R01 ES019667	6/1/12	5/31/13	370,213
93.113	CADMIUM EXPOSURE AND RISK OF BREAST CANCER IN THE WOMEN'S HEALTH INITIATIVE	R01 ES019667	6/1/13	5/31/14	6,167
93.113	EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	R01 ES020116	6/1/11	5/31/12	30,970
93.113	EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	R01 ES020116	6/1/12	4/30/13	534,172
93.113	EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	R01 ES020116	5/1/13	4/30/14	59,147
93.113	FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER DATA	R01 ES017030	6/1/11	5/31/12	(5,311)

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.113	FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER DATA	R01 ES017030	6/1/12	5/31/14	\$ 252,505
93.113	MECHANISMS OF ENVIRONMENTAL AND NUCLEAR AND MITOCHONDRIAL MUTAGENESIS	R01 ES019319	7/25/11	4/30/12	(355)
93.113	MECHANISMS OF ENVIRONMENTAL AND NUCLEAR AND MITOCHONDRIAL MUTAGENESIS	R01 ES019319	5/1/12	4/30/13	427,614
93.113	MECHANISMS OF ENVIRONMENTAL AND NUCLEAR AND MITOCHONDRIAL MUTAGENESIS	R01 ES019319	5/1/13	4/30/14	95,613
93.113	POSTDOCTORAL FELLOW: SEAN TAYLOR	F32 ES021703	8/1/12	7/31/13	47,828
93.113	STATISTICAL METHODS FOR GXE INTERACTIONS: MEASUREMENT ERROR AND TIME VARYING EXPOSURES	R21 ES022332	2/1/13	1/31/14	30,120
Total – NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES					2,456,653
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES:					
93.701	ARRA – REGULATION OF CHROMOSOME SEGREGATION	R01 GM064386	9/29/09	6/30/12	369
93.839	PREDOCTORAL FELLOW: ERIC ALCID	F31 GM101944	5/15/12	5/14/13	30,474
93.839	PREDOCTORAL FELLOW: ERIC ALCID	F31 GM101944	5/15/13	5/14/14	5,819
93.859	CELL CYCLE REGULATION OF THE YEAST HO GENE	R01 GM041073	5/1/10	4/30/12	(5,651)
93.859	CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	U01 GM070749	5/1/11	4/30/12	379,199
93.859	CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	U01 GM070749	5/1/12	4/30/13	871,624
93.859	CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	U01 GM070749	5/1/13	4/30/14	52,626
93.859	DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS	R01 GM097479	4/18/11	3/31/12	27,492
93.859	DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS	R01 GM097479	4/1/12	3/31/13	444,438
93.859	DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS	R01 GM097479	4/1/13	3/31/14	113,438
93.859	FUNCTIONS AND MECHANISMS OF THE ENDOCYTOTIC ADAPTOR DAB2	R01 GM066257	6/1/11	5/31/13	4,061
93.859	GENETIC CONFLICT SHAPES CENTROMERES AND HETEROCHROMATIN	R01 GM074108	7/1/11	6/30/12	(23,973)
93.859	GENETIC CONFLICT SHAPES CENTROMERES AND HETEROCHROMATIN	R01 GM074108	7/1/12	6/30/13	383,764
93.859	MAPPING EPISTASIS IN MOLECULAR EVOLUTION: THE INFLUENZA NUCLEOPROTEIN	R01 GM102198	9/1/12	5/31/13	281,798
93.859	MAPPING EPISTASIS IN MOLECULAR EVOLUTION: THE INFLUENZA NUCLEOPROTEIN	R01 GM102198	6/1/13	5/31/14	32,320
93.859	MECHANISMS AND FUNCTIONS OF ATP-DEPENDENT CHROMATIN REMODELING	R01 GM058465	7/1/11	9/16/12	62,229
93.859	MECHANISMS AND FUNCTIONS OF ATP-DEPENDENT CHROMATIN REMODELING	R01 GM058465	9/17/12	8/31/13	367,230
93.859	MECHANISMS OF EPITHELIAL REMODELING DURING ORGAN DEVELOPMENT IN C. ELEGANS	R01 GM098583	9/1/11	8/31/12	34,331
93.859	MECHANISMS OF EPITHELIAL REMODELING DURING ORGAN DEVELOPMENT IN C. ELEGANS	R01 GM098583	9/1/12	8/31/13	203,005
93.859	MECHANISMS OF EUKARYOTIC TRANSCRIPTION ACTIVATION	R01 GM075114	2/1/12	1/31/13	366,249
93.859	MECHANISMS OF EUKARYOTIC TRANSCRIPTION ACTIVATION	R01 GM075114	2/1/13	1/31/14	232,262
93.859	MOLECULAR ANALYSIS OF EUKARYOTIC TRANSCRIPTION	R01 GM053451	5/1/11	4/30/12	119
93.859	MOLECULAR ANALYSIS OF EUKARYOTIC TRANSCRIPTION	R01 GM053451	5/1/12	4/30/13	589,350
93.859	MOLECULAR ANALYSIS OF EUKARYOTIC TRANSCRIPTION	R01 GM053451	5/1/13	4/30/14	93,776
93.859	MOLECULAR ANALYSIS OF HOTSPOTS OF GENETIC RECOMBINATION	R01 GM031693	8/1/11	7/31/12	65,946
93.859	MOLECULAR ANALYSIS OF HOTSPOTS OF GENETIC RECOMBINATION	R01 GM031693	8/1/12	7/31/13	624,659
93.859	MOLECULAR AND CELLULAR MECHANISMS OF WOUND REPAIR AND MORPHOGENESIS	R01 GM092731	9/1/11	8/31/12	88,205
93.859	MOLECULAR AND CELLULAR MECHANISMS OF WOUND REPAIR AND MORPHOGENESIS	R01 GM092731	9/1/12	8/31/13	435,742
93.859	MOLECULAR MECHANISMS OF GENETIC RECOMBINATION	R01 GM032194	7/1/11	6/30/12	1,649
93.859	MOLECULAR MECHANISMS OF GENETIC RECOMBINATION	R01 GM032194	7/1/12	6/30/13	481,850
93.859	PHOSPHORYLATION OF GAP JUNCTION PROTEINS	R01 GM055632	1/1/12	12/31/12	202,427
93.859	PHOSPHORYLATION OF GAP JUNCTION PROTEINS	R01 GM055632	1/1/13	12/31/13	180,808
93.859	POSTDOCTORAL FELLOW – MIA LEVINE	F32 GM097897	5/1/12	4/30/13	45,914
93.859	PREDICTING PROTEIN-DNA INTERACTIONS WITH STRUCTURAL MODELS	R01 GM088277	8/1/11	7/31/12	39,751
93.859	PREDICTING PROTEIN-DNA INTERACTIONS WITH STRUCTURAL MODELS	R01 GM088277	8/1/12	7/31/13	232,285
93.859	REGULATION OF CENTROMERIC CHROMATIN	R01 GM078069	2/10/12	1/31/13	208,343
93.859	REGULATION OF CENTROMERIC CHROMATIN	R01 GM078069	2/1/13	1/31/14	131,192
93.859	REGULATION OF CHROMOSOME SEGREGATION	R01 GM064386	7/1/11	6/30/12	1,479
93.859	REGULATION OF CHROMOSOME SEGREGATION	R01 GM064386	7/1/12	6/30/13	384,768
93.859	REGULATION OF DNA REPLICATION BY HISTONE MODIFICATIONS	R01 GM078259	8/1/11	7/31/12	29,257
93.859	REGULATION OF DNA REPLICATION BY HISTONE MODIFICATIONS	R01 GM078259	8/1/12	7/31/13	259,801
93.859	REGULATION OF MEMBRANE-CORTICAL CYTOSKELETON CROSSTALK BY WASH	R01 GM097083	7/1/11	6/30/12	(8,303)
93.859	REGULATION OF MEMBRANE-CORTICAL CYTOSKELETON CROSSTALK BY WASH	R01 GM097083	7/1/12	6/30/13	374,203

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.859	STATISTICAL METHODS FOR INTEGRATIVE ANALYSIS OF GENOMICS AND PROTEOMICS DATA	R01 GM082802	5/1/12	12/30/13	\$ 164,853
93.859	STATISTICAL METHODS FOR MEDICAL TESTS AND BIOMARKERS	R01 GM054438	4/1/12	3/31/13	200,090
93.859	STATISTICAL METHODS FOR MEDICAL TESTS AND BIOMARKERS	R01 GM054438	4/1/13	3/31/14	54,981
93.859	STATISTICAL METHODS FOR PROSPECTIVE EVALUATION OF BIOMARKERS	R01 GM085047	8/1/11	7/31/12	48,216
93.859	STATISTICAL METHODS FOR PROSPECTIVE EVALUATION OF BIOMARKERS	R01 GM085047	8/1/12	7/31/14	287,709
93.859	STRUCTURE, FUNCTION, AND ENGINEERING OF NUCLEASE CATALYSTS	R01 GM049857	1/1/12	12/31/12	194,683
93.859	STRUCTURE, FUNCTION, AND ENGINEERING OF NUCLEASE CATALYSTS	R01 GM049857	1/1/13	12/31/13	246,765
93.859	THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICKLEBACK SPECIES PAIRS	R01 GM089733	9/1/11	8/31/12	95,353
93.859	THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICKLEBACK SPECIES PAIRS	R01 GM089733	9/1/12	8/31/14	330,000
93.859	VARIATION, FUNCTIONS, AND DYNAMICS OF HUMAN SUBTELOMERES	R01 GM057070	9/1/10	11/30/12	117,084
	Total – NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES				<u>10,066,059</u>
	NATIONAL INSTITUTE OF MENTAL HEALTH:				
93.242	DESIGNS AND METHODS FOR SEQUENCE-BASED VALIDATION ANALYSIS	R01 MH084621	7/1/10	10/31/12	52,384
93.242	MECHANISMS OF SYNAPSE REMODELING	R00 MH085039	8/22/11	6/30/12	(340)
93.242	MECHANISMS OF SYNAPSE REMODELING	R00 MH085039	7/1/12	6/30/13	240,243
	Total – NATIONAL INSTITUTE OF MENTAL HEALTH				<u>292,287</u>
	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE:				
93.853	FETAL MICROCHIMERISM IN THE HUMAN BRAIN	R21 NS071418	2/1/12	1/31/13	118,524
93.853	FETAL MICROCHIMERISM IN THE HUMAN BRAIN	R21 NS071418	2/1/13	1/31/14	115,651
93.853	IDENTIFICATION OF GENES THAT REGULATE ELECTRICAL SYNAPSE FORMATION IN VIVO	R21 NS076950	7/1/12	6/30/13	192,182
93.853	POSTDOCTORAL FELLOW: ADAM MILLER	F32 NS074839	3/15/12	3/14/13	38,325
93.853	POSTDOCTORAL FELLOW: ADAM MILLER	F32 NS074839	3/15/13	3/14/14	16,443
93.853	REGULATION OF CORTICAL NEURON MIGRATION	R01 NS080194	2/1/12	1/31/13	229,072
93.853	REGULATION OF CORTICAL NEURON MIGRATION	R01 NS080194	2/1/13	1/31/14	124,757
93.853	THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	P01 NS069539	4/1/11	3/31/12	7,455
93.853	THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	P01 NS069539	4/1/12	3/31/13	829,447
93.853	THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	P01 NS069539	4/1/13	3/31/14	138,606
	Total – NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE				<u>1,810,462</u>
	NATIONAL INSTITUTE ON AGING:				
93.866	DISSECTING THE MECHANISM OF INCREASED GENOMIC INSTABILITY IN AGING YEAST	R37 AG023779	9/1/11	8/31/12	100,257
93.866	DISSECTING THE MECHANISM OF INCREASED GENOMIC INSTABILITY IN AGING YEAST	R37 AG023779	9/1/12	8/31/13	350,733
93.866	GENETIC EPIDEMIOLOGY OF BREAST CANCER: RISK, INSTABILITY AND STATISTICAL METHODS	R01 AG014358	7/1/11	6/30/12	(31)
93.866	GENETIC EPIDEMIOLOGY OF BREAST CANCER: RISK, INSTABILITY AND STATISTICAL METHODS	R01 AG014358	7/1/12	6/30/13	308,895
93.866	MECHANISMS OF ORGANELLE DETERIORATION	R01 AG037512	4/1/12	3/31/13	324,091
93.866	MECHANISMS OF ORGANELLE DETERIORATION	R01 AG037512	4/1/13	3/31/14	63,840
93.866	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	U01 AG032699	9/1/11	8/31/12	620,852
93.866	MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	U01 AG032699	9/1/12	8/31/14	1,415,533
93.866	PREDOCTORAL FELLOW: NATHANIEL THAYER	F31 AG041579	3/16/12	3/15/13	19,427
93.866	PREDOCTORAL FELLOW: NATHANIEL THAYER	F31 AG041579	3/16/13	3/15/14	14,688
	Total – NATIONAL INSTITUTE ON AGING				<u>3,218,285</u>
	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS:				
93.173	CHEMOPROTECTION AGAINST AMINOGLYCOSIDE-INDUCED OTOTOXICITY	R01 DC009807	8/1/11	7/31/12	41,803
93.173	CHEMOPROTECTION AGAINST AMINOGLYCOSIDE-INDUCED OTOTOXICITY	R01 DC009807	8/1/12	7/31/13	431,186
93.173	MOLECULAR MECHANISMS OF OLFACTION IN MAMMALS	R01 DC009324	12/1/11	11/30/13	233,674
93.173	POSTDOCTORAL FELLOW – KYOUNG-HYE YOON	F32 DC011699	7/1/11	6/30/12	9
93.173	POSTDOCTORAL FELLOW – KYOUNG-HYE YOON	F32 DC011699	7/1/12	6/30/13	56,598
	Total – NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS				<u>763,270</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.279	NATIONAL INSTITUTE ON DRUG ABUSE: HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	R01 DA032106	5/1/12	4/30/13	\$ 872,544
93.279	HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	R01 DA032106	5/1/13	4/30/14	33,481
93.279	IMPROVING SMOKING CESSATION QUITLINES: PILOT STUDY OF ACCEPTANCE THERAPY	R21 DA030646	5/1/12	4/30/13	257,894
93.279	POSTDOCTORAL FELLOW; JIN IL LEE	F32 DA033741	10/1/12	7/19/13	41,935
93.279	TARGETED INTERVENTION FOR BIPOLAR SMOKERS	K23 DA026517	9/1/12	8/31/13	88,779
	Total – NATIONAL INSTITUTE ON DRUG ABUSE				<u>1,294,633</u>
93.310	OFFICE OF THE DIRECTOR, NIH: CELLULAR COOPERATION AND CHEATING: AN EXPERIMENTAL AND MATHEMATICAL ANALYSIS	DP2 OD006498	9/30/09	6/30/14	690,773
93.310	DEFINING THE IMPACT OF LIPID SYNTHESIS AND TURNOVER ON AGING IN C. ELEGANS	DP5 OD009189	9/20/11	8/31/12	55,689
93.310	DEFINING THE IMPACT OF LIPID SYNTHESIS AND TURNOVER ON AGING IN C. ELEGANS	DP5 OD009189	9/1/12	8/31/13	343,382
93.351	COMPLETE GENOMIC DNA SEQUENCE OF THE SOOTY MANGABEY MHC	R24 OD012212	1/1/12	12/31/13	507,747
	Total – OFFICE OF THE DIRECTOR, NIH				<u>1,597,591</u>
	Total Direct Grants – Department of Health and Human Services				<u>266,391,424</u>
93.847	Pass-Through Funds – Department of Health and Human Services and Other Federal Agencies: ADAPTIVE BIOTECHNOLOGIES CORPORATION: DEVELOPMENT OF T-CELL RECEPTOR REPERTOIRE PROFILING AS A DIAGNOSTIC FOR T1D	FHCRC089783-02	8/1/11	7/31/12	(1,689)
	Total – ADAPTIVE BIOTECHNOLOGIES CORPORATION				<u>(1,689)</u>
N/A	ALBERT EINSTEIN COLLEGE OF MEDICINE: EVIDENCE FOR ESTABLISHING OPTIMUM PROTEIN INTAKE IN OLDER ADULTS-OTHER FUNDED PORTION	NA	2/1/12	2/2/12	(11,159)
93.393	SERUM LEVELS OF EGFR-SIGNALING-NETWORK ACTIVATORS/INHIBITOR AND RISK OF LUNG CANCER	9-526-2623	9/1/11	8/31/12	1,041
93.393	SERUM LEVELS OF EGFR-SIGNALING-NETWORK ACTIVATORS/INHIBITOR AND RISK OF LUNG CANCER	9-526-6923	9/1/12	8/31/13	4,373
93.853	INTERNATIONAL STROKE GENETICS CONSORTIUM STUDY	9-526-8580	7/1/11	6/30/12	17,883
93.866	EVIDENCE FOR ESTABLISHING OPTIMUM PROTEIN INTAKE IN OLDER ADULTS	9-526-5111	2/1/12	1/31/13	54,216
93.866	EVIDENCE FOR ESTABLISHING OPTIMUM PROTEIN INTAKE IN OLDER ADULTS	310455	2/1/13	1/31/14	30,529
	Total – ALBERT EINSTEIN COLLEGE OF MEDICINE				<u>96,883</u>
93.172	ARIZONA STATE UNIVERSITY: CEGS TECH: INTEGRATE BIOLOGICALLY-ACTIVE MICROSYSTEMS	11-440	8/1/10	7/31/12	3,378
93.172	CEGS TECH: INTEGRATE BIOLOGICALLY-ACTIVE MICROSYSTEMS	13-119	8/1/12	7/31/13	51,389
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY	13-013	9/1/12	8/31/13	85,320
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY/CORE 2	13-012	9/1/12	8/31/13	100,104
93.701	ARRA – A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY	12-843	9/1/11	8/31/12	13,482
93.701	ARRA – A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY/ CORE 2	12-842	9/1/11	8/31/12	54,101
	Total – ARIZONA STATE UNIVERSITY				<u>307,774</u>
93.213	BASTYR UNIVERSITY: BASTRY/UW ONCOMYCOLOGY TRANSLATIONAL RESEARCH CENTER	H34B11-02	9/1/11	8/31/12	4,346
93.213	BASTRY/UW ONCOMYCOLOGY TRANSLATIONAL RESEARCH CENTER	H34B11-03	9/1/12	8/31/13	19,816
93.213	BREAST CANCER INTEGRATIVE ONCOLOGY: PROSPECTIVE MATCHED CONTROLLED OUTCOMES STUDY	H33B11-01	8/1/10	4/30/13	357,546

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.213	BREAST CANCER INTEGRATIVE ONCOLOGY: PROSPECTIVE MATCHED CONTROLLED OUTCOMES STUDY	H33B11-01 (4)	5/1/13	4/30/14	\$ 29,333
	Total – BASTYR UNIVERSITY				411,041
N/A	BATTELLE MEMORIAL INSTITUTE: CENTER FOR BIOLOGICAL FUTURES	272328	4/13/11	4/12/12	(5,617)
N/A	CENTER FOR BIOLOGICAL FUTURES	329889	5/7/12	4/30/13	708,209
	Total – BATTELLE MEMORIAL INSTITUTE				702,592
93.393	BAYLOR COLLEGE OF MEDICINE: ADVANCED GLYCATION END PRODUCTS, THE RECEPTOR, AND COLORECTAL CANCER RISK IN WOMEN	101537407	9/1/11	8/31/13	18,069
93.395	ADULT NEUROBEHAVIORAL LATE EFFECTS OF PEDIATRIC LOW GRADE BRAIN TUMORS	5600476674	6/1/09	4/30/14	18,204
	Total – BAYLOR COLLEGE OF MEDICINE				36,273
93.393	BECKMAN RESEARCH INSTITUTE -CITY OF HOPE: ROLE OF GENETIC SUSCEPTIBILITY IN THERAPY-RELATED MALIGNANCIES	22175.915021.6693	12/1/12	11/30/13	20,592
93.397	CITY OF HOPE LYMPHOMA SPORE	50127.916760.6693	9/23/11	8/31/12	374
93.397	CITY OF HOPE LYMPHOMA SPORE	50127.916768.68	9/1/12	8/31/13	8,500
	Total – BECKMAN RESEARCH INSTITUTE -CITY OF HOPE				29,466
93.866	BETH ISRAEL DEACONESS MEDICAL CENTER: BREAST CANCER RISK FACTORS AMONG WOMEN AGED 75 AND OLDER	01026387	4/1/13	3/31/14	1,360
	Total – BETH ISRAEL DEACONESS MEDICAL CENTER				1,360
93.393	BIOFORMATIX: ULTRASENSITIVE BIOASSAYS USING PALLADIUM CATALYZED CHEMICAL AMPLIFICATION	NA	9/2/11	2/28/14	4,532
	Total – BIOFORMATIX				4,532
N/A	BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY: THERAPIES FOR HEMATOPOIETIC SYNDROME, BONE MARROW STROMAL CELL LOSS, AND VASCULAR INJURY RESULTING FROM ACUTE EXPOSURE TO IONIZING RADIATION	HHSO100200800064C	9/16/08	9/15/12	133,193
	Total – BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY				133,193
93.172	BOSTON UNIVERSITY: METHODS FOR THE ANALYSIS AND INTEGRATIONS OF NEXT-GENERATION SEQUENCING	4500000944	3/1/12	2/28/14	118,805
	Total – BOSTON UNIVERSITY				118,805
93.701	BRIGHAM AND WOMEN'S HOSPITAL: ARRA – GENOME-WIDE ASSOCIATION STUDY OF ENDOMETRIAL CANCER	105130	9/30/09	8/31/12	13,766
	Total – BRIGHAM AND WOMEN'S HOSPITAL				13,766
93.394	BROAD INSTITUTE: PROTEO-GENOMIC DISCOVERY, PRIORITIZATION, AND VERIFICATION OF CANCER BIOMARKERS	6610200-5500000391	8/26/11	7/31/12	552,856
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION, AND VERIFICATION OF CANCER BIOMARKERS	6610202-5500000391	8/1/12	7/31/13	1,252,464
	Total – BROAD INSTITUTE				1,805,320
93.113	BROWN UNIVERSITY: AMBIENT AIR POLLUTION AND INCIDENT STROKE	00000541	7/1/12	3/31/14	22,533
	Total – BROWN UNIVERSITY				22,533

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.395	CANCER RESEARCH AND BIOSTATISTICS: STAFF ASSIGNMENT: RANKIN – CRAB	AWOA	1/1/12	1/2/12	\$ (17,033)
93.399	STAFF ASSIGNMENT AGREEMENT FOR GARNET ANDERSON	SA20110601AND	6/1/11	5/31/12	(638)
93.399	STAFF ASSIGNMENT AGREEMENT FOR KATIE ARNOLD	SA20100701ARN	6/1/10	5/31/11	(634)
93.399	STAFF ASSIGNMENT AGREEMENT FOR KATIE ARNOLD	SA20110601ARN	6/1/11	5/31/12	(3,403)
	Total – CANCER RESEARCH AND BIOSTATISTICS				<u>(21,708)</u>
	CASE WESTERN RESERVE UNIVERSITY: GENETIC DETERMINANTS OF BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RES506500	9/26/11	8/31/12	79,134
93.399	GENETIC DETERMINANTS OF BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RES507597	9/1/12	8/31/13	101,873
	Total – CASE WESTERN RESERVE UNIVERSITY				<u>181,007</u>
93.396	CEDARS-SINAI MEDICAL CENTER: PROSTATE CANCER BONE METASTASIS: BIOLOGY AND TARGETING/PATHOLOGY AND LABORATORY SUPPORT CORE	0000799454	8/1/11	7/31/12	708
93.396	PROSTATE CANCER BONE METASTASIS: BIOLOGY AND TARGETING/PATHOLOGY AND LABORATORY SUPPORT CORE	894218	8/1/12	7/31/13	7,106
	Total – CEDARS-SINAI MEDICAL CENTER				<u>7,814</u>
N/A	CELGENE: LARGE-SCALE HUMAN PLACENTA PROGENITOR CELL-DERIVED ERYTHROCYTE PRODUCTION – CONTINUOUS RED BLOOD CELL PRODUCTION	FA9550-08-01-0392	10/1/09	6/30/12	22,648
	Total – CELGENE				<u>22,648</u>
93.393	CITY OF HOPE NATIONAL MEDICAL CENTER: ROLE OF GENETIC SUSCEPTIBILITY IN THERAPY-RELATED SUBSEQUENT MALIGNANCIES	22175/915021/6693	1/1/10	11/30/12	20,895
	Total – CITY OF HOPE NATIONAL MEDICAL CENTER				<u>20,895</u>
93.067	COLUMBIA UNIVERSITY MEDICAL CENTER: RAPID SCALE UP OF HIV/AIDS CARE AND TREATMENT SERVICES IN KINGDOM OF SWAZILAND	5U2GPS002005-04	9/30/12	9/29/13	129,658
93.067	RAPID SCALEUP OF HIV/AIDS CARE AND TREATMENT SERVICES IN THE KINGDOM OF SWAZILAND	NA	8/1/10	9/29/12	56,578
93.701	ARRA – MOLECULAR EPIDEMIOLOGY AND LUNG CANCER	5-37897 SUBAWARD 1	8/1/09	7/31/12	1,249
93.847	ANALYSIS OF NGAL METABOLISM IDENTIFIES A THERAPY FOR IRON OVERLOAD	1 (GG006245)	9/1/11	8/31/13	52,249
93.847	IRON LIPOCALIN NGAL IN KIDNEY DISEASE	GG006353	12/12/11	11/30/13	91,190
	Total – COLUMBIA UNIVERSITY MEDICAL CENTER				<u>330,924</u>
N/A	COURTESY ASSOCIATES: BURKITT LYMPHOMA TRIAL NETWORK	GS-23-F-0274M-59	1/1/13	9/30/13	114,050
	Total – COURTESY ASSOCIATES				<u>114,050</u>
93.393	DANA-FARBER CANCER INSTITUTE: PROSPECTIVE COHORT COLLABORATIVE IN PANCREATIC CANCER EPIDEMIOLOGY AND PATHOGENESIS	1144806	9/1/11	8/31/12	2,512
93.393	PROSPECTIVE COHORT COLLABORATIVE IN PANCREATIC CANCER EPIDEMIOLOGY AND PATHOGENESIS	1144807	9/1/12	8/31/13	4,350
93.855	FUNCTIONAL GENOMIC ANALYSIS OF THE CD8 T CELL RESPONSE TO HIV VACCINES IN HUMANS	1194802	9/1/11	8/31/12	90,895
93.855	FUNCTIONAL GENOMIC ANALYSIS OF THE CD8 T CELL RESPONSE TO HIV VACCINES IN HUMANS	1194803	9/1/12	8/31/13	122,186
	Total – DANA-FARBER CANCER INSTITUTE				<u>219,943</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.393	DARTMOUTH: TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	NA	1/1/12	1/2/12	\$ (143,838)
	Total – DARTMOUTH				(143,838)
N/A	DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER: TOBACCO USE AND ALCOHOL MISUSE AMONG PARTICIPANTS OF THE MILLENNIUM COHORT STUDY	VA PO 663-D20023	5/9/12	4/30/13	49,779
N/A	TOBACCO USE AND ALCOHOL MISUSE AMONG PARTICIPANTS OF THE MILLENNIUM COHORT STUDY	VA PO #663D30015	5/1/13	4/30/14	10,253
	Total – DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER				60,032
N/A	DUKE UNIVERSITY: SCLERODERMA CYCLOPHOSPHAMIDE OR TRANSPLANTATION (SCOT) – FIXED PRICE COMPONENT	102970	1/1/08	7/31/11	(9,658)
N/A	SCOT: A RANDOMIZED, OPEN-LABEL, PHASE II/III MULTICENTER STUDY OF HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY	HHSN272201100025C-SI	11/1/11	10/31/12	7,009
93.855	CHAVI STATISTICAL AND DATA MANAGEMENT CENTER	209382	7/1/11	6/30/12	5
93.855	CHAVI-ID: OPERATIONS AND MANAGEMENT SUPPORT COMPONENT SCHARP	2031957	7/15/12	6/30/13	322,128
	Total – DUKE UNIVERSITY				319,484
93.855	FAMILY HEALTH INTERNATIONAL (FHI360): LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORK: HIV PREVENTION TRIALS NETWORK 065 SDMC PERSONNEL	ID 0080.0187/985	6/1/12	5/31/13	465,317
	Total – FAMILY HEALTH INTERNATIONAL (FHI360)				465,317
93.846	GEORGETOWN UNIVERSITY: VALIDATION OF PROMIS IN DIVERSE CANCER POPULATIONS	RX 4442-007-FHCRC	8/1/11	7/31/12	10,594
93.846	VALIDATION OF PROMIS IN DIVERSE CANCER POPULATIONS	4442-007-FHCRC	8/1/12	7/31/14	140,785
	Total – GEORGETOWN UNIVERSITY				151,379
93.172	GROUP HEALTH COOPERATIVE: E-MERGE II	2011119340	8/15/11	7/31/12	1,850
93.172	GENETIC DISCOVERY AND APPLICATION IN A CLINICAL SETTING: CONTINUING A PARTNERSHIP	2012119952	8/1/12	7/31/13	32,591
93.393	SYSTEMS OF SUPPORT (SOS) TO INCREASE COLON CANCER SCREENING AND FOLLOW-UP	2012113478	6/1/12	5/31/13	38,727
93.397	STUDYING COLORECTAL CANCER EFFECTIVENESS OF SCREENING STRATEGIES (SUCCESS)	2011120262	9/20/11	8/31/12	3,809
93.397	STUDYING COLORECTAL CANCER: EFFECTIVENESS OF SCREENING STRATEGIES (SUCCESS)	2012121497	9/1/12	5/31/13	7,416
93.866	ALZHEIMER'S DISEASE PATIENT REGISTRY	2012121173	9/1/12	8/31/13	17,977
93.866	ALZHEIMER'S DISEASE PATIENT REGISTRY (ADPR)	2011118912	9/1/11	8/31/12	3,881
93.866	ORAL CONTRACEPTIVE USE AND FRACTURES AROUND THE MENOPAUSAL TRANSITION	2012110773	6/1/12	5/31/13	20,527
	Total – GROUP HEALTH COOPERATIVE				126,778
93.395	GYNECOLOGIC ONCOLOGY GROUP: GOG AGREEMENT – FUNDS FOR COCHAIR OF THE GOG CERVIX COMMITTEE	CA27469-32 CERVIX CO	4/1/12	3/31/13	6,872
93.395	GOG AGREEMENT – FUNDS FOR COCHAIR OF THE GOG CERVIX COMMITTEE	CA27469-33 CERVIX CO	4/1/13	2/28/14	1,380
93.395	GYNECOLOGICAL ONCOLOGY GROUP	27469-23	4/1/04	3/31/16	125,829
	Total – GYNECOLOGIC ONCOLOGY GROUP				134,081
93.393	H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE: FOLLOW-UP OF OVARIAN CANCER GENETIC ASSOCIATION AND INTERACTION STUDIES (FOCI)	10-15915-02-05-G2	7/1/11	6/30/12	(26)
93.393	FOLLOW-UP OF OVARIAN CANCER GENETIC ASSOCIATION AND INTERACTION STUDIES (FOCI)	10-15915-03-05-G2	7/1/12	6/30/13	19,386
	Total – H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE				19,360

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.393	HARVARD UNIVERSITY: TRANSDISCIPLINARY CANCER GENOMICS RESEARCH: POST-GWA INITIATIVE	114080_5029131	7/1/12	6/30/13	\$ 87,770
	Total – HARVARD UNIVERSITY				87,770
93.393	HEALTH RESEARCH INCORPORATED: FLAXSEED EFFECTS ON HORMONES AND LIGNANS: ROLE OF RACE, GENES, AND GUT MICROBIOME	83-01	9/25/12	8/31/14	65,864
	Total – HEALTH RESEARCH INCORPORATED				65,864
N/A	HENRY M. JACKSON FOUNDATION: STATISTICAL AND DATA MANAGEMENT SUPPORT FOR ANALYSIS RELATED TO VACCINE TRIAL (RV144) AND ASSOCIATED TRIALS	694251	2/1/10	9/30/13	993,045
	Total – HENRY M. JACKSON FOUNDATION				993,045
93.393	INSTITUTE FOR CANCER RESEARCH: GENETIC FACTORS AND THEIR ROLE IN DETERMINING CHEMOPREVENTION EFFECTIVENESS (SELECT) AND BIOPSY OUTCOME IN A CHEMOPREVENTION COHORT (PCPT)	ELLIPSE	5/1/13	4/30/14	619
	Total – INSTITUTE FOR CANCER RESEARCH				619
93.393	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER: ONE-CARBON METABOLISM BIOMARKERS AND LUNG CANCER RISK	GEP/12/02	1/31/12	8/31/13	41,474
	Total – INTERNATIONAL AGENCY FOR RESEARCH ON CANCER				41,474
93.862	IOWA STATE UNIVERSITY: DNA TARGETING BY TAL EFFECTORS	430-46-05A	9/1/11	4/30/14	126,355
	Total – IOWA STATE UNIVERSITY				126,355
12.420	JOHNS HOPKINS UNIVERSITY: PROSPECTIVE EVALUATION OF INTRAPROSTATIC INFLAMMATION AND FOCAL ATROPHY AS A PREDICTOR OF RISK OF HIGH GRADE PROSTATE CANCER AND RECURRENCE POST POSTATECTOMY	200155522	7/1/12	6/30/13	27,750
93.242	INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS GROUP (IMPAACT)	2001664569	6/1/12	12/31/13	140,978
93.393	PROSTATE CANCER SUSCEPTIBILITY: THE ICPCG STUDY	2000347454	9/1/11	8/31/13	167,549
93.839	MECHANISMS OF GVHD PREVENTION WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE	2001414485	12/15/11	11/30/13	194,451
93.855	EPIDEMIOLOGY AND ECOLOGY OF VIBRIO CHOLERAE IN BANGLADESH	2000990845	6/15/10	5/31/14	82,414
93.855	STATISTICAL METHODS FOR HIV/AIDS RESEARCH	2000533818	6/5/08	5/31/12	(27)
	Total – JOHNS HOPKINS UNIVERSITY				613,115
93.393	KAISER FOUNDATION RESEARCH INSTITUTE: CRN4: CANCER RESEARCH RESOURCES AND COLLABORATION IN INTEGRATED HEALTHCARE SYSTEMS	115-9341-FHCRC-01	9/25/12	8/31/13	21,080
93.701	ARRA – ADIPOKINES AND BARRETT'S ESOPHAGUS	115-9607-03	9/1/10	8/31/12	(1,494)
	Total – KAISER FOUNDATION RESEARCH INSTITUTE				19,586
93.855	MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION: MICROBICIDE TRIALS NETWORK	9246	6/1/12	12/31/13	231,901
93.855	MICROBICIDE TRIALS NETWORK: COMPLETED TRIAL/LAB ANALYSES	9264	6/1/12	12/31/13	239,136
93.855	MICROBICIDE TRIALS NETWORK: MTN 003	9263	6/1/12	12/31/13	1,192,953
	Total – MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION				1,663,990

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
	MASSACHUSETTS GENERAL HOSPITAL:				
93.393	COMPARATIVE MODELING OF LUNG CANCER CONTROL POLICIES	217238	9/1/11	8/31/12	\$ 73,134
93.393	COMPARATIVE MODELING OF LUNG CANCER CONTROL POLICIES	217238	9/1/12	8/31/13	170,713
93.393	CONTROLLING ESOPHAGEAL CANCER IN THE US: A COLLABORATIVE MODELING PROJECT	217155	9/1/11	8/31/12	59,654
93.393	ESOPHAGEAL CANCER IN THE US: A COMPARATIVE MODELING PROJECT	217155	9/1/12	8/31/13	167,451
	Total – MASSACHUSETTS GENERAL HOSPITAL				470,952
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY:				
93.172	A DATA ANALYSIS CENTER FOR INTEGRATION OF FLY AND WORM MODENCODE DATASETS	5710003101	9/1/11	8/31/12	14,291
	Total – MASSACHUSETTS INSTITUTE OF TECHNOLOGY				14,291
	MAYO CLINIC:				
93.855	BENCHMARKING AND STANDARDIZING HIGH DIMENSIONAL SINGLE CELL DATA ANALYSIS METHODS	5 U01 AI089859-03	7/1/12	11/30/13	146,719
93.855	BIOINFORMATICS INFRASTRUCTURE FOR HIPC: PLANNING AND INITIATION PHASE	4U01AI089859-02	7/1/11	8/31/12	2,854
93.855	ENABLING ADVANCED HIGH AND LOW LEVEL ANALYTICS FOR LUMINEX TECHNOLOGY	5U01AI089859-03	10/1/12	9/30/13	41,470
93.855	HIPC DATABASE INFRASTRUCTURE	62989847	10/1/12	9/30/13	43,128
93.855	STANDARDIZATION OF FLOW CYTOMETRY DATA ANALYSIS USING LYOPLATES AND FITMAN MARKER PANELS	4U01 AI089859-02	12/1/11	11/30/12	100,582
93.855	STANDARDIZATION OF FLOW CYTOMETRY DATA ANALYSIS USING LYOPLATES AND FITMAN MARKER PANELS	63009749	12/1/12	11/30/13	159,236
	Total – MAYO CLINIC				493,989
	MOLECULAR SCIENCES INSTITUTE:				
93.859	SYSTEMS BIOLOGY OF SIGNAL CONTROL IN YEAST	570-30-04	1/1/12	12/31/12	73,337
	Total – MOLECULAR SCIENCES INSTITUTE				73,337
	NATIONAL MARROW DONOR PROGRAM:				
N/A	09-SQOL: PILOT STUDY TO ASSESS THE FEASIBILITY OF COLLECTING QUALITY OF LIFE DATA IN COLLABORATION WITH THE STEM CELL THERAPEUTIC OUTCOMES DATABASE	20014	1/1/11	7/31/12	1,500
93.837	RDSAFE: A MULTICENTER STUDY OF HEMATOPOIETIC STEM CELL DONOR SAFETY AND QUALITY OF LIFE	18817	1/1/10	9/30/14	11,110
93.839	TRANSPLANT CENTER CLINICAL STUDY AGREEMENT	NA	10/10/06	6/30/13	93,522
	Total – NATIONAL MARROW DONOR PROGRAM				106,132
	NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT FOUNDATION:				
93.399	NSABP COMMUNITY CLINICAL ONCOLOGY PROGRAM RESEARCH BASE	PUG-YR27	6/1/12	5/31/13	118,766
93.399	NSABP PREVENTION MAIN MEMBER	AWOA	6/1/13	5/31/14	947
93.399	NSABP PREVENTION MAIN MEMBER AGREEMENT	PUG-YR 26	6/1/11	5/31/12	(323)
93.399	NSABP TREATMENT PROTOCOLS FEDERAL MASTER PURCHASED SERVICES AGREEMENT	287591TFED38-247	2/1/06	1/31/14	37,539
	Total – NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT FOUNDATION				156,929
	OHIO STATE UNIVERSITY RESEARCH FOUNDATION:				
N/A	NOVEL PREDICTORS OF EXCESS MORTALITY IN WOMEN WITH RHEUMATOID ARTHRITIS	RF01314090	3/6/13	9/30/13	1,120
93.701	ARRA – WHI SEQUENCING PROJECT (WHISP)	60028291	8/1/10	3/31/13	329,224
	Total – OHIO STATE UNIVERSITY RESEARCH FOUNDATION				330,344
	OREGON HEALTH & SCIENCE UNIVERSITY:				
93.855	PROGRAMMING HIV IMMUNE RESPONSE FOR BROADLY NEUTRALIZING ANTIBODIES BY VACCINATION	GPRC00816A2	7/1/11	6/30/12	(1,699)
93.855	PROGRAMMING HIV IMMUNE RESPONSE FOR BROADLY NEUTRALIZING ANTIBODIES BY VACCINATION	GPRC00816A2	7/1/12	6/30/13	71,984

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.855	STRATEGIES TO PREVENT AND TREAT EV71 INFECTION	GVGTI0104-FHCRC-GALL	3/1/12	2/28/13	\$ 173,348
93.855	STRATEGIES TO PREVENT AND TREAT EV71 INFECTION	9004157_FHCRC_GALLOW	3/1/13	2/28/14	55,742
	Total – OREGON HEALTH & SCIENCE UNIVERSITY				299,375
	PRESAGE BIOSCIENCES:				
93.393	SIDEPORT NEEDLE ARRAY TECHNOLOGIES FOR PRIORITIZING DRUGS FOR CANCER PATIENTS	PRESAGE STTR SUBAWAR	5/1/12	4/30/14	150,739
	Total – PRESAGE BIOSCIENCES				150,739
	PRESIDENT AND FELLOWS OF HARVARD COLLEGE:				
93.393	GENE-ENVIRONMENT EBV INTERACTIONS IN THE ETIOLOGY OF NPC	23570-114011	9/22/08	7/31/13	24,387
	Total – PRESIDENT AND FELLOWS OF HARVARD COLLEGE				24,387
	PROGRAM FOR APPROPRIATE TECHNOLOGY/PATH:				
93.283	ASSESSMENT OF THE EFFECTIVENESS OF SEASONAL TRIVALENT INFLUENZA VACCINE AMONG CHILDREN IN SENEGAL	CDC.1421-02-0716-SUB	8/1/10	7/31/12	4,524
93.283	SEASONAL INFLUENZA VACCINE EFFECTIVENESS IN A TROPICAL DEVELOPING AFRICAN COUNTRY	CDC.1654-02-05831-SU	8/1/12	3/31/13	33,528
93.855	RECOMBINASE POLYMERASE AMPLIFICATION FOR POINT-OF-CARE DIAGNOSIS OF INFANT HIV-1	NA	7/1/11	6/30/14	162,265
93.856	A MULTIPLEX POINT OF CARE TEST FOR VAGINAL INFECTIONS	NIH-1311-07262-SUB	7/1/10	6/30/13	45,661
	Total – PROGRAM FOR APPROPRIATE TECHNOLOGY/PATH				245,978
	PUGET SOUND BLOOD CENTER:				
93.839	HIGH DOSE GRANULOCYTE TRANSFUSIONS FOR THE TREATMENT OF INFECTION IN NEUTROPENIA THE RING STUDY	948-FHCRC-2009-01	10/1/08	8/31/13	25,741
	Total – PUGET SOUND BLOOD CENTER				25,741
	SCIENCE APPLICATIONS INTERNATIONAL CORPORATION:				
N/A	ARRA – FHCRC ORALCHIP STUDY	12XS531 – ST01	11/7/12	3/31/14	3,761
N/A	ARRA – TRANSLATION STATE PROFILING IN CANCER	12ST1102	10/29/12	9/30/13	382,866
N/A	CABIG-ISRCE: IN SILICO RESEARCH CENTERS OF EXCELLENCE	29XS196	8/24/09	5/23/12	(5,252)
N/A	COLON CFR BIOBANK SUPPLEMENT PROJECT	11YS220	9/1/11	8/31/12	73,919
N/A	HUMAN TO MOUSE LUNG CANCER CHEMOPREVENTION PILOT STUDIES	12XS532	8/16/12	8/15/13	72,021
N/A	REPOSITORY OF MOUSE TISSUES AND PLASMA	12XS485	7/1/12	6/30/14	20,058
	Total – SCIENCE APPLICATIONS INTERNATIONAL CORPORATION				547,373
	SEATTLE BIOMEDICAL RESEARCH INSTITUTE:				
93.855	IDENTIFYING, CHARACTERIZING, AND INDUCING EFFECTIVE ANTI-HIV T CELL RESPONSES	FH-12534XY	7/22/11	5/31/13	26,764
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	FH-16546-2	9/1/11	8/31/12	15,455
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	FH-16546-3	9/1/12	8/31/13	139,200
93.855	OPTIMIZING HIV IMMUNOGEN-BCR INTERACTIONS FOR VACCINE DEVELOPMENT	FH-16062	5/1/11	4/30/14	464,101
	Total – SEATTLE BIOMEDICAL RESEARCH INSTITUTE				645,520
	SEATTLE CHILDREN'S HOSPITAL:				
93.113	GENETICS AND THE ENVIRONMENT ASSOCIATED WITH MALE REPRODUCTION	10370SUB	8/18/11	7/31/13	23,317
93.121	ORAL PATHOGENESIS AND HOST INTERACTION OF KSHV INFECTION	10359SUB	6/7/11	4/30/12	17
93.121	ORAL PATHOGENESIS AND HOST INTERACTION OF KSHV INFECTION – PROJECT 4	10703SUB	5/1/12	4/30/13	27,674
93.121	ORAL PATHOGENESIS AND HOST INTERACTION OF KSHV INFECTIONS – PROJECT 4	10779SUB	5/1/13	4/30/14	2,260
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – ADMINISTRATIVE CORE	10699SUB	5/1/12	4/30/13	14,222
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – ADMINISTRATIVE CORE	10777SUB	5/1/13	4/30/14	10,236
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – CLINICAL CORE	10702SUB	5/1/12	4/30/13	98,997
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION – CLINICAL CORE	10778SUB	5/1/13	4/30/14	15,910
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION -PROJECT 4 PROTEOMICS	10701SUB	5/1/12	4/30/13	25,011

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.121	SITE-DIRECTED GENE CORRECTION OF IPS CELLS FROM PATIENTS WITH INHERITED MARROW FAILURE SYNDROMES-NGEC	10344SUB	7/1/11	6/30/12	\$ (70)
93.837	INTERDISCIPLINARY TRAINING IN GENOME ENGINEERING (COMPONENT 10 OF 11) RL9	10352SUB	7/1/11	6/30/12	1,451
93.839	ULTRASOUND-MEDIATED GENE THERAPY FOR HEMOPHILIA B	10242SUB	7/1/10	6/30/14	54,372
93.847	CHRONIC KIDNEY DISEASE IN SURVIVORS OF HEMATOPOIETIC CELL TRANSPLANT	10378SUB	7/1/11	6/30/12	7,596
93.847	SUBCLINICAL VIRAL INFECTION AND RENAL ALLOGRAFT INJURY	10339SUB	7/1/11	4/30/14	45,318
93.855	CHARACTERISTICS OF IMMUNE DEFICIENCY IN CONGENITAL BONE MARROW FAILURE SYNDROMES	10375SUB	8/11/11	7/31/13	17,084
93.855	FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY – CORE D	10683SUB	8/7/12	7/31/13	183,734
93.855	FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY – PROJECT 2	10684SUB	8/7/12	7/31/13	193,823
93.855	LENTIVIRAL GENE THERAPY FOR WISKOTT-ALDRICH SYNDROME	10190SUB	3/1/10	2/28/14	48,609
93.855	PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM, PROJECT 3	10563SUB	9/1/11	8/31/12	26,886
	Total – SEATTLE CHILDREN’S HOSPITAL				796,447
93.847	SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH: EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	UK16-FHCRC-2	6/1/12	5/31/13	85,682
93.847	EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	UK16-FHCRC-3	6/1/13	5/31/14	9,617
	Total – SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH				95,299
93.393	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH: GENOME-WIDE ASSOCIATION STUDY OF RADIATION EXPOSURE AND BILATERAL BREAST CANCER	BD514957	3/1/12	2/28/13	238,181
93.393	GENOME-WIDE ASSOCIATION STUDY OF RADIATION EXPOSURE AND BILATERAL BREAST CANCER	BD515757	3/1/13	2/28/14	35,109
93.393	MAMMOGRAPHIC DENSITY AND RISK OF CONTRALATERAL BREAST CANCER	BD515247	9/19/12	8/31/13	114,855
	Total – SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH				388,145
93.855	SOLIGENIX, INCORPORATED: BECLOMETHASONE POSTEXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROME	SUB1R43AI100417FHA	7/16/12	6/30/14	60,047
	Total – SOLIGENIX, INCORPORATED				60,047
93.361	ST JUDE CHILDRENS RESEARCH HOSPITAL: EVALUATION OF CARDIOVASCULAR OUTCOMES AMONG CHILDHOOD CANCER SURVIVORS	111504030-7437894	8/1/11	7/31/12	4,898
93.361	EVALUATION OF CARDIOVASCULAR OUTCOMES AMONG CHILDHOOD CANCER SURVIVORS	111504030-7437893	8/1/11	7/31/12	6,933
93.361	EVALUATION OF CARDIOVASCULAR OUTCOMES AMONG CHILDHOOD CANCER SURVIVORS	111504030-7490973	8/1/12	7/31/13	22,245
93.361	EVALUATION OF CARDIOVASCULAR OUTCOMES AMONG CHILDHOOD CANCER SURVIVORS	111504040-7490974	8/1/12	7/31/13	34,386
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287180-7466330	12/1/11	11/30/12	6,120
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287180-7466323	12/1/11	11/30/12	412,107
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287190-7522130	12/1/12	11/30/13	7,548
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287190-7524262	12/1/12	11/30/13	503,529
	Total – ST JUDE CHILDRENS RESEARCH HOSPITAL				997,766
N/A	STANFORD UNIVERSITY: VALIDATING THE CHRONIC CONDITION WAREHOUSE (CCW) ALZHEIMER’S DISEASE AND RELATED DISORDERS OF SENILE DEMENTIA IDENTIFICATION ALGORITHM IN WHI-LINKED CMS DATA	60269608	9/1/12	8/31/13	1,484
93.393	COLON CANCER FAMILY REGISTRY COHORT	AWOA	5/1/13	4/30/14	13,026
93.846	CHEMOPREVENTION OF BASAL CELL CARCINOMA WITH VITAMIN D	60090585-45720-A	7/1/12	6/30/13	44,449
93.855	AUTOMATED COMPARISON OF FLOW DATA FROM HIV AND VACCINE INFECTED SUBJECTS	60036089-52940-A	4/6/12	3/31/14	48,900
	Total – STANFORD UNIVERSITY				107,859

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.395	SWEDISH MEDICAL CENTER: SOUTHWEST ONCOLOGY GROUP (SWOG) SUBAWARD FROM SWEDISH	7701.36 NIH FHCRC	1/1/12	12/31/12	\$ 53,999
	Total – SWEDISH MEDICAL CENTER				53,999
93.865	TEMPLE UNIVERSITY: BV-ASSOCIATED BACTERIA AND ADVERSE PREGNANCY OUTCOMES AMONG URBAN WOMEN	36-0910-172/1(07-08)	4/1/08	9/30/12	23,883
	Total – TEMPLE UNIVERSITY				23,883
N/A	THE CHILDREN'S HOSPITAL OF PHILADELPHIA: RISK-BASED THERAPY ALLOCATION IN CHILDHOOD AML – INTEGRAL STUDIES	960417RSUB_960004061	3/30/12	6/30/14	376,753
93.395	CHILDREN'S ONCOLOGY GROUP CHAIR GRANT – AML COMMITTEE CHAIR	960326-RSUB/95000102	4/13/12	2/28/13	11,081
93.395	CHILDREN'S ONCOLOGY GROUP CHAIR GRANT – AML COMMITTEE CHAIR	PO 960734-RSUB.ACTIV	3/1/13	2/28/14	3,245
93.395	MYELOID LEUKEMIA REFERENCE LABORATORY	960277-RSUB/95000102	4/13/12	2/28/13	146,400
93.395	MYELOID LEUKEMIA REFERENCE LABORATORY	AWOA	3/1/13	2/28/14	69,547
	Total – THE CHILDREN'S HOSPITAL OF PHILADELPHIA				607,026
N/A	THE COALITION OF CANCER COOPERATIVE GROUPS: INFRASTRUCTURE FOR TRANSPLANT PROTOCOLS FOR HIV PLUS PATIENTS WITH HEMATOLOGIC MALIGNANCIES	N02-CM-62212	9/1/12	6/30/13	174,214
N/A	S0518 PHASE III PROSPECTIVE RANDOMIZED COMPARISON OF DEPOT OCTREOTIDE PLUS INTERFERON ALPHA VERSUS DEPOT OCTREOTIDE PLUS BEVACIZUMAB (NSC #704865) IN ADVANCED, POOR PROGNOSIS CARCINOID PATIENTS	CTSU – STATISTICAL S	7/1/12	6/30/13	123,021
	Total – THE COALITION OF CANCER COOPERATIVE GROUPS				297,235
93.395	THE EMMES CORPORATION: AIDS MALIGNANCY CLINICAL TRIALS (AMC)	1568 G NA643	9/1/11	8/31/12	12,307
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	1568 G NA643 – 3	9/1/12	8/31/13	94,834
	Total – THE EMMES CORPORATION				107,141
12.420	THE GENEVA FOUNDATION: CIRCADIAN GENES AND RISK FOR PROSTATE CANCER	S-1241-03	9/1/11	8/31/12	2,368
	Total – THE GENEVA FOUNDATION				2,368
93.395	THE GEORGE WASHINGTON UNIVERSITY: EAST COAST AIDS AND CANCER SPECIMEN RESOURCE	12-M76	9/1/12	8/31/14	40,027
93.395	EC ACSR: AMC HIV POSITIVE TUMOR MOLECULAR CHARACTERIZATION PROJECT	11-M90	9/1/11	8/31/12	37,495
93.395	THE EAST COAST AIDS AND CANCER SPECIMEN RESOURCE (SUPPLEMENT)	12-M79R	9/1/12	8/31/14	300,700
	Total – THE GEORGE WASHINGTON UNIVERSITY				378,222
N/A	THE MITRE CORPORATION: MOLECULAR AND CELLULAR TECHNOLOGIES AND IMPLICATIONS	91687	11/3/11	11/2/13	588,366
	Total – THE MITRE CORPORATION				588,366
93.394	THE REGENTS OF UNIVERSITY OF MICHIGAN: SERUM GLYCO-MARKERS OF EARLY HEPATOCELLULAR CARCINOMA USING A MASS SPEC APPROACH	3002360680	5/1/12	3/30/13	31,104
93.394	SOUTHWEST ONCOLOGY GROUP BIOREPOSITORY	F032175	9/1/12	6/30/13	61,721
93.395	CANCER CONTROL AND PREVENTION BIOSTATISTICS CORE	F0032195	6/1/12	5/31/13	501,165
93.395	PCPT-SELECT COMBINED ACTIVITIES AT SWOG STATISTICAL CENTER	F0032195	6/1/12	5/31/13	579,383
93.395	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT	F026171	1/1/12	12/31/12	10,013
93.395	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT	F027026	1/1/12	12/31/12	20,542
93.395	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT	F025171	1/1/13	6/30/13	10,200
93.395	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT – REPOSITORY TRANSFER	F029717	9/1/11	12/31/12	22,423

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.395	SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT – REPOSITORY TRANSFER	NA	1/1/12	1/2/12	\$ (22,423)
93.395	SUBAWARD TO SUPPORT APPELBAUM AS CHAIR, SWOG LEUKEMIA COMMITTEE	FO25169	1/1/12	10/20/12	20,910
93.395	SWOG CLINICAL COMMUNITY ONCOLOGY PROGRAM RESEARCH BASE	F0032201	6/1/12	5/31/13	23,490
93.396	TRANSDISCIPLINARY STUDIES OF GENETIC VARIATION FOR COLORECTAL CANCER	3002074154	7/1/11	6/30/12	1,052
93.399	PROSTATE CANCER PREVENTION TRIAL – SELECT COMBINED	F021100	6/1/11	5/31/12	2,858
93.399	SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE COCHAIR	F021100	6/1/11	5/31/12	(1,919)
93.701	ARRA – SOUTHWEST ONCOLOGY GROUP OPERATIONS OFFICE GRANT	F027026	1/1/13	6/30/13	10,914
	Total – THE REGENTS OF UNIVERSITY OF MICHIGAN				<u>1,271,433</u>
N/A	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK: A PILOT STUDY OF URINARY BISPHENOL-A IN THE WOMEN’S HEALTH INITIATIVE	R835510	11/1/12	9/30/13	5,515
N/A	DEFINING AND TIMING SUDDEN CARDIAC DEATH/SUDDEN ARRHYTHMIC DEATH IN THE WOMEN’S HEALTH INITIATIVE	R835508	11/1/12	9/30/13	1,666
N/A	SYSTEMIC AND BREAST-CANCER SPECIFIC AUTOIMMUNITY IN THE WHI	R835521	11/1/12	9/30/13	4,690
	Total – THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK				<u>11,871</u>
93.855	THE SCRIPPS RESEARCH INSTITUTE: CENTER FOR HIV/AIDS VACCINE IMMUNOLOGY AND IMMUNOGEN DISCOVERY	5-24912	7/15/12	6/30/13	48,279
	Total – THE SCRIPPS RESEARCH INSTITUTE				<u>48,279</u>
93.395	THE UNIVERSITY OF TEXAS: TARGETING AKT SIGNALING IN AML	31746/98010711	9/20/11	8/31/12	2,876
93.395	TARGETING AKT SIGNALING IN AML	PO# 124691-2100	9/1/12	8/31/14	85,401
	Total – THE UNIVERSITY OF TEXAS				<u>88,277</u>
93.855	UNIVERSITY OF ALABAMA: THE BIOPHYSICAL UNDERPINNINGS OF GP 120 EVOLVABILITY	000384599-014	6/1/12	5/31/13	206,866
93.855	THE BIOPHYSICAL UNDERPINNINGS OF GP 120 EVOLVABILITY	AWOA	6/1/13	5/31/14	10,100
	Total – UNIVERSITY OF ALABAMA				<u>216,966</u>
93.866	UNIVERSITY OF ARIZONA: BIOMARKERS AND GENETIC FACTORS RELATED TO SARCOPENIA IN OLDER WOMEN	Y482831	9/15/07	6/30/13	21,833
	Total – UNIVERSITY OF ARIZONA				<u>21,833</u>
93.121	UNIVERSITY OF CALIFORNIA LOS ANGELES: SALIVARY BIOMARKERS FOR SJORGREN’S SYNDROME DETECTION – DEFINITIVE CLINICAL VALIDATION	1350 G PC349	9/1/12	4/30/13	89,060
93.121	SALIVARY BIOMARKERS FOR SJORGREN’S SYNDROME DETECTION DEFINITIVE CLINICAL VALIDATION	1350 G PC349	9/15/11	8/31/12	55,115
93.393	INCREASING HEPATITIS B SCREENING AMONG KOREAN CHURCH ATTENDEES – LIVER CANCER CONTROL INTERVENTIONS FOR ASIAN AMERICANS	1916 G HB554	9/1/10	8/31/12	4,998
93.393	INCREASING HPV VACCINE UPTAKE IN A LOW INCOME ETHNIC MINORITY POPULATION	1916 G QA044	5/1/12	3/31/13	23,756
93.393	METHODOLOGY CORE – LIVER CANCER CONTROL INTERVENTIONS FOR ASIAN AMERICANS	1916 G HB555	9/1/10	8/31/12	1,999
93.396	INFLUENCES OF MICROENVIRONMENT ON CANCER STEM CELLS	1490 G PB453	9/15/11	8/31/12	32,736
93.396	INFLUENCES OF THE MICROENVIRONMENT ON CANCER STEM CELLS	1490 G PB453	9/1/12	8/31/13	179,098
	Total – UNIVERSITY OF CALIFORNIA LOS ANGELES				<u>386,762</u>
N/A	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO: AN INTEGRATED COMPUTATIONAL PLATFORM FOR FLOW DATA ANALYSIS WITH INTEROPERABILITY BETWEEN DOMAIN EXPERTS	107991	1/1/11	4/30/14	79,719
N/A	PROTOCOL 1997 – HIGH-DOSE IMMUNOSUPPRESSION AND AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE SCLEROSIS (HALT MS) STUDY	ITN10118-00sc	10/1/07	4/30/14	331,226
12.420	PREDICTING PROSTATE CANCER PROGRESSION AT TIME OF DIAGNOSIS	6744SC	6/15/11	6/14/14	62,271

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.393	MODELING NEOPLASTIC PROGRESSION IN BARRETT'S ESOPHAGUS	6797SC	6/1/11	5/31/13	\$ 129,682
93.394	VALIDATION OF PROGNOSTIC AND PATHWAY SIGNATURES IN LETHAL PROSTATE CANCER	6961SC	10/1/11	8/31/12	15,058
93.394	VALIDATION OF PROGNOSTIC AND PATHWAY SIGNATURES IN LETHAL PROSTATE CANCER	6961SC	9/1/12	8/31/13	41,325
93.855	PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM	7365SC	9/1/12	8/31/13	27,674
93.855	VIRAL ONCOLOGY TRANSLATIONAL RESEARCH INITIATIVE SUPPLEMENT TO UCSF-GIVI CENTER FOR AIDS RESEARCH	7278SC	9/1/12	8/31/13	51,338
	Total – UNIVERSITY OF CALIFORNIA, SAN FRANCISCO				<u>738,293</u>
N/A	UNIVERSITY OF FLORIDA: CONTAINING BIOTERRORIST AND EMERGING INFECTIOUS DISEASES	NA	7/1/11	7/2/11	(449,977)
	Total – UNIVERSITY OF FLORIDA				<u>(449,977)</u>
	UNIVERSITY OF HAWAII:				
93.393	COLLABORATIVE GENETIC STUDY OF OVARIAN CANCER RISK	KA0002 (PO ZA08059)	6/1/11	10/31/12	2,588
93.393	INFLAMMATION AND INNATE IMMUNITY GENES AND COLORECTAL CANCER RISK	ZA12148	8/1/11	10/31/12	118,994
93.393	OBESITY, BODY FAT DISTRIBUTION AND CANCER RISK IN THE MULTIETHNIC COHORT	KA0100	9/1/12	8/31/13	153,115
	Total – UNIVERSITY OF HAWAII				<u>274,697</u>
	UNIVERSITY OF MARYLAND, BALTIMORE:				
93.837	INCREASING STEM CELL NUMBERS WHILE RETAINING STEM CELL FUNCTION – NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM	SR00002708	5/1/13	4/30/14	83,838
93.837	INCREASING STEM CELL NUMBERS WHILE RETAINING STEM CELL FUNCTION-NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM	SR00002323	8/1/12	4/30/13	423,194
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM PILOT STUDY	SR00002156	3/1/12	2/28/14	117,936
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM PILOT STUDY	7421-SR00002589	3/1/13	2/28/14	44,324
	Total – UNIVERSITY OF MARYLAND, BALTIMORE				<u>669,292</u>
	UNIVERSITY OF MASSACHUSETTS:				
93.393	URINARY LEVELS OF MELATONIN AND RISK OF BREAST CANCER	11 006242B01	8/1/11	7/31/13	7,242
	Total – UNIVERSITY OF MASSACHUSETTS				<u>7,242</u>
	UNIVERSITY OF MINNESOTA:				
93.394	IMPACT OF GENETIC VARIATION ON RESPONSE TO GO THERAPY IN COG-AML CLINICAL TRIALS	P002603502	4/5/12	3/31/14	65,779
93.865	VIRAL IMMUNOMODULATION AND RATIONAL CMV VACCINE DESIGN	N001926102	4/1/11	1/31/14	116,292
	Total – UNIVERSITY OF MINNESOTA				<u>182,071</u>
	UNIVERSITY OF NEBRASKA:				
93.394	EARLY DIAGNOSIS OF PANCREATIC CANCER	34-1905-2192-007	8/15/11	6/30/12	65,898
93.395	DCTC CLINICAL TRIALS	34-5410-2003-001	4/13/12	2/28/13	9,814
	Total – UNIVERSITY OF NEBRASKA				<u>75,712</u>
	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL:				
93.113	EPIGENETIC MECHANISMS OF PM-MEDIATED CVD RISK	5-32973	8/6/12	4/30/14	48,710
93.113	GENETIC MODIFICATION OF PM-MEDIATED ARRHYTHMOGENESIS	5-30764	8/1/10	5/31/14	9,997
93.855	CAUSAL INFERENCE IN INFECTIOUS DISEASE PREVENTION STUDIES	5-30444	12/1/09	11/30/13	101,975
93.855	SYSTEMS IMMUNOGENETICS OF BIODEFENSE PATHOGENS IN THE COLLABORATIVE CROSS	5-33048	8/5/12	7/31/13	292,648
93.859	ROSETTA: AN INTEGRATED PROTEIN STRUCTURAL MODELING SUITE	5-30195	9/1/09	8/31/13	53,736
	Total – UNIVERSITY OF NORTH CAROLINA CHAPEL HILL				<u>507,066</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.393	UNIVERSITY OF PENNSYLVANIA: POSTGWA STUDIES IN TESTICULAR GERM CELL TUMORS	560146	9/21/12	8/31/13	\$ 48,835
93.396	STEM CELLS, DIFFERENTIATION, AND THERAPEUTIC RESISTANCE IN AML	2674944	2/10/11	1/31/14	90,719
	Total – UNIVERSITY OF PENNSYLVANIA				139,554
N/A	UNIVERSITY OF PITTSBURGH: PROPHYLAXIS VERSUS PREEMPTIVE THERAPY FOR CMV IN R-D+ LIVER TRANSPLANT RECIPIENTS	0024031-2	9/26/11	9/25/13	54,987
93.397	SPORE IN LUNG CANCER PROJECT 4: TARGETING NEUTROPHIL ELASTASE IN LUNG CANCER	9007675 (121211-1)	3/1/12	8/31/12	8,441
93.397	SPORE IN LUNG CANCER PROJECT 4: TARGETING NEUTROPHIL ELASTASE IN LUNG CANCER	9007675 (121211-1)	9/1/12	8/31/13	17,000
93.837	THE EMPHYSEMATOUS MICROENVIRONMENT PROMOTES LUNG TUMORIGENESIS AND PROGRESSION	0021343(121170-1)	3/1/12	4/30/14	46,579
93.855	THE ROLE OF NOVEL, UNCULTIVABLE BACTERIA IN INCIDENT PID	0022494(119409-1)	8/5/11	8/4/13	311,799
	Total – UNIVERSITY OF PITTSBURGH				438,806
	UNIVERSITY OF SOUTHERN CALIFORNIA: FUNCTIONAL ANALYSIS OF GENOME WIDE ASSOCIATIONS IN COLORECTAL CANCER	H44554	2/1/10	1/31/14	57,431
93.393	IDENTIFYING OVARIAN CANCER SUSCEPTIBILITY ALLELES USING GENOME-WIDE SCAN DATA	H47764	8/1/10	7/31/13	67,227
93.393	TRANSDISCIPLINARY STUDIES OF GENETIC VARIATION FOR COLORECTAL CANCER	Y92562	7/1/12	6/30/13	447,308
93.397	MULTI-SCALE COMPLEX SYSTEMS TRANSDISCIPLINARY ANALYSIS OF RESPONSE TO THERAPY	36469328	3/1/13	7/31/13	4,756
	Total – UNIVERSITY OF SOUTHERN CALIFORNIA				576,722
	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER: IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM – ADMIN SUPPLEMENT	152907	6/30/12	6/29/13	129,343
93.394	Total – UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER				129,343
	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO: EDRN DMCC SCIENTIFIC WORKSHOP COORDINATION – MARCH 2013	NA	1/1/13	4/30/13	53,095
93.394	EDRN: CANARY PROSTATE ACTIVE SURVEILLANCE	153609	12/1/12	6/30/13	64,368
93.399	BIOLOGY OF THE PCPT: BIostatISTICS CORE	130636/130629	5/1/09	4/30/14	125,099
	Total – UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO				242,562
	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER: SAN ANTONIO CENTER FOR BIOMARKERS OF RISK FOR PROSTATE CANCER (SABOR)/CFDA TITLE: CANCER DETECTION AND DIAGNOSIS RESEARCH	RGC000000277-110604	2/1/11	6/30/12	310,696
93.394	Total – UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER				310,696
	UNIVERSITY OF WASHINGTON: EAGLE-I INTEGRATION	745745	10/5/12	4/30/13	15,000
N/A	GENETIC RISK FOR SMALLPOX VACCINE RELATED TO MYOCARDITIS	713535	9/30/10	9/29/13	182,892
N/A	SCHOLARLY COMMUNICATIONS LAB	NNLM/TIA	11/1/12	4/30/13	7,270
N/A	STAFF ASSIGNMENT: BALKUS: A DOUBLE BLIND, RANDOMIZED TRIAL OF MONTHLY TREATMENT WITH TOPICAL METRONIDAZOLE AND MICONAZOLE COFORMULATED SUPPOSITORIES	741870	7/1/12	12/31/12	14,190
12.420	VACCINE TO PREVENT BREAST CANCER	731007	9/30/11	9/29/13	16,165
12.910	NEW TECHNOLOGY FOR INSIDE-OUT DESIGN OF NOVEL PROTEIN CATALYSTS	737825	4/1/12	6/7/13	174,423
47.074	THRUST GROUP 3-EVOLUTION OF COOPERATION AND GROUP PROBLEM SOLVING	715531	2/1/11	7/31/12	11,242
66.509	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS – EPA FUNDS	710279	10/1/10	8/31/13	146,077
93.113	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS RESEARCH	728658	8/1/11	7/31/12	8,529
93.113	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS RESEARCH	745341	8/1/12	7/31/13	86,510
93.113	ENDOTOXIN EXPOSURE AND RISK OF PARKINSONISM	664729	9/1/09	7/31/13	147,411

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.113	POLYCYCLIC AROMATIC HYDROCARBON EXPOSURE FROM URBAN AIR POLLUTION, HERPES VIRUS INFECTION AND IMMUNE FUNCTION IN UGANDAN CHILDREN	751574	4/1/13	3/31/14	\$ 1,149
93.113	STATISTICAL METHODS FOR GENE-ENVIRONMENT INTERACTION IN THE PRESENCE OF MEASUREMENT ERROR	738268	4/1/12	3/31/13	17,242
93.135	ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW)	727360	9/30/11	9/29/12	26,474
93.135	ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW) – TALBOT SUBAWARD	745327	9/30/12	9/29/13	44,078
93.135	ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW) [TAYLOR STAFF ASSIGNMENT]	727359	9/30/11	9/29/12	19,118
93.135	LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	727927	9/30/11	9/29/12	37,274
93.135	LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	745351	9/30/12	9/29/13	122,893
93.135	STAFF ASSIGNMENT: TAYLOR – ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW)	745325	9/30/12	9/29/13	38,132
93.172	A COMPREHENSIVE CATALOG OF DNASE1 HYPERSENSITIVE SITES	746123	9/21/12	7/31/13	68,800
93.172	CLINICAL SEQUENCING IN CANCER	734037	12/5/11	11/30/12	17,435
93.172	CLINICAL SEQUENCING IN CANCER: CLINICAL, ETHICAL AND TECHNOLOGICAL STUDIES	748628	12/1/12	11/30/13	10,948
93.242	FOGARTY GLOBAL HEALTH FELLOWSHIP – UPCI	750139	3/1/13	2/28/14	9,502
93.242	OPTIMIZING ANTIRETROVIRAL-BASED HIV PREVENTION FOR HIV AFRICAN DISCORDANT COUPLES	724156	8/10/11	5/31/14	23,674
93.279	REDUCING RISK AND ENHANCING PROTECTIVE FACTORS IN CHILDREN	727192	10/1/11	6/30/12	(201)
93.286	INTRACELLULAR DELIVERY OF PROAPOPTOTIC PEPTIDE DRUGS	739117	4/9/12	3/31/14	72,294
93.286	NRI SMALL: ADVANCED BIOPHOTONICS FOR IMAGE-GUIDED ROBOTIC SURGERY	745215	9/1/12	8/31/14	9,066
93.286	OPTIMIZING DELIVERY OF ANTI-Bc12 siRNA AND ANTI-SENSE OBLIGONUCLEIDES (AS-ODN) TO LYMPHOMA CELLS USING MEMBRANE DISRUPTIVE POLYMERS	546645	3/1/08	2/28/13	157,350
93.310	STAFF ASSIGNMENT FROM UW HORWITZ LAB-NIH PIONEER AWARD	701717	7/1/10	6/30/13	51,862
93.350	ELUCIDATING MICRORNAS IN MYELOID DIFFERENTIATION IN LEUKEMIA	743958	6/1/12	5/31/13	5,856
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	743751	6/1/12	5/31/13	421,735
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (KL2)	742307	6/1/12	5/31/13	108,554
93.350	SUBAWARD FROM THE INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	AWOA	6/1/13	5/31/14	11,222
93.361	PALLIATIVE CARE SYMPTOM MANAGEMENT IN RURAL COMMUNITIES	728816	9/12/11	12/31/12	15,206
93.389	SUBAWARD OF THE INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	724934	6/1/11	5/31/12	(8,543)
93.393	ACCURACY OF BREAST PATHOLOGY AND THE IMPACT OF TECHNOLOGY AND DOUBLE READING	660067	7/7/09	5/31/14	88,723
93.393	ACCURACY OF THE DIAGNOSIS OF MELANOMA AND THE IMPACT OF TECHNOLOGY AND DOUBLE READING	724565	8/1/11	5/31/14	32,333
93.393	CANCER CONTROL DISSEMINATION TO ASIAN AMERICANS	491963	9/29/07	10/31/12	66,449
93.393	CANCER RISKS AMONG TEXTILE WORKERS IN CHINA	522190	4/11/08	2/28/13	88,078
93.393	DIGITAL PATHOLOGY: ACCURACY, VIEWING BEHAVIOR, AND IMAGE CHARACTERIZATION	749763	12/31/12	11/30/13	13,071
93.393	HUMAN RECQ HELICASES IN BIOLOGY AND ONCOLOGY – PROJECT 5: HUMAN TUMOR ANALYSES	742886	7/1/12	6/30/13	123,381
93.393	HUMAN RECQ HELICASES IN BIOLOGY AND ONCOLOGY – PROJECT 5: HUMAN TUMOR ANALYSIS	722118	7/1/11	6/30/12	(9)
93.394	ABERRANT GLYCOSYLATION SIGNATURE IN PANCREATIC CANCER	711818	1/1/11	12/31/12	24,906
93.394	ADVANCED PET/CT IMAGING FOR IMPROVING CLINICAL TRIALS	742846	4/1/12	1/31/13	32,564
93.394	MITOCHONDRIA PROTEOME OF ULCERATIVE COLITIS ASSOCIATED DYSPLASIA	742849	7/13/12	6/30/13	11,262
93.394	MOLECULAR IMAGING OF CANCER AND ITS RESPONSE TO THERAPY	728919	10/1/11	8/31/12	6,912
93.394	MOLECULAR IMAGING OF CANCER AND ITS RESPONSE TO THERAPY	746425	9/1/12	1/31/13	3,144
93.394	MR DIFFUSION TENSOR IMAGING FOR DETECTION AND CHARACTERIZATION OF BREAST LESIONS	700336	7/16/10	5/31/14	20,072
93.394	PANCREATIC JUICE BIOMARKER FOR PANCREATIC CANCER	726037	8/1/11	7/31/13	11,333
93.394	ULTRASOUND ENHANCED DRUG PENETRATION FOR TREATMENT OF PANCREATIC CANCER	735227	12/1/11	8/31/13	43,366
93.395	ADOPTIVE T-CELL THERAPY FOR THE TREATMENT OF HER2-OVEREXPRESSION CANCERS	656643	8/1/09	7/31/12	(385)
93.395	ASSESSMENT OF COGNITIVE AND MOOD EFFECTS FROM ADT IN MEN WITH PROSTATE CANCER	449774	8/7/07	5/31/13	4,021
93.395	ERYTHROPOIETIN BLOCKADE FOR THE TREATMENT OF CANCER	583994	9/25/08	7/31/13	35,078
93.395	PHARMACOGENETICS OF CYCLOPHOSPHAMIDE ADRS IN CHILDREN	729004	9/1/11	8/31/13	96,875

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.395	PHASE II STUDY OF TOPICAL IMIQUIMOD AND WEEKLY ABRAXANE FOR THE TREATMENT OF BREAST CANCER CUTANEOUS METASTASES	661381	8/1/09	5/31/13	\$ 1,678
93.395	VIRAL ONCOPROTEIN TARGETED IMMUNE THERAPY FOR MERKEL CELL CARCINOMA	750685	4/1/13	3/31/14	20,682
93.396	DETECTION, ISOLATION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS	725638	8/1/11	7/31/12	33,584
93.396	DETECTION, ISOLATION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS	745485	8/1/12	7/31/13	231,142
93.396	IMMUNE DIAGNOSTICS AND VACCINE TARGETS: BREAST CANCER ANTIGENS FROM MICE TO WOMEN	728879	9/1/11	8/31/12	65,085
93.396	MECHANISMS AND MARKERS OF PROSTATE CANCER METASTASES	725674	8/1/11	7/31/12	6,801
93.396	MECHANISMS AND MARKERS OF PROSTATE CANCER METASTASES	745494	8/1/12	7/31/13	71,515
93.396	PROJECT 2: TRANSMEMBRANE PROTEASES AND PROSTATE CARCINOGENESIS	725670	8/1/11	7/31/12	29,439
93.396	PROJECT 2: TRANSMEMBRANE PROTEASES AND PROSTATE CARCINOGENESIS	745492	8/1/12	7/31/13	378,046
93.397	LAMININ DYSREGULATION AND PROSTATE CANCER	702935	9/1/10	8/31/12	21,277
93.397	PROJECT 2: LAMININ DYSREGULATION AND PROSTATE CANCER	AWOA	9/1/10	9/2/10	(66)
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	726506	8/5/11	7/31/12	819
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	726508	8/5/11	7/31/12	826
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	726510	8/5/11	7/31/12	1,049
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	746437	8/1/12	7/31/13	29,648
93.398	CANCER PREVENTION TRAINING-NUTRITION EXERCISE AND GENETICS	743561	7/1/12	6/30/14	34,588
93.701	ARRA – A COMPREHENSIVE CATALOGUE OF MOUSE DNASEI HYPERSENSITIVE SITES	709037Z	8/1/10	1/31/13	32,225
93.701	ARRA – ADVANCING INNOVATIVE COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER DIAGNOSTICS	702676Z	9/1/10	8/31/12	121,887
93.701	ARRA – APPLICATION OF RIBO TAG-SEQ TO EXPLORATION OF TUMOR MICROENVIRONMENTS	701967Z	9/1/10	8/31/12	5,739
93.701	ARRA – COMPARATIVE EFFECTIVENESS OF LIPID-LOWERING AND ANTIHYPERTENSIVE MEDICATIONS AMONG PATIENTS INFECTED WITH HIV	716652Z	3/15/11	9/29/12	2,111
93.701	ARRA – MEASURES OF ENDOCRINE SENSITIVITY IN EARLY BREAST CANCER	667640Z	9/28/09	8/31/13	38,766
93.837	HEMATOLOGY K12 FELLOWSHIP	748840	1/1/13	5/31/13	38,941
93.837	HEMATOLOGY K12 FELLOWSHIP	752623	6/1/13	12/31/13	8,309
93.837	OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE	716038	6/1/10	5/31/13	51,241
93.837	STAFF ASSIGNMENT: DAI – CFAR	752529	6/1/13	5/31/14	1,445
93.837	STAFF ASSIGNMENT: LONGITUDINAL MEHTODS FOR CARDIOVASCULAR DISEASE RESEARCH	727661	9/16/11	5/31/14	18,092
93.837	STEM CELLS AND CARDIOVASCULAR REPAIR – PROJECT 3	741402	6/1/12	5/31/13	220,188
93.837	STEM CELLS AND CARDIOVASCULAR REPAIR – PROJECT 3	753008	6/1/13	5/31/14	23,413
93.838	STAFF ASSIGNMENT: BROWN – DATA COORDINATING FOR SYSTEMS BIOLOGY APPROACH TO THE MECHANISMS OF TB	745769	9/1/12	8/31/13	4,523
93.839	PROJECT 3 OF STEM CELL GENE THERAPY FOR HEMOGLOBINOPATHIES	751143	4/1/13	3/31/14	8,367
93.839	STRATEGIES TO PROMOTE ENGRAFTMENT OF GENETICALLY MODIFIED HEMOPOIETIC STEM CELLS	739019	4/1/12	3/31/13	46,568
93.847	A TWIN STUDY OF OBESITY PATHOGENESIS USING FMRI	729356	9/20/11	8/31/13	15,744
93.847	CHROMATIN RESPONSE TO ACUTE RENAL INJURY	700940	8/1/10	7/31/14	195,587
93.847	CLINICAL AND MOLECULAR CHARACTERIZATION OF FAMILIAL MARROW FAILURE SYNDROMES	746003	9/1/12	8/31/13	118,459
93.847	DIABETES RESEARCH CENTER	751171	5/1/13	11/30/13	22,651
93.847	DIETARY FRUCTOSE AND INTESTINAL PERMEABILITY	736222	12/1/11	3/12/13	39,024
93.847	EXPLAINING THE SES/OVERWEIGHT AND OBESITY RELATIONSHIP	646880	3/1/09	2/28/14	43,340
93.847	FEASIBILITY, EFFICACY, AND MECHANISMS OF SURGICAL VS MEDICAL DIABETES TREATMENT	715230	8/18/10	6/30/14	123,631
93.847	HFMC PROSPECTIVE BIOREPOSITORY	748869	6/1/12	5/31/13	22,218
93.847	INTESTINAL MICROBIOTA IN DIVERTICULAR DISEASE	701877	7/26/10	6/30/14	119,494
93.847	VITAMIN D AND CHRONIC LOW-GRADE ADIPOSE TISSUE INFLAMMATION	742963	7/1/12	6/30/13	76,642
93.853	DRUG DISCOVERY FOR THE PREVENTION OF HEARING LOSS	742840	7/1/12	6/30/13	24,823
93.853	JOUBERT SYNDROME AND RELATED DISORDERS OF HINDBRAIN DEVELOPMENT	745169	9/1/12	6/30/14	20,277
93.853	PROJECT 2: MUSCLE CELL TRANSPLANTATION IN CANINE DMD	737466	4/1/12	3/31/13	216,138
93.853	PROJECT 2: MUSCLE CELL TRANSPLANTATION IN CANINE DMD	750389	4/1/13	3/31/14	88,798
93.855	AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES SCIENTIFIC PROGRAM	743409	6/1/12	5/31/13	19,975
93.855	ANTIRETROVIRAL THERAPY AND HIV-1 INFECTIVITY IN WOMEN	725202	8/10/11	7/31/12	18,111

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.855	B CELL RESPONSES AT THE FORESKIN	745363	6/1/12	5/31/13	\$ 39,023
93.855	CENTER FOR AIDS RESEARCH (CFAR) BIOMETRICS CORE	743407	6/1/12	5/31/13	71,774
93.855	CENTER FOR AIDS RESEARCH (CFAR) BIOMETRICS CORE	752299	6/1/13	5/31/14	4,055
93.855	CFAR ADMINISTRATIVE CORE – CODIRECTOR	752301	6/1/13	5/31/14	3,228
93.855	CFAR INFRASTRUCTURE AWARD	750269	4/3/13	5/31/13	2,244
93.855	COOPERATION OF THE HLA-F AND MHC CLASS I IN CROSS-PRESENTATION OF HIV ANTIGEN/SUPPLEMENT	744603	6/1/12	5/31/13	19,776
93.855	DESIGN AND FUNCTION OF FLAGELLIN-BASED IMMUNOGENS FOR BROADLY NEUTRALIZING IMMUNITY TO HIV	672286	9/4/09	8/31/14	210,721
93.855	EVALUATING THE EFFECT OF PERIODIC PRESUMPTIVE TREATMENT FOR VAGINAL INFECTIONS ON THE VAGINAL MICROBIOTA: A DETAILED MOLECULAR ANALYSIS OF SAMPLES FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL.	736792	2/6/12	1/31/14	114,822
93.855	EVOLUTION AND EMERGENCE OF SIMIAN RETROVIRUSES IN SOUTH ASIA	572286	8/1/08	7/31/13	274,092
93.855	HPV DISEASE IN THE ERA OF HPV VACCINES	738833	5/1/12	8/31/12	18,483
93.855	IMMUNE MECHANISMS OF FLAVIVIRUS CONTROL: PROJECT 5	738704	5/1/12	4/30/13	185,573
93.855	IMMUNE MECHANISMS OF FLAVIVIRUS CONTROL: PROJECT 5	751480	5/1/13	4/30/14	13,932
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	727268	7/1/11	6/30/12	19,323
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	749466	7/1/12	6/30/13	70,506
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	749725	7/1/12	6/30/13	75,742
93.855	INTENSE VALIDATION OF A MATHEMATICAL MODEL OF HERPES SIM	714348	3/1/11	2/28/14	113,509
93.855	MECHANISMS OF CD8+ T CELL IMMUNE SURVEILLANCE IN HUMAN GENITAL SKIN AND MUCOSA AFTER HSV REACTIVATION	744456	8/1/12	7/31/13	64,378
93.855	PHENOTYPIC, FUNCTIONAL, AND KINETIC PROPERTIES OF NK CELLS INDUCED BY HIV VACCINES	746698	6/1/12	10/31/12	5,271
93.855	PREP AND PROTECTIVE IMMUNE RESPONSE AGAINST HIV-1	737619	4/1/12	3/31/14	295,015
93.855	PREP AND PROTECTIVE IMMUNE RESPONSE AGAINST HIV-1	AWOA	4/1/13	4/2/13	43,682
93.855	PREP AND PROTECTIVE IMMUNE RESPONSES AGAINST HIV-1	737618	4/1/12	3/31/14	23,674
93.855	SEVERE CHRONIC NEUTROPENIA INTERNATIONAL REGISTRY	705277	9/1/10	8/31/13	43,232
93.855	STAFF ASSIGNMENT: BALKUS – IMPACT OF SUPPRESSIVE ANTIMICROBIAL THERAPY ON THE VAGINAL MICROBIOTA	747246	1/1/13	6/30/14	17,028
93.855	STAFF ASSIGNMENT: DAI CFAR-BIOMETRICS CORE ASSOCIATE DIRECTOR	743403	6/1/12	5/31/13	5,950
93.855	STAFF ASSIGNMENT: SCHOUTEN – UW CLINICAL HIV INTERGRATED RESEARCH PROGRAM	751119	12/1/12	11/30/13	6,056
93.855	STATISTICAL ISSUES IN AIDS RESEARCH	638936	5/1/09	4/30/14	115,934
93.855	THE ACQUISITION OF BACTERIAL VAGINOSIS IN LESBIANS	703785	9/15/10	8/31/13	123,739
93.855	THE ROLE OF NOVEL BACTERIA IN MALE URETHRITIS	724851	7/25/11	6/30/14	125,231
93.855	UW CLINICAL HIV INTEGRATED RESEARCH PROGRAM	739787	11/30/11	12/1/12	1,539
93.859	UW POSTBACCALAUREATE RESEARCH EDUCATION PROGRAM (PREP)	733206	2/1/12	1/31/14	14,130
93.865	CELLULAR AND MOLECULAR BIOLOGY OF CHILDHOOD DISEASE	743096	7/1/12	7/31/12	7,073
93.865	GENOME EDITING TO ENHANCE ADOPTIVE IMMUNOTHERAPY OF ALL	735393	12/1/11	6/30/12	452
93.865	MALE CONTRACEPTION RESEARCH CENTER GRANT: PROJECT IV	747844	9/17/12	6/30/13	35,946
93.865	ORGANIZATION AND FUNCTION OF TRANSCRIPTION-CONTROL ELEMENTS AT THE HUMAN FRAGILE-X LOCUS	728721	7/1/11	6/30/12	(6)
93.865	ORGANIZATION AND FUNCTION OF TRANSCRIPTION-CONTROL ELEMENTS AT THE HUMAN FRAGILE-X LOCUS	744263	7/1/12	6/30/13	196,633
93.865	REGULATION OF THE FANCONI ANEMIA PATHWAY BY PHOSPHATASES	745289	9/1/12	11/30/13	74,331
93.866	DOSE-RESPONSE RELATIONSHIPS BETWEEN CIRCULATING AND INTRAPROSTATIC ANDROGENS IN MEN	721448	7/1/11	6/30/14	41,585
93.866	STAFF ASSIGNMENT: SCHWARTZ – BEHAVIORAL HEALTH COLLABORATIVE FOR RURAL AMERICAN INDIAN COMMUNITIES	749605	1/1/13	6/30/13	9,562
93.989	AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM, AIDS-RELATED MALIGNANCIES RESEARCH TRAINING	743714	6/1/12	5/31/14	23,175
93.989	FOGARTY GLOBAL HEALTH FELLOWSHIP	743679	9/1/12	2/28/13	14,205
93.989	B CELL RESPONSES AT THE FORESKIN	AWOA	6/1/13	5/31/14	13,035

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (KL2)	AWOA	6/1/13	5/31/14	\$ 9,869
	Total – UNIVERSITY OF WASHINGTON				8,052,365
93.867	UNIVERSITY OF WISCONSIN: DIET AND LIFESTYLE FACTORS REDUCING RISK FOR AGE-RELATED EYE DISEASE	277K314	12/1/10	11/30/13	12,494
	Total – UNIVERSITY OF WISCONSIN				12,494
93.394	VAN ANDEL RESEARCH INSTITUTE: DETECTION OF PREINVASIVE PANCREATIC CYSTS USING PROTEIN AND GLYCAN BIOMARKERS	FHCRC-NCI-BH-10-4018	7/1/11	6/30/12	2,207
93.394	TARGETED GLYCOMICS AND AFFINITY REAGENTS FOR PANCREATIC CANCER BIOMARKER DEVELOPMENT	FHCRC-BH-10-40234-1	7/1/12	6/30/13	31,415
93.396	ROLE OF ALPHA6 BETA1 INTEGRIN IN PROSTATE CANCER	FHCRC-NIH-CM-10-4022	5/1/12	9/30/13	23,079
	Total – VAN ANDEL RESEARCH INSTITUTE				56,701
93.393	VANDERBILT UNIVERSITY MEDICAL CENTER: CANCER MORTALITY AMONG MILITARY PARTICIPANTS AT U.S. NUCLEAR WEAPONS TESTS	VUMC 37160	7/1/11	6/30/12	(1,280)
93.393	CANCER MORTALITY AMONG MILITARY PERSONNEL AT U.S. NUCLEAR WEAPONS TESTS	VUMC 37160	7/1/12	6/30/13	31,716
93.393	MODIFIABLE RISK FACTORS FOR FATAL PROSTATE CANCER: A PROSPECTIVE STUDY IN ASIA	VUMC 39615	4/1/12	3/31/13	53,121
93.393	MODIFIABLE RISK FACTORS FOR FATAL PROSTATE CANCER: A PROSPECTIVE STUDY IN ASIA	VUMC 39615	4/1/13	3/31/14	4,886
	Total – VANDERBILT UNIVERSITY MEDICAL CENTER				88,443
N/A	VETERANS MEDICAL RESEARCH FOUNDATION: AD5 NEUTRALIZING ANTIBODY TESTING FOR VMRF	297730 08082-FHCRC S	6/1/10	6/30/14	26,690
	Total – VETERANS MEDICAL RESEARCH FOUNDATION				26,690
N/A	WAKE FOREST UNIVERSITY HEALTH SCIENCES: VALIDATING THE CHRONIC CONDITION OF WAREHOUSE (CCW) ALZHEIMER'S DISEASE AND RELATED DISORDERS OF SENILE DEMENTIA IDENTIFICATION ALGORITHM IN WHI-LINKED CMS DATA	2013028381	3/1/13	9/30/13	2,747
93.393	GENE-HORMONE THERAPY INTERACTION AND THE RISK OF BREAST CANCER	10633	3/1/11	2/28/14	41,357
93.393	GENETIC PROFILING IN PCPT: PROSTATE CANCER RISK, PSA, LEVEL, AND CHEMOPREVENTION	10342	7/1/11	6/30/13	33,037
	Total – WAKE FOREST UNIVERSITY HEALTH SCIENCES				77,141
N/A	WESTAT: CANCER IMMUNOTHERAPY TRIAL NETWORK (CITN)	8339-S07	8/31/12	8/30/13	29,410
	Total – WESTAT				29,410
93.866	YALE UNIVERSITY: PROJECT 4: MECHANISMS OF AGING IN THE OLFACTORY SYSTEM	A06505 (M07A00246)	9/1/10	8/31/12	21,480
	Total – YALE UNIVERSITY				21,480
	Total Pass-Through Funds – Department of Health and Human Services and Other Federal Agencies				31,642,947
	Direct Grants – Other Federal Agencies:				
	DEPARTMENT OF DEFENSE:				
12.420	EXPLORING THE ROLE OF GENETIC MODIFIERS IN DNA REPAIR AND BREAST CANCER	W81XWH-09-1-0029	9/1/09	8/31/13	12,307
12.420	MICRORNA BIOMARKERS OF EARLY DISEASE IN OVARIAN CANCER	W81XWH-09-1-0268	4/1/09	3/31/13	75,161
12.420	MITOCHONDRIAL DNA BIOMARKER DISCOVERY AND VALIDATION FOR THE DETECTION, PROGNOSIS, AND TREATMENT OF PROSTATE CANCER	W81XWH-10-1-0563	7/19/10	7/18/13	104,051
12.420	OPTIMIZING TREATMENT OF ADVANCED PROSTATE CANCER AND EXPLOITING MECHANISMS DRIVING CASTRATION RESISTANCE	W81XWH-10-1-0228	4/1/10	3/31/13	100,674
12.420	ANALYZING HETEROGENEITY OF ONCOGENIC PATHWAY ACTIVATION IN OVARIAN CANCER USING A NOVEL, HIGH-THROUGHPUT	W81XWH-10-1-0530	9/1/10	8/31/14	167,612

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
12.420	TARGETING CELL SURFACE PROTEINS IN MOLECULAR PHOTOACOUSTIC IMAGING TO DETECT OVARIAN CANCER EARLY	W81XWH-10-1-0422	7/1/10	6/30/13	\$ 164,893
12.420	GLOBAL CHARACTERIZATION OF PROTEIN-ALTERING MUTATIONS IN PROSTATE CANCER	W81XWH-10-1-0590	7/15/10	7/14/13	179,834
12.420	CHARACTERIZING AND TARGETING ANDROGEN RECEPTOR PATHWAY-INDEPENDENT PROSTATE CANCER	W81XWH-10-1-0771	9/1/10	8/31/13	180,708
12.420	BLOOD-BASED BIOMARKERS FOR LUNG CANCER EARLY DETECTION AND EVALUATION OF CT-BASED LESIONS	W81XWH-10-1-0632	9/25/10	9/24/13	38,936
12.420	TRANSGENERATIONAL RADIATION EPIGENETICS	W81XWH-10-1-0711	9/1/10	8/31/14	181,087
12.420	REDEFINING THE HEMATOPOIETIC MICROENVIRONMENT	W81XWH-11-1-0732	9/30/11	3/29/13	103,003
12.420	POSTDOCTORAL FELLOW -XI TANG	W81XWH-11-1-0622	8/19/11	8/18/13	56,457
12.420	STEROID TRANSPORT PROTEINS IN CASTRATION-RESISTANT PROSTATE CANCER	W81XWH-11-2-0154	7/1/11	6/30/14	217,785
12.420	VALIDATION OF BIOMARKERS FOR PROSTATE CANCER PROGNOSIS	W81XWH-11-1-0381	9/30/11	9/29/14	92,180
12.420	PEDIATRIC GLIOBLASTOMA THERAPIES BASED ON PATIENT-DERIVED STEM CELL RESOURCES	W81XWH-11-1-0756	9/1/11	8/31/14	227,475
12.420	EARLY DIAGNOSIS OF CLEAR CELL KIDNEY CANCER VIA VHL/HIF PATHWAY-REGULATED CIRCULATING MICRORNA	W81XWH-11-1-0714	9/1/11	8/31/14	224,372
12.420	BLOOD-BASED BIOMARKERS FOR LUNG CANCER EARLY DETECTION AND EVALUATION OF CT-BASED LESIONS	W81XWH-10-1-0632	9/25/10	9/24/13	132,438
12.420	POSTDOCTORAL FELLOW: DANIELLA BIANCHI-FRIAS	W81XWH-12-1-0050	3/15/12	3/14/14	54,982
12.420	POSTDOCTORAL FELLOW: RYAN GORDON	W81XWH-12-1-0094	2/28/12	2/27/14	50,246
12.420	INDUCTION OF ANDROGEN RECEPTOR SPLICE VARIANTS AS DETERMINANTS OF TAXANE SENSITIVITY IN PROSTATE CANCER	W81XWH-12-1-0055	4/1/12	3/31/13	100,294
12.420	TARGETING THE PROSTATE CANCER MICROENVIRONMENT TO IMPROVE THERAPEUTIC OUTCOMES	W81XWH-12-1-0182	5/15/12	8/22/12	18,240
12.420	IDENTIFYING AUTOANTIBODY BIOMARKERS DERIVED FROM CANCER-SPECIFIC SPLICING AND VALIDATING THEM IN PRECLINICAL AND OCCULT OVARIAN CANCER PLASMA SAMPLES	W81XWH-12-1-0349	9/30/12	9/29/14	185,408
12.420	LOOKING BEYOND CYP17A: EXPLOITING PRERECEPTOR REGULATION TO OPTIMIZE NEXT-GENERATION STEROID-SYNTHESIS INHIBITION IN CASTRATION-RESISTANT PROSTATE CANCER	W81XWH-12-1-0208	7/1/12	6/30/15	156,846
12.420	ADVANCING OUR UNDERSTANDING OF THE ETIOLOGIES AND MUTATIONAL LANDSCAPES OF BASAL-LIKE, LUMINAL A, AND LUMINAL B BREAST CANCERS	W81XWH-12-1-0079	9/15/12	9/14/17	393,075
	Total – DEPARTMENT OF DEFENSE				<u>3,218,064</u>
	DEPARTMENT OF THE INTERIOR (DARPA):				
12.910	AN ALGORITHM FOR CONTROL OF BIOLOGICAL TIME	D12AP00008	1/16/12	1/15/13	587,616
12.910	AN ALGORITHM FOR CONTROL OF BIOLOGICAL TIME	D12AP00008	1/16/13	1/15/14	463,490
	Total – DEPARTMENT OF THE INTERIOR (DARPA)				<u>1,051,106</u>
	NATIONAL SCIENCE FOUNDATION:				
47.049	ATD COLLABORATIVE RESEARCH: NEW THEOREMS AND ALGORITHMS FOR COMPREHENSIVE ANALYSIS OF METAGENOMIC DATA VIA STATISTICAL PHYLOGENETICS	DMS-1223057	9/1/12	8/31/17	61,783
47.074	DOMESTICATED RETROVIRAL GENES IN EUKARYOTIC GENOMES	MCB-0746886	7/1/09	6/30/13	218,589
47.074	COLLABORATIVE RESEARCH: PARALLEL AND NONPARALLEL EVOLUTION AT MULTIPLE LEVELS: ENVIRONMENT, SELECTION, PHENOTYPE, AND GENOTYPE	DEB-1144556	7/15/12	6/30/15	34,864
47.074	GENETIC AND NEURAL CONTRIBUTIONS TO THE EVOLUTION OF THE SCHOOLING BEHAVIOR IN STICKLEBACKS	IOS-1145866	6/15/12	5/31/15	216,862
	Total – NATIONAL SCIENCE FOUNDATION				<u>532,098</u>
	Total Direct Grants – Other Federal Agencies				<u>4,801,268</u>
	Total Research and Development cluster				<u>302,835,639</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2013

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
98.006	UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT: UGANDA PROGRAM ON CANCER AND INFECTIOUS DISEASES	HSH-G-00-09-00030-00	9/25/09	9/30/14	\$ 90,000
	Total – UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT				90,000
	Total of SEFA				\$ <u>302,925,639</u>

See accompanying notes to schedule of expenditures of federal awards.

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

(1) Basis of Presentation

The accompanying schedule of expenditures of federal awards (SEFA) includes the federal grant activity of Fred Hutchinson Cancer Research Center and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the financial statements.

(2) Subrecipients

Of the federal expenditures presented in the Schedule of Federal Expenditures of Federal Awards, Fred Hutchinson Cancer Research Center provided federal awards to subrecipients as follows:

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
A MULTISTATE STUDY OF CANCER TREATMENT AND OUTCOMES	93.393	\$ 28,041
A POOLED ANALYSIS OF RISK FACTORS OF SMALL INTESTINE CANCER	93.393	3,774
A PROSPECTIVE STUDY OF COLORECTAL CANCER: ONE-CARBON METABOLISM AND INFLAMMATION	93.393	140,731
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	511,434
ABS DEVELOPMENT OF CCB – MPI: CFWD	93.394	19,689
ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	93.393	313,700
ACQUISITION AND LOSS OF NEISSERIA MENINGITIDIS CARRIAGE IN HOUSEHOLDS IN MALI	93.855	45,981
ADIPOSE TISSUE INFLAMMATION AND ESTROGEN SYNTHESIS	93.393	7,289
AFFINITY-BASED STRATEGIES TO FAST TRACK DEVELOPMENT	93.394	29,364
AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM, AIDS-RELATED MALIGNANCIES RESEARCH TRAINING	93.989	1,831
AIDS MALIGNANCY CLINICAL TRIALS (AMC)	93.395	8,365
AIDS MALIGNANCY CLINICAL TRIALS CONSORTIUM (AMC)	93.395	5,007
ALPHA RADIOIMMUNOTHERAPY FOR LYMPHOMA TREATMENT	93.395	19,672
AML PROGNOSTIC BIOMARKERS	93.394	59,495
AN ALGORITHM FOR CONTROL OF BIOLOGICAL TIME	12.910	23,635

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
ANALYZING HETEROGENEITY OF ONCOGENIC PATHWAY ACTIVATION IN OVARIAN CANCER USING A NOVEL, HIGH-THROUGHPUT PLASMONIC TWEEZER ARRAY APPROACH	12.420	\$ 36,884
ARRA: A STUDY OF CANCER DIAGNOSIS AS A RISK FACTOR FOR PERSONAL BANKRUPTCY	93.701	12,467
ARRA: CTRIP: NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITOR FOR CORD BLOOD TRANSPLANT	93.701	100,028
ARRA: GENOME-WIDE ASSOCIATION STUDY OF ENDOMETRIAL CANCER	93.701	712
ARRA: ORAL CANCER: MOLECULAR PROFILES AND CLINICAL OUTCOMES	93.701	531
ARRA: TOWARDS A MODEL OF FANCONI ANEMIA	93.701	14,119
ARRA: A PHASE 1/2 STUDY OF VORINOSTAT (ZOLINZA) IN COMBINATION WITH GEMTUZUMAB	93.701	6,342
ARRA: CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER – CANCERGEN-RESTRICTED CF	93.701	250,962
ARRA: CENTER FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CANCER GENOMICS-CANCERGEN	93.701	486,428
ARRA: MEASUREMENT OF CANCER-ASSOCIATED BIOMARKER PROTEINS IN COMPLEX BIOLOGICAL SAMPLES	93.701	379,615
ARRA: MECHANISM-BASED CLASSIFICATION AND TARGETING OF CASTRATION-RESISTANT PROSTATE CANCER	93.701	13,679
ARRA: THE TIME-DISTRIBUTION METHOD FOR MEASURING CLINICALLY VALID QUALITY OF LIFE STATES	93.701	11,315
BARRETT'S AND ESOPHAGEAL ADENOCARCINOMA GENETIC SUSCEPTIBILITY STUDY (BEAGESS)	93.393	599,111
BARRETT'S ESOPHAGUS: CORE B – CLINICAL	93.394	26,660
BARRETT'S ESOPHAGUS: CORE C – BIostatISTICS AND EVOLUTIONARY ANALYSIS	93.394	9,141
BARRETT'S ESOPHAGUS: PROJECT 3 – PREDICTORS OF PROGRESSION – GENETIC INSTABILITY	93.394	4,119
BCD CORE B: ETHICS AND POLICY	93.399	55,237

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
BCD PROJECT 1: SCREENING MAMMOGRAPHY AND LATINAS – A MULTILEVEL INTERVENTION	93.399	\$ 192,217
BCD PROJECT 3: RISK FACTORS FOR TRIPLE-NEGATIVE AND HER2-OVER EXPRESSING BREAST CANCER AMONG HISPANIC WOMEN AND NONHISPANIC WOMEN	93.399	103,570
BCD PROJECT 4: RELATIONSHIP OF BREAST CANCER SUBTYPE, RISK FACTORS AND ANCESTRY IN HISPANIC AND NONHISPANIC WHITE WOMEN	93.399	156,678
BCD SUPPLEMENT – PROJECT 4: RELATIONSHIP OF BREAST CANCER SUBTYPE, ANCESTRY, AND RISK FACTORS IN HISPANIC WOMEN	93.399	25,476
BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	93.172	224,216
BIOCONDUCTOR: CFWD YR06 TO YR07	93.172	86,412
BIOLOGY AND PROGNOSTIC IMPLICATIONS OF FLT3 MUTATIONS IN AML	93.394	11,638
BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS USING METABOLIC FOOTPRINTING	93.113	84,237
BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT	93.395	178,719
BREAST CANCER RISK AND MOLECULAR CHANGE AFTER CHERNOBYL	93.393	314,250
BUILDING SUSTAINABLE TRANSLATIONAL RESEARCH TEAMS IN HIV-ASSOCIATED MALIGNANCIES	93.395	31,322
CANCER CENTER SUPPORT GRANT	93.397	1,070,324
CANCER IMMUNOTHERAPY TRIAL NETWORK (CITN): TASK ORDERS 1 – 7	N/A	16,710
CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	93.395	682,836
CCEH: PILOT (UW)	93.847	19,703
CCSG HIVAM PILOT: (UW)	93.397	54,116
CCSG NEW RECRUIT: (UW)	93.397	130,557
CCSG PILOT	93.397	83,592
CCSG PILOT: (SCH)	93.397	147,903
CCSG PILOT: (UW)	93.397	16,433
CCSG PILOT: CHIU, D (UW)	93.397	71,466
CCSG PILOT: HINGORANI, S	93.397	19,650
CCSG PSRS: (UW)	93.397	27,226

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
CCSG SENIOR LEADERSHIP	93.397	\$ 78,352
CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	93.395	86,867
CD45 PRETARGETED RADIOIMMUNOTHERAPY FOR AML	93.395	78,452
CD8+ CELL IMMUNITY TO CYTOMEGALOVIRUS	93.855	93,411
CENTER FOR BIOLOGICAL FUTURES	N/A	332,000
CHARACTERIZATION OF HIV-1 ANTIBODY RESPONSES	93.865	77,557
CHARACTERIZE AB: SUBAWARDS	93.855	33,076
CHEMOPROTECTION AGAINST AMINOGLYCOSIDE-INDUCED OTOTOXICITY	93.173	62,642
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE	N/A	28,147
CNP: FULL PROJECT – CARRYFORWARD – ON SITE	93.397	6,769
CNP: FULL PROJECT – ON SITE	93.397	48,946
CNP: OUTREACH PROGRAM – CARRYFORWARD – ON SITE	93.397	5,307
COLORECTAL CANCER GENOME-WIDE ASSOCIATION STUDIES CONSORTIUM	93.393	859,940
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	336,020
CONTROLLING HEMATOPOIETIC LINEAGE COMMITMENT FROM ESC TO PLATELETS	93.837	204,994
CORD BLOOD EXPANSION AND TRANSPLANTATION IN A NONHUMAN PRIMATE MODEL	93.839	21,289
CORE CENTER OF EXCELLENCE IN HEMATOLOGY PILOT	93.847	20,797
CYTOTOXIC T-CELL RESPONSE TO HERPES SIMPLEX VIRUS (HSV)	93.855	192,212
DETECTION OF COLORECTAL CANCER SUSCEPTIBILITY LOCI USING GENOME-WIDE SEQUENCING	93.393	90,620
DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES	93.855	227,391
DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	93.839	217,020
DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION	93.837	19,353

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS	93.859	\$ 105,791
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	310,928
EDRN – CVC: CLINICAL	93.394	53,108
EDRN – CVC: LI (CERC SUPPLEMENT)	93.394	29,470
EDRN LAB	93.394	198,263
EDRN: GRADY LAB-RESTRICTED CF	93.394	26,574
EDRN: LAB RESTRICTED	93.394	6,754
EDRN: LAB-RESTRICTED COLLABORATIVE STUDY	93.394	88,021
ENGRAFTMENT AND INVIVO SELECTION OF HIV-PROTECTED STEM CELLS	93.839	18,237
EPIDEMIOLOGY OF PUTATIVE GENETIC GENUINE VARIANT: THE WOMEN’S HEALTH INITIATIVE	93.172	43,223
EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	93.113	158,388
EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	93.393	39,839
EVOLUTION OF CANCER-SPECIFIC MOLECULAR REQUIREMENTS FOR GLIOBLASTOMA MULTIFORME (PQ8) – PADDISON	93.396	31,850
EXPANSION OF CHP	93.837	533,985
FOAMY VIRUS ZONOTIC TRANSMISSION FROM NEW WORLD MONKEYS	93.855	51,442
FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER DATA	93.113	20,266
GENE THERAPY FOR FANCONI ANEMIA	93.839	3,357
GENETIC MECHANISMS OF SURVIVORSHIP DISPARITIES AFTER UNRELATED HCT	93.393	32,127
GENETIC PROGRESSION OF PANCREATIC MUCINOUS CYSTIC NEOPLASMS TO INVASIVE CARCINOMA	93.396	8,628
GENOME-WIDE ASSOCIATION STUDY OF NONSYNONYMOUS SNPS IN COLON CANCER	93.393	13,585
GENOME-WIDE PROFILING OF HISTONE VARIANTS IN DROSPHILA AND CAENORHABDITIS	93.172	41,034
GUT MICROBIOTA AND COLONIC GENE EXPRESSION: A LIGNAN TRIAL IN HUMANS	93.393	166,532
GWAS OF HORMONE TREATMENT AND CVD AND METABOLIC OUTCOMES IN THE WHI	93.172	56,128
HEMATOPOIETIC CELL TRANSPLANTATION AND IRON OVERLOAD	93.839	31,171

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
HEMATOPOIETIC CHEMOPROTECTION IN GIOBLASTOMA PATIENTS	93.395	\$ 1,923
HEMATOPOIETIC SC AND CBT: ADMIN SUPPLEMENT	93.855	35,879
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	461,272
HIV PIW: CORE A – ADMINISTRATIVE	93.865	120,240
HIV PIW: CORE A RESTRICTED	93.865	304
HIV PIW: PROJECT 1 – INCIDENCE, TIMING, AND COFACTORS THAT CONTRIBUTE TO THE HIGH RISK OF HIV-1 INFECTION IN PERI AND POSTPARTUM WOMEN	93.865	544,175
HIV PIW: PROJECT 2 SUBAWARD	93.865	351,778
HIV PIW: RESTRICTED PROJECT 1 CF	93.865	172,140
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	622,983
HPTN SDMC: HPTN 065 TEST AND TREAT	93.855	742,482
HPTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	93.855	318,252
HPV CAPSID ANTIBODIES	93.855	34,432
HPV: BIOLOGY, CLINICAL SIGNIFICANCE AND EPIDEMIOLOGY – PROJECT 1: EPIDEMIOLOGY OF HPV-RELATED SCSC IN TRANSPLANT PATIENTS	93.393	662
HSV P01: CORE A: CLINICAL	93.855	251,442
HSV P01: CORE B: LAB	93.855	221,824
HSV P01: CORE C: STATISTICAL AND DATA	93.855	237,373
HSV P01: CORE D: ADMINISTRATIVE	93.855	175,183
HSV P01: PROJECT 1 – MECHANISMS OF REACTIVATION AND CLEARANCE OF MUCOSAL HSV INFECTION	93.855	201,303
HSV P01: PROJECT 2 – PREVENTION OF HSV MORBIDITY IN PREGNANCY AND THE NEWBORN	93.855	85,092
HSV P01: PROJECT 3 – LOCAL DETERMINANTS OF HSV-2 SHEDDING IN HUMANS	93.855	244,528
HVTN 503	93.855	40,413
HVTN LAB – HVTN 505	93.855	460,390
HVTN LAB – MUCOSAL SUPPLEMENT	93.855	549,054
HVTN LAB – RESTRICTED C/F – HVTN 502/STEP STUDY	93.855	17,743

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
HVTN LAB – TB VACCINE WORK	93.855	\$ 116,653
HVTN LAB PROGRAM – RESTRICTED C/F	93.855	265,546
HVTN LAB SUPPLEMENT	93.855	30,837
HVTN LAB: CARRYFORWARD – HVTN 503 FUNDS	93.855	80,384
HVTN LAB: FOLLOW-UP CORRELATE ANALYSIS OF RV144 AND RELATED STUDIES	93.855	238,371
HVTN LABORATORY PROGRAM	93.855	3,112,262
HVTN SDMC: LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS	93.855	298,606
HVTN: 505	93.855	9,992,867
HVTN: CORE OPERATIONS	93.855	1,377,179
HVTN: CORE PROTOCOL IMPLEMENTATION	93.855	40,722
HVTN: HANC	93.855	71,343
HVTN: HANC GENERATION BRIDGE SUPPLEMENT	93.855	231,903
HVTN: HANC NAECHR	93.855	183,954
HVTN: HANC WORKING GROUP TRANSITIONAL ACTIVITIES	93.855	53,655
HVTN: PIF	93.855	42,510
HVTN: RESTRICTED CARRYOVER	93.855	256,384
HVTN: SCIENTIFIC LEADERSHIP	93.855	1,186,007
HVTN: HANC BEHAVIORAL SCIENCES WORKING GROUP	93.855	143,179
HVTN: HANC EMTF CARRYOVER	93.855	261,302
HVTN: HANC LEGACY PROJECT	93.855	57,592
HVTN: RAMP	93.855	73,542
HVTN: SITE PIF	93.855	6,290,205
IMMUNE MD AFTER ALLO HCT: PILOT 1	93.855	61,691
IMMUNE MD AFTER ALLO HCT: PROJECT 1	93.855	104,533
IMMUNE MD AFTER ALLO HCT: PROJECT 2	93.855	115,618
IMMUNE MD AFTER ALLO HCT: SUBAWARDS	93.855	245,188
IMMUNE MD AFTER ALLO HCT: TRAINING	93.855	26,094
IMMUNIZATION OF ORAL MUCOSA FOR INDUCTION OF RECTAL AND GENITAL MUCOSAL IMMUNITY	93.121	223,373
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GVHD	93.395	131,325
IMPROVING SMOKING CESSATION QUITLINES: PILOT STUDY OF ACCEPTANCE THERAPY	93.279	36,137
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	174,308

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
INFRASTRUCTURE FOR TRANSPLANT PROTOCOLS FOR HIV PLUS PATIENTS WITH HEMATOLOGIC MALIGNANCIES	N/A	\$ 23,285
INTEGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF FOOD INTAKE: CARRYFORWARD ID	93.393	38,499
INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF FOOD INTAKE	93.393	130,083
INTERNET STUDIES TO ENHANCE LONG-TERM SURVIVORSHIP AFTER HEMATOLOGIC MALIGNANCY	93.395	14,249
ITFAHCT-PROJECT 1: H-Y-SPECIFIC T-CELL RESPONSES IN CHRONIC GVHD	93.837	12,729
LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	93.393	40,735
MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	93.866	896,525
METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMIA	93.855	137,624
MIDAS: ADMINISTRATIVE SUPPLEMENT FY 2012	93.859	33,515
MIDAS: RESTRICTED FOR EV-71 HAND-FOOT-MOUTH	93.859	69,338
MIXED CHIMERISM: PROJECT 1: ESTABLISHING STABLE MIXED HEMATOPOIETIC CHIMERISM IN A CANINE MODEL	93.395	25,117
MIXED CHIMERISM: PROJECT 2: IDENTIFICATION OF CANINE MINOR HISTOCOMPATIBILITY	93.393	573,960
MIXED CHIMERISM: PROJECT 2: IDENTIFICATION OF CANINE MINOR HISTOCOMPATIBILITY ANTIGENS	93.395	198,182
MODELING PROSTATE CANCER CONTROL: MODELING GROUP – PREVENTION, SCREENING TREATMENT, FOLLOWUP CARE	93.393	55,170
MTN PRIME AWARD	93.855	253,270
NIGHT SHIFT WORK AND HORMONE LEVELS IN MEN	93.393	1,035
NOTCH-MED EXP OF CB FOR SCT – SUBAWARDS	93.837	10,584
NOVEL COMPUTATIONAL TOOLS FOR STUDYING THE HUMAN MICROBIOME	93.301	67,591

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	93.310	\$ 372,400
NPAAS CCC – (MPI)	93.393	24,408
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	297,042
ON-SITE: PARTNERSHIP FOR A HISPANIC DIABETES PREVENTION PROGRAM	93.307	48,861
OPTION C – WHIMS GWAS	—	2,087,315
OUTCOMES-BASED GUIDELINE DEVELOPMENT FOR PROSTATE CANCER SCREENING AND TREATMENT	93.393	21,643
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER	93.395	15,870
PAGE: SUPPLEMENT: EPIDEMIOLOGY OF PUTATIVE GENETIC GENUINE VARIANT: THE WOMEN’S HEALTH INITIATIVE	93.172	34,240
PEDIATRIC GLIOBLASTOMA THERAPIES BASED ON PATIENT-DERIVED STEM CELL RESOURCES	12.420	11,349
PERIPHERAL BLOOD BIOPSY FOR MOLECULAR DIAGNOSIS OF PANCREATIC CANCER	93.394	49,677
PFMD – CORE A: FSHD BIORESOURCES CORE	93.853	125,472
PFMD – PROJECT 1: THE GENETIC AND EPIGENETIC BASIS FOR FSHD	93.853	130,042
PFMD – PROJECT 4: FSH-PATIENT DERIVED IPS CELLS TO STUDY THE DEVELOPMENTAL REGULATION OF DUX4 TRANSCRIPTION	93.853	197,253
POCRC: CORE B – CLINICAL SPECIMEN MANAGEMENT AND CHARACTERIZATION CORE	93.397	29,156
POCRC: CORE D – BIOSTATISTICS AND INFORMATICS CORE	93.397	6,088
POCRC: DRP – A COMBINATION THERAPY	93.397	11,282
POCRC: DRP – TOWARDS INDIVIDUALIZED	93.397	60,786
POCRC: PROJECT 1 – RANDOMIZED CONTROLLED TRIAL (RCT) USING NOVEL MARKERS TO PREDICT MALIGNANCY IN ELEVATED RISK WOMEN	93.397	38,379
POCRC: PROJECT 2 – TARGET MICROBUBBLE CONTRAST ENHANCED ULTRASOUND IMAGING OF THE OVARIAN CANCER VASCULAR NETWORK FOR EARLY DETECTION	93.397	131,966

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
POCRC: PROJECT 4 – CLINICAL IMPLICATION OF THE ACQUISITION OF BRCA1/2 FUNCTION IN BRCA1/2-DEFICIENT OVARIAN CARCINOMA	93.397	\$ 141,200
POCRC: PROJECT 5 – VACCINATING AGAINST IGFBP-2 TO PREVENT OVARIAN CANCER RELAPSE	93.397	220,939
POPULATION PHARMACOKINETICS/ PHARMACODYNAMICS IN NONABLATIVE STEM CELL RECIPIENTS	93.839	3,597
PQ12: PROJECT 1 DAG – NOVEL PATHOGEN ASSOCIATED CANCERS (PQ12): GALLOWAY	93.393	48,934
PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYSTROPHY	93.846	55,362
PRETARGETED RADIOIMMUNOTHERAPY OF CD20 + LYMPHOMAS	93.395	77,741
PROGNOSTIC AND FUNCTIONAL SIGNIFICANCE OF ADHESION MOLECULES IN PEDIATRIC AML	93.394	14,293
PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	93.393	21,474
PROSTAGLANDIN SYNTHESIS, GENETICS, AND COLORECTAL CANCER	93.393	21,563
PROSTATE SPORE: CAREER DEVELOPMENT	93.399	725
PROSTATE SPORE: CORE B BRIDGE FUNDING	93.399	73,610
PROSTATE SPORE: CORE D – CLINICAL	93.399	38,837
PROSTATE SPORE: DEVELOPMENTAL RESEARCH	93.399	35,220
PROSTATE SPORE: PROJECT 4 BRIDGE FUNDING	93.399	23,292
PROSTATE SPORE: UW SUBAWARD	93.399	16,833
PROSTATE SPORE: CAREER DEVELOPMENT CARRYOVER	93.399	35,817
PROSTATE SPORE: ISPBN/CORE B – TISSUE AND SPECIMEN	93.399	60,369
PROSTATE SPORE: PROJECT 3 – TARGETING THE CYTOPROTECTIVE CHAPERONE, HSP27, IN CASTRATE RESISTANT PROSTATE CANCER	93.399	55,018
PROSTATE SPORE: PROJECT 4 – MECHANISMS FOR TYPE 1 IGF-IR FACTOR INHIBITION ENHANCING EFFECTS OF CASTRATION	93.399	101,270
PROSTATE SPORE: UW SUB BRIDGE FUNDING – SALARY	93.399	25,058
PROTEIN BIOMARKERS IN CHILDHOOD ACUTE MYELOID LEUKEMIA	93.394	23,311

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
RAPID SCALEUP OF HIV/AIDS CARE AND TREATMENT SERVICES IN THE KINGDOM OF SWAZILAND	93.067	\$ 3,226
RESTRICTED SUPPLEMENT – NOVEL CULTIVATION METHODS FOR THE DOMESTICATION OF VAGINAL BACTERIA	93.310	15,646
SCCBS CORE C: CLINICAL CORE	93.397	127,645
SCCBS PROJECT 2: TARGETED IMMUNOTHERAPY OF BREAST CANCER WITH CENTRAL MEMORY T CELLS	93.397	48,623
SCCBS PROJECT 3: METABOLIC ALTERATIONS IN ADVANCED BREAST CANCER AND RESPONSE TO SYSTEMIC THERAPY	93.397	88,780
SCCBS-RESTRICTED CF PROJECT 3: HOCKENBERY SEATTLE VACCINE TRIALS UNIT	93.397 93.855	26,362 359,412
SHARE ANALYTIC CENTERS	N/A	178,967
SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER	93.395	2,734,439
STAT METHODS: PROJECT 1 – CHRONIC DISEASE POPULATION RESEARCH ISSUES AND STRATEGIES	93.393	30,330
STATISTICAL METHODS FOR INTEGRATIVE ANALYSIS OF GENOMICS AND PROTEOMICS DATA	93.859	3,644
STATISTICAL METHODS FOR PROSPECTIVE EVALUATION OF BIOMARKERS	93.859	55,916
STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS	93.855	120,339
STATISTICAL METHODS IN HIV/AIDS RESEARCH	93.855	50,924
STEM CELL TRANSPLANT: CORE	93.839	492
T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	93.855	263,208
TARGETED MODIFICATION: CORE A – NONHUMAN PRIMATE CORE	93.855	380,381
TARGETED MODIFICATION: CORE B – TRANSPLANTATION CORE	93.855	234,991
TARGETED MODIFICATION: CORE C – SEQUENCING CORE	93.855	122,135
TARGETED MODIFICATION: CORE E – ADMINISTRATIVE CORE	93.855	21,186

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

Subaward title	CFDA number	Amount
TARGETED MODIFICATION: PROJECT 2 – ZFN-MODIFIED STEM CELLS FOR HIV ERADICATION	93.855	\$ 108,479
TARGETED MODIFICATION: PROJECT 4 – TARGETED DISRUPTION OF INTEGRATED SHIV BY ENGINEERED HOMING ENDONUCLEASES	93.855	284,305
TARGETED MODIFICATION: PROJECT 5 – APTAMER AND DENDRIMER DELIVERY OF ZN FINGER NUCLEASE AND HOMING ENDONUCLEASES MRNA AND CDNA	93.855	135,574
TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY FLUDARABINE AND TBI FOLLOWED BY HLA-MATCHED, ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THE TREATMENT OF MULTIPLE MYELOMA	93.395	82,266
TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	93.395	146,635
TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL: CERC	93.393	147,721
THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICKLEBACK SPECIES PAIRS	93.396	163,512
THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSION	93.855	29,713
THE ROLE OF COORDINATING CENTERS IN COLLABORATIVE CANCER-EPIDEMIOLOGY STUDIES	93.393	7,708
THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS	93.855	172,387
THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	93.286	86,717
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETIC APPROACH	93.172	155,385
TLLMAB CORE A: ADMINISTRATIVE AND STATISTICAL CORE	93.395	13,874
TLLMAB CORE B: NUCLEAR MEDICINE CORE	93.395	283,626
TLLMAB PROJECT 2: RADIOIMMUNOTHERAPY FOR LYMPHOMA	93.395	54,968
TLLMAB PROJECT 3: PRETARGETED RADIOIMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES	93.395	28,733

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2013

<u>Subaward title</u>	<u>CFDA number</u>	<u>Amount</u>
TREC COORDINATION CENTER	93.394	\$ 40,479
VITAMIN D AND PROSTATE CANCER: BIOMARKERS AND GENETIC VARIATION	93.393	41,102
W54 CVD BIOMARKERS FOR 2010 – 2015	N/A	41,335
WEIGHT LOSS AND CANCER BIOMARKERS IN WOMEN: OXIDATIVE STRESS AND INFLAMMATION	93.393	17,554
WEIGHT LOSS AND EXERCISE EFFECTS ON TELOMERE LENGTH IN POSTMENOPAUSAL WOMEN	93.393	18,993
WHI: CCC – BAA SUPPORT AND PULLS	N/A	301
WHI: CCC – W66 LLS-PHASE III BIOMARKERS AND GWAS	N/A	22,262
WHI: OPTION B – IN HOME VISIT	N/A	1,833,653
WHI: PILOT – AS417 DIET METABOLITE PROFILE	N/A	138
WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	93.839	14,754
WOMEN'S HEALTH INITIATIVE – CCC	N/A	1,490,090
		<u>\$ 61,236,702</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Findings and Questioned Costs

June 30, 2013

(1) Summary of Auditors' Results

Financial Statements

Type of auditors' report issued: **Unqualified**

Internal control over financial reporting:

- Material weakness(es) identified: **No**
- Significant deficiency(ies) identified that are not considered to be material weaknesses: **No**

Noncompliance material to financial statements noted: **No**

Federal Awards

Internal control over major programs:

- Material weakness(es) identified: **No**
- Significant deficiency(ies) identified that are not considered to be material weaknesses: **Yes**

Type of auditors' report issued on compliance for major programs: **Unmodified**

Any audit findings disclosed that are required to be reported in accordance with Section 510(a) of OMB Circular A-133: **Yes**

Identification of major program:

Federal grantor and program title	CFDA number
Research and Development Cluster	Various

Dollar threshold used to distinguish between type A and type B programs: **\$3,000,000**

Auditee qualified as low-risk auditee: **Yes**

(2) Financial Statement Findings

None.

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Findings and Questioned Costs

June 30, 2013

(3) Federal Award Findings and Questioned Costs

Finding: 13-001

Federal Programs, Federal Agencies, Award Years

Research and Development cluster – refer to SEFA for details.

Criteria

Per 45 CFR Part 74, *Uniform Administrative Requirements for Awards and Subawards to Institutions of Higher Education, Hospitals, Other Non-Profit Organizations, and Commercial Organizations; and Certain Grants and Agreements with States, Local Governments and Indian Tribal governments* (Subpart C), recipients shall submit the SF-269 and SF-269A (an original and two copies) no later than 30 days after the end of each specified reporting period for quarterly and semi-annual reports, and 90 calendar days for annual and final reports.

Statement of Condition

During our testing of reporting (FFR – federal financial reports), we tested the submittal of 15 reports throughout the year. In one instance, we found a report that was submitted approximately 3½ months after the 90-day deadline.

Questioned Costs

Not applicable.

Cause and Effect

The Center does not have adequate controls in place to ensure timely submittals of federal financial reports. If the Center does not ensure the timely submittal of federal financial reports, the Center is in violation of the applicable grant agreement.

Recommendation

KPMG recommends that the Center implement adequate controls to ensure the timely submittal of federal financial reports.

Views of Responsible Officials

The Center will revise the current standard operating procedure for the close out of sponsored projects and begin communications with Subrecipients regarding prompt invoicing early in the process to ensure timely submissions of FFR's.

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Findings and Questioned Costs

June 30, 2013

Finding: 13-002

Federal Programs, Federal Agencies, Award Years

Research and Development cluster – refer to SEFA for details.

Criteria

Per 2 CFR Part 180, *Grants and Agreements; OMB Guidelines to Agencies on Governmentwide Debarment and Suspension*, recipients shall not enter into covered transactions where the entity or its principals are considered excluded parties.

Statement of Condition

During our testing of procurement, specifically suspension and debarment of vendors, it was we observed there were not adequate controls in place to determine if the principals of vendors were considered excluded parties; the process was limited to the contracting entity.

Questioned Costs

Not applicable.

Cause and Effect

The Center does not have adequate controls in place to ensure principals of vendors for covered transactions are not excluded parties. If the Center does not ensure the principals are not excluded parties, the Center is in violation of the applicable grant agreement.

Recommendation

KPMG recommends that the Center implement adequate controls to ensure the principals of vendors for covered transactions are not excluded parties.

Views of Responsible Officials

Procurement staff will review and update their business processes relating to disbarment to ensure vendors as well as their principals are not suspended or debarred.